HIV-1 and the Nucleolus: A Role for Nucleophosmin/NPM1 in Viral Replication: A Dissertation by Schmidt, Tracy E.
University of Massachusetts Medical School 
eScholarship@UMMS 
GSBS Dissertations and Theses Graduate School of Biomedical Sciences 
2013-08-21 
HIV-1 and the Nucleolus: A Role for Nucleophosmin/NPM1 in 
Viral Replication: A Dissertation 
Tracy E. Schmidt 
University of Massachusetts Medical School 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss 
 Part of the Cell Biology Commons, Cellular and Molecular Physiology Commons, and the Virology 
Commons 
Repository Citation 
Schmidt TE. (2013). HIV-1 and the Nucleolus: A Role for Nucleophosmin/NPM1 in Viral Replication: A 
Dissertation. GSBS Dissertations and Theses. https://doi.org/10.13028/M2MK6V. Retrieved from 
https://escholarship.umassmed.edu/gsbs_diss/690 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and 
Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
 HIV-1 AND THE NUCLEOLUS: A ROLE FOR NUCLEOPHOSMIN/ NPM1 IN 
VIRAL REPLICATION 
 
A Dissertation Presented 
By 
TRACY ELLEN SCHMIDT 
 
Submitted to the Faculty of the  
University of Massachusetts Graduate School of Biomedical Sciences, Worcester  
in partial fulfillment of the requirements for the degree of 
 
DOCTOR OF PHILOSPHY 
 
August 21, 2013 
 
INTERDICIPLINARY GRADUATE PROGRAM 
 
 
 
 
 
 
 
 HIV-1 AND THE NUCLEOLUS: A ROLE FOR NUCLEOPHOSMIN/ NPM1 IN 
VIRAL REPLICATION 
 
A Dissertation Presented 
By 
 
TRACY ELLEN SCHMIDT 
 
The signatures of the Dissertation Defense Committee signifies completion and approval 
as to style and content of the Dissertation 
 
 
         
Maria Zapp, Ph.D., Thesis Advisor 
 
 
         
Heinrich Göttlinger, M.D., Ph.D., Committee Member 
 
 
         
Mohan Somasundaran, Ph.D., Committee Member  
 
 
         
Richard Sutton, M.D., Ph.D., Committee Member 
 
The signature of the Chair of the Committee signifies that the written dissertation meets 
the requirements of the Dissertation Committee 
 
 
         
Paul Clapham, Ph.D., Chair of Committee 
 
The signature of the Dean of the Graduate School of Biomedical Sciences signifies that 
the student has met all graduation requirements of the School 
 
 
         
Anthony Carruthers, Ph.D., 
Dean of the Graduate School of Biomedical Sciences 
 
Interdisciplinary Graduate Program  
 
August 21, 2013
 iii
DEDICATION 
 
 
To my husband, Mickaёl; 
  
 
To my Mom, Martha; 
  
 
To my brother, Chris. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iv
ACKNOWLEDGEMENTS 
 
 The journey from initial consideration through the actual achievement of a 
doctoral thesis is not one accomplished alone, it takes a community of people to guide, 
encourage and support you along the way.  I have had the privilege to be a part an 
amazing community throughout my years of graduate school that has contributed 
tremendously to my growth, both professionally and personally, and I am truly grateful.   
 First and foremost I thank my thesis advisor Maria Zapp for the opportunity to be 
a part of her laboratory and the mentorship she has given me while within it.  I am 
grateful for her unyielding support, patience, generosity, ceaseless energy and unmatched 
scientific knowledge that have guided me over the years.  Maria’s remarkable ability to 
both challenge and encourage has enabled me to achieve more than I ever thought 
possible and I can’t thank her enough. 
 Maria has not only provided me personal support, but has also surrounded me in 
company with an outstanding group of people.  I thank all members of the laboratory, 
past and present, for their time, assistance, discussions and camaraderie: Ellie Kittler, 
Zhong Yu, Kim Long, Irina Catrina, Adonia Kim, Lynn Kerr, Daniella Wilmot, 
Stephanie Kappopoulos, Betsy Carr, Edwin Perez and Nick Stone. I especially thank 
Zhong Yu for his patience in answering any and all questions I have had, particularly 
when learning a new protocol, and assistance with experimental execution and scientific 
guidance and Nick Stone for his time and contribution to my thesis project. I am deeply 
grateful to Adonia Kim for her scientific insight, encouragement, support, and above all, 
her friendship. 
 v
 I sincerely thank my Thesis Committee members Paul Clapham, Heinrich 
Gottlinger, Mohan Somasundaran and Richard Sutton for their invaluable discussions, 
encouragement and advice that have pushed me and this thesis to completion.  I 
especially thank and express tremendous gratitude to Paul Clapham for opening his 
laboratory to me, for always finding the time and patience to guide me when I needed 
direction and for his remarkable support during the final stages of thesis completion. I am 
grateful to Richard Sutton for his participation and critical review of this thesis as my 
external examiner, Mohan Somasundaran for being so generous with his time and 
offering vital guidance, especially with several significant experiments in this thesis, and 
Heinrich Gottlinger, not only for providing key reagents but also for addressing important 
questions with his boundless knowledge in HIV-1 biology.   
 I am also grateful to my colleagues and friends that have enriched and supported 
me.  I thank the Clapham lab, particularly Paul Peters and Olivia O’Connell, who have 
given me the space and advice to conduct my viral experiments.  I thank Linda 
Lambrecht for her expertise and use of equipment that enabled me to perform the p24 
ELISA experiments.  I am eternally indebted to Kendall Knight, Eric Weiss and Jennifer 
Pirri for their unyielding support and critical reading of this manuscript.  I sincerely thank 
my mentors Anita Ballesteros and Michelle Runge, two remarkable, insightful and 
inspirational women that have unselfishly provided me with wisdom and guidance. I also 
thank Thomas Hope for his infectious enthusiasm and incredible passion for unraveling 
the complexities of HIV-1 replication, both of which fueled my pursuit of this degree.  
Importantly, I thank Catherine Yin, Brian Farley, Bill Monis, Karen Mruk and Jennifer 
 vi
Pirri for their friendship, encouragement and incredible scientific talents that have been 
both inspiring and instrumental to my completion of graduate school. 
 To end, this thesis and my journey would never have been possible without the 
unconditional love and support from my family.  I thank my father, Chris, step-mother, 
Rosa and Grandma, Muriel, for their persistent confidence in me.  I am very grateful for 
my inspiring sister-in-law Angelia, who is truly a remarkable person and professional.  I 
thank Hudson and Amelia for filling my heart with such immense joy.  I infinitely thank 
my brother Chris for being an incredible shining light that has and always will be there 
for me.   I thank my Mom, Martha for being my role model of strength, intelligence, 
compassion and success as an independent woman.  I am eternally grateful to her for 
surrounding me with love every day and giving me the encouragement and freedom to 
dream out loud, to explore life and to follow my own path, no matter how winding it may 
seem to be.  Most significantly, I thank my husband, Mickaёl, whose immeasurable love, 
remarkable patience and unwavering belief in me is nothing short of extraordinary.  
Mickaёl started this journey together with me, and without him none of this would ever 
have been possible. From the moment we met, each new day is better than the one before 
it.  I am beholden to have found a partner to embrace life with and to live forward in our 
very own love story.  Forever is not long enough. 
 vii
ABSTRACT 
 
 
 The nucleolus is a plurifunctional organelle with dynamic protein exchange 
involved in diverse aspects of cell biology.  Additionally, the nucleolus has been shown 
to have a role in the replication of numerous viruses, which includes HIV-1.  Several 
groups have reported HIV-1 vRNA localization within the nucleolus.  Moreover, it has 
been demonstrated the HIV-1 Rev protein localizes to the nucleolus and interacts with 
nucleolar proteins, including NPM1. Despite evidence for a nucleolar involvement during 
replication, a functional link has not been demonstrated.  I investigated whether intron-
containing vRNAs have a Rev-mediated nucleolar localization step prior to export.  
Furthermore, I examined whether NPM1 mediates Rev nucleolar localization, 
participates in Rev function, and/or post-transcriptional events during viral replication.  I 
used coupled RNA fluorescence in situ hybridization and indirect immunofluorescence to 
visualize intron-containing vRNA relative to the nucleolus in the absence or presence of 
Rev expression.  An RNAi-based approach was used to examine the role of NPM1 in Rev 
function and viral replication in cell lines and primary human macrophages.  My research 
findings support a model for a Rev-independent nucleolar localization step of intron-
containing vRNA prior to export. Intriguingly, my results also suggest NPM1 does not 
participate in Rev nucleolar localization or Rev-mediated vRNA export, as previously 
proposed. Rather, my findings support a novel role for NPM1, the cytoplasmic 
localization and utilization of a select class of Rev-dependent vRNAs.  Collectively, my 
 viii
findings provide novel insight for a functional role of the nucleolus and NPM1 in HIV-1 
replication, which enhances our current understanding of HIV-1 biology. 
 ix
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CHAPTER I: INTRODUCTION 
 
1.1 HIV-1 and AIDS: A Global Epidemic 
1.1.1 Discovery 
 Human Immunodeficiency Virus Type I (HIV-1) is the etiological agent of 
acquired immunodeficiency syndrome (AIDS) and responsible for more than 30 million 
deaths worldwide (318).  The beginning of the HIV-1/AIDS epidemic is marked as June 
5, 1981 when the Centers for Disease Control (CDC) published a report observing cases 
of the lung infection Pneumocystis carinii pneumonia (PCP) in a small population of 
young, previously healthy, homosexual males (54).  The report noted the incidence of 
PCP was exceedingly rare and usually manifested in severely immunocompromised 
individuals.  Within weeks, increased accounts of other unrelated opportunistic 
infections, such as Kaposi Sarcoma, mucosal candidiasis and chronic ulcerating lesions 
by herpes simplex virus, were being reported in men across metropolitan areas that were 
also displaying similar unexplained immunological defects, suggesting an outbreak of a 
common, transmissible cause (53, 129, 164, 219, 290).  Soon after, the new acquired 
immunodeficiency disease was also observed in the larger population, such as in 
heterosexuals, hemophiliacs (51, 219) and later in women and children (52, 55), 
demonstrating more than one population was at risk.    
 The observations that patients receiving blood transfusions and the sexual partners 
of individuals with AIDS, both who were previously healthy, were then later seen with 
AIDS symptoms, clearly demonstrated the causative agent was transmitted through blood 
 3
and sexual activities and its persistence and spread throughout the larger population 
suggested a virus.  Luc Montagnier and colleagues from the Pasteur Institute were the 
first to publish on a virus isolated from AIDS patients, a retrovirus which they termed 
lymphadenopathy-associated virus (LAV), and suggested that it might be the cause of 
AIDS (15).  Shortly after, Robert Gallo and his research group at the National Cancer 
Institute isolated and described what they designated as human T-lymphotropic virus type 
III (HTLV-III) as the probable cause of AIDS (120, 261, 280, 284).  Meanwhile, Levy 
and colleagues also isolated a retrovirus which they named AIDS-Related virus (236).  
After much debate and sequence verification, it was clear that each group identified a 
variant of the same retrovirus which was assigned the single name, Human 
Immunodeficiency Virus (67).  While Gallo was not the first to isolate HIV-1, he was the 
first to establish an enzyme-linked immunosorbent assay (ELISA) that enabled 
researchers and physicians to test individuals for HIV-1 infection (120, 280).   
 
1.1.2 Disease progression 
 There are three major routes an individual may contract HIV-1; through sexual 
intercourse; exchange of contaminated blood, such as through intravenous drug use or 
blood transfusions; and mother to child, either intrapartum, perinatally, or through breast 
milk.  Although there are several modes of transmission, the subsequent course of HIV-1 
infection if left untreated remains the same.  HIV-1 targets and depletes CD4 positive 
(CD4+) cells of the immune system and is characterized by three stages of progression, 
acute, chronic and AIDS  followed by death (Figure 1-1) (5, 87, 88, 303).  
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 The acute phase begins with the primary infection and continues through the 
development of an HIV-1 specific immune response.  Upon infection, the virus quickly 
replicates, disseminates through and establishes a latent reservoir in the lymphoid tissues 
and causes a sharp decrease in CD4+ T cells (88).  Although virus populations are found 
throughout the blood and lymph tissues, it is the gut-associated lymphoid tissue (GALT) 
that is the most affected, seeing a massive and permanent depletion of CD4+ T cells 
during this time (37, 88, 303).  An infected individual may experience mononucleosis-
like symptoms such as fever and pharyngitis, also referred to as acute HIV-1 syndrome, 
within 3-6 weeks following infection. This corresponds to the detectable specific antiviral 
immune response (68, 118).  These antiviral immune responses are associated with the 
observed decline in viral load and a temporary rise in the number of CD4+ T cells 
primarily due to the activation and expansion of CD8+ cytolytic T cells (CTL) (28, 68, 
145, 253). 
 Following the induction of the immune response there is a relatively long period 
in which an infected individual appears asymptomatic, termed the chronic phase.  There 
is an initial stabilization of viral load, called the viral set point, which can be correlated to 
the time interval from infection to development of opportunistic infections (263) as well 
as a modest, delayed and temporary recovery of CD4+ T cells from their lowest point.  
This increase slowly declines over time, an average of 10 years, until the progression to 
AIDS (88).  Although sometimes referred to as clinical latency period, this implies the 
virus is dormant. In actuality there is continual, rapid viral replication in the progression 
to disease and is characterized by a remarkable increase of genetic variation in the virus 
 5
population and high level of immune activation of CD4+ and CD8+ T cells (88, 142).  
Eventually, the unstable equilibrium between viral replication and T cell activation, death 
and renewal breaks down.  When CD4+ T cells reach approximately 500 cells/μL certain 
constitutional infections and malignancies manifest, such as oral lesions, carcinomas of 
the skin and reactivation of latent herpes zoster virus, all which mark the progression to 
the final disease state, AIDS (103). 
 Once the CD4+ cells counts fall below 200 cells/μL, the individual is considered 
in the AIDS phase of the disease.  At this stage, an individual is susceptible to 
opportunistic infections and neoplasms, such as Pneumocytisis carinii pneumonia, 
Kaposi’s sarcoma and herpes simplex virus, as described in the first cases of AIDS.   
Patients may also develop HIV-1 induced encephalopathy known as AIDS dementia 
complex (ADC) (94, 103).  The viral load continues to rise and the CD4+ T cell counts 
continue to decrease until virtually all CD4+ T cells are lost, leading to eventual death 
due to opportunistic infection or cancer.  
 6
 
 
 
Figure 1-1. Pathogenesis of HIV-1 infection.  The typical course of infection in an 
untreated individual.  Primary infection causes rapid viral replication (red), spread of the 
virus throughout lymphoid tissues where the virus establishes a reservoir and causes a 
significant decrease in CD4+ T cells (blue).   Flu-like symptoms (Acute HIV syndrome) 
appear with the development of a HIV-1 specific immune response. Next, is the chronic 
phase where a drop and stabilization of viral load (setpoint viral load) and slight increase 
in CD4+ T cell counts is seen, lasting several years.  Progressively, the number of CD4+ 
T cells slowly drops and viremia rises.  When CD4+ T cells decline to 500 cells/mm3, 
constitutional symptoms begin.  Progression into AIDS is associated with a CD4+ T cell 
count of ±200 cells/mm3 (blue dotted line) and opportunistic disease manifestation, 
leading to death.  Adapted from An Ping and Cheryl A. Winkler. Trends Genet. (2010).  
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1.1.3 Antiviral therapy 
 The development of antiviral therapies has allowed for long-lasting suppression of 
viral replication, thus greatly increasing the longevity spent within the clinically latent 
period of infection and the quality of life of infected individuals.  There are now 
numerous drugs that exist in a variety of categories based on their enzymatic and/or 
cellular targets.  The first class of therapy introduced for the treatment of HIV-1 infection 
was a nucleoside reverse transcriptase (RT) inhibitor (NRTI), called zidovudine (AZT) in 
1987 (96).  AZT and other first class RT inhibitors were administered to patients as a 
monotherapy and were able to prolong life for 6-18 months (81).  However, the 
therapeutic potential of these drugs alone proved ineffective, as they displayed high 
toxicity and the emergence of viral resistance (94). 
 The next class of HIV-1 antiviral drugs approved was the PIs (protease 
inhibitors), the first being Saquinavir in 1995, which revolutionized how antiretroviral 
therapy was administered.  Introduction of PIs began the era of Highly Active Antiviral 
Therapy (HAART) in which using drugs from different classes in combination proved to 
drastically reduce viral replication and the incidence of opportunistic infections in AIDS 
patients (81, 252).  A year later, non-nucleoside RT inhibitors (NNRTIs) were introduced 
further expanding the HAART repertoire.  Over the years, treatments have improved not 
only because of the increased efficacy of the drugs available, but also because the newer 
compounds have far less toxicity and dosages have been simplified. In some cases a 
combination of drugs is made into a single pill given once daily, which is more practical, 
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allowing for easier adherence to the treatment regime, leading to the transformation of 
AIDS to a chronic disease. 
 Drug resistance is one of the frequent causes of treatment failure. Viral resistance 
to drug therapy has been reported for every antiviral drug available (84) and therefore 
emphasizes the critical need for new HIV-1 drug discoveries, and more importantly, 
development of a HIV-1 vaccine. The extraordinary viral diversity and rapid error-prone 
replication of the virus are not only reasons for drug resistance but are considerable 
challenges faced in the development of a vaccine.  Incomplete understanding of HIV-1 
immunopathogenesis as well as the fact that HIV-1 targets the immune system and the 
very cells that prevent or clear infections further complicates vaccine strategies.   
 Despite these obstacles, there have been four vaccines that have been brought 
from concept to human clinical efficacy trials to date (222), unfortunately there still is no 
vaccine available and only one of the trials has actually shown promise with a modest 
protection against infection.   The first trial was completed in 2003 with two parallel 
vaccine products (AIDSVAX B/E and AIDSVAX B/B) of HIV-1 envelope proteins and 
failed to show any effectiveness (107, 258).   The second trial, known as the STEP trial, 
used an attenuated adenovirus vector approach, fared worse and was stopped prematurely 
in 2007 due to evidence that the vaccine actually increased susceptibility of HIV-1 
infection in some populations (102). Optimism of reaching an HIV-1 vaccine increased 
upon announcement of results in the RV144 Thailand community-based trial that showed 
a 31.2% protective effect against infection using a canarypox vector and recombinant  
glycoprotein 120 (gp120) approach (222).  However, researchers and physicians are still 
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far from a safe and effective prophylactic vaccine for HIV-1. This is exemplified by the 
April 25, 2013 announcement from the US National Institute of Allergy and Infectious 
Diseases that it has halted the most recent vaccine efficacy trial, HTVN 505, due to its 
lack of ability to prevent infection or reduce viremia (239).   
 Irrespective of this disappointment, the universal necessity for a vaccine continues 
to drive the coordinated international effort towards its goal of HIV-1 eradication.  
Scientists are confident that a cure for HIV-1 can be reached.  To date there are three 
cases in which a ‘functional’ cure of HIV-1 has been documented, meaning a previously 
HIV-1 positive individual has no to barely detectable levels of the virus within their 
blood or other latent reservoirs after an extended period of time and no longer requires 
antiretroviral therapy.  Normally, once antiviral therapy is ceased virus replication 
rebounds and if not controlled, disease progression continues until death.   
 The first case of a functional cure was Timothy Brown, known as the Berlin 
patient, in 2009.  Brown was living with HIV-1 for 10 years and on antiretroviral therapy 
before he was diagnosed with acute myeloid leukemia (AML), a cancer of the myeloid 
cell lineage causing rapid growth and accumulation of abnormal white blood cells in 
bone marrow.  To treat the cancer, Brown underwent a hematopoietic stem cell transplant 
using a matched donor that also had the rare, homozygous genetic mutation CCR5Δ32 in 
the coreceptor utilized by macrophage-tropic HIV-1 to enter a cell.  This mutation 
renders an individual highly resistant to infection and is present in only 1-2% of 
Caucasians (163, 172).   Since his transplant, researchers and physicians have been 
unable to detect levels of HIV-1 in blood or other tissues and he remains off antiviral 
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therapy (163, 172).  While this procedure is not possible for widespread use, this provides 
proof-of-concept that a cure is attainable. 
 Further promise towards HIV-1 eradication came from two separate reports 
within weeks of each other in March of this year.  Researchers at the Conference on 
Retroviruses and Opportunistic Infections (CROI) announced a case of a functional cure 
in a 26 month old infant that began antiretroviral therapy within 30 hours of birth and 
continued until 18 months of age.  Although at age 26 months HIV-1 DNA was 
detectable (4 copies/million), there were no detectable levels of plasma viral load or HIV-
1 specific antibodies by standard clinical methods, and therefore the infant was 
recognized as functionally cured (83).  This case strongly argues for aggressive and early 
treatment in infants to inhibit latent reservoir establishment as a cure, and is currently 
being pursued in a clinical trial. This is a difficult but potentially achievable solution that 
can be applied with current procedures used globally to reduce mother-to-child 
transmission.  
 Aggressive, prolonged antiviral therapy early in infection has also been shown to 
provide a functional cure in adults for the first time.  French researchers have reported 14 
individuals that were treated within weeks of initial infection for an average of 3 years 
now have normal CD4+ T cell counts, low viral load, and have been off antiretroviral 
therapy for an average of 7 years (276).   Although extremely encouraging, evidence 
suggests that only 10-15% of adults may be cured by this approach (172, 276), and only 
if exposed individuals actually receive immediate treatment.  This presents a method that 
 11
is neither relevant for those with chronic infection nor realistic to those affected the 
greatest, individuals from developing countries. 
 
1.1.4 Global Impact 
 The global need for an HIV-1 vaccine and a cure is obvious.  There are 
approximately 34 million people currently living with HIV-1 worldwide and it has caused 
more than 30 million deaths since its discovery (318). Moreover, chronic management of 
HIV-1 has not been realized in mid to low-income countries.  More than 97% of the 2.5 
million new infections occur in these nations, with only 7% in developing countries 
having access to antiretroviral drugs and only 20% worldwide being reached by 
prevention programs (319, 325).  Restrictions such as poor governmental support, limited 
health infrastructure, licensing and cost of available drugs, have all contributed to the 
inability to reach those needing treatment in these regions (291).   Joint United Nations 
Programme on HIV/AIDS (UNAIDS) has a new “15 by 15” campaign, with a goal to 
provide 15 million people in developing countries with treatment by 2015 (319). Other 
extraordinary, organized initiatives targeting underserved populations provide 
encouraging advances towards the goal of global access for treatment and preventative 
care of HIV-1.  Progression towards this objective is reflected in the 20% decrease in 
reported newly infected people since its peak in 2001, with the sharpest declines being in 
the Caribbean (42%) and sub-Saharan Africa (25%) (319), but is far from being fully 
realized.  This provides further evidence for the need to push for even greater scale-up 
initiatives, development of alternative treatments and preventative measures, such as 
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microbicides, circumcision and pre/post exposure prophylaxes.  Furthermore, equally if 
not more importantly, increased support in basic science research to be able to fully 
unravel the complexity of HIV-1 pathogenesis and supply the world with a much needed 
cure. 
 
1.2 The HIV-1 Replication Cycle 
 HIV-1 is part of the Retroviridae family of viruses, a family with a unique life 
cycle that differentiates them drastically from other viruses.  Replication is an intricate, 
multiple step process that is regulated by both viral and cellular proteins which confers 
the ability to perform a reverse flow of genetic information from RNA to DNA and 
insertion of the proviral genetic information into the host genome.  Integration into the 
host genome allows the virus to maintain a persistent infection irrespective to the host 
immune response.  The HIV-1 life cycle can be divided into a series of events occurring 
at two stages, early or late, based on the relationship of the steps to viral DNA integration 
into the host genome (Figure 1-2).  Replication begins with the attachment of the viral 
surface envelope glycoprotein gp120 (SU) to the host cell surface receptor CD4, an 
Immuglobulin (Ig)-like protein found on a subset of T-cells, macrophages and dendritic 
cells.  Binding of gp120 to CD4 induces a conformational change and enables its 
subsequent binding to one of two co-receptors; host seven-transmembrane chemokine 
receptors CXCR4 or CCR5.  Further structural changes occur upon co-receptor binding 
in both gp120 and the envelope transmembrane glycoprotein gp41 (TM). This promotes 
viral envelope and cell plasma membrane fusion and allows the release of the viral core 
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into the host cell cytoplasm (63, 281).  Once in the cytoplasm the viral core, comprised of 
viral and host proteins surrounded by a capsid protein (CA) hexameric lattice, undergoes 
uncoating, a process that is poorly understood.  During this step CA is shed, in part or in 
total, to reveal the reverse transcriptase complex (RTC) made up of the genomic RNA 
(gRNA), the viral proteins matrix (MA), nucleocapsid (NC), reverse transcriptase (RT), 
integrase (IN), and viral protein R (Vpr).  Next, reverse transcription of the gRNA into 
linear double stranded DNA occurs (101).  As uncoating and reverse transcription of the 
RTC are taking place, the complex is being transported towards the nucleus, first by 
associating with actin then by interactions with the microtubule network (40, 44, 221). 
Completion of reverse transcription results in the formation of the large nucleoprotein 
complex known as the preintegration complex (PIC) which is then imported from the 
cytoplasm through the intact nuclear envelope to the nucleus using a combination of viral 
and cellular proteins. The precise mechanism, along with viral and cellular proteins 
involved in this step remains controversial (39).  Once in the nucleus, IN mediates 
integration of the viral DNA into the host genome, where it is known as the provirus, 
allowing for the permanent propagation of virus within the viable cell (111).  
 Following the integration of the viral genome is the late stage of viral replication.  
The late stage begins with cellular RNA Polymerase II driving transcription of the viral 
DNA from the promotor located in the 5’ long terminal repeat (LTR).  Transcription also 
requires the viral protein Tat for enhanced rate, processing and elongation of the viral 
transcripts (111).  The vRNA that is produced is then either completely spliced by the 
cellular splicing machinery and exported to the cytoplasm through the typical TAP (Tip-
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associated protein) mRNA export pathway, or is partially spliced or remains full-length 
(unspliced) and exported to the cytoplasm by the viral protein Rev through the CRM1 
(Chromosome Maintenance 1) pathway typical for cellular small nuclear RNAs 
(snRNAs) and ribosomal RNA (rRNA) (72).   After nuclear export viral RNAs (vRNAs) 
are translated, followed by viral protein and gRNA transportation to sites of virus 
assembly at the plasma membrane.  The functional domains of the viral polyprotein Gag 
coordinate particle assembly and release. Briefly, matrix (MA) targets and binds the 
polyprotein to the membrane as well as promoting assembly and Env incorporation, 
capsid (CA) mediates Gag:Gag interactions and Gag-Pol incorporation with nucleocapsid 
(NC), which also facilitates dimerization and packaging of gRNA, while p6 promotes 
Vpr (viral protein R) incorporation into the virus and recruitment of the cellular 
machinery needed for virus budding and release (112).  As the virion buds and is released 
from the cell membrane it undergoes its final step, maturation.  Maturation is a 
morphological rearrangement that involves the proteolytic processing of the Gag and 
Gag-Pol polyproteins by the viral protein protease (PR) and once completed the virus is 
infectious and ready to begin another round of replication in a new target cell (111, 329). 
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Figure 1-2. The HIV-1 replication cycle.  HIV-1 replication is divided into two 
stages classified by the relationship of the steps to viral DNA integration: early 
(preintegration) and late (postintegration).  Early stage begins with viral attachment 
followed by viral core penetration and uncoating, reverse transcription of the vRNA into 
DNA, nuclear import of the preintegration complex and concludes with incorporation of 
the viral DNA into the host genome.  The late stage consists of viral gene transcription, 
export of unsliced, partially spliced and fully-spliced vRNA to the cytoplasm, translation, 
viral particle assembly, budding and release from the host cell and finally, maturation of 
the virion.  Reproduced with permission from Furtado, MR, et al. N. Engl. J. Med. 
(1999), Copyright Massachusetts Medical Society. 
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1.3 The HIV-1 Genome: Organization and Viral Proteins 
1.3.1 Virion and Genome Organization 
 An infectious, mature HIV-1 virion is a sphere of approximately 125 nm in 
diameter containing a protein dense conical viral core (Figure 1-3) (38, 345).  The 
spherical outer shell is an envelope lipid membrane bilayer containing 8-10 trimers of 
non-covalently interacting Env glycoproteins SU (gp120) and TM (gp41) and is 
supported by an inner layer of MA (38, 345).  Moving inward, the interior of the virion is 
comprised of protease (PR), cellular cyclophylin A (CypA) and the viral core (123, 322).  
The viral core is a protein complex of predicted fullerene conical shape (124) with 
approximately 250 hexameric and 12-15 pentameric rings of CA making up the outer 
lattice shell (123) that encases the inner core viral proteins RT, IN, p6, PR, Nef (negative 
regulatory factor), Vif (viral infectivity factor) and Vpr (38, 123, 183, 322).  Also making 
up the inner core is NC, which is responsible for the packaging of the viral genome, a 
condensed dimer of two copies of the HIV-1 genome (123, 234, 322).   
 The HIV-1 genome is a positive-sense, single-stranded RNA and is packaged as a 
dimer (116).  The genome is approximately 9.7 kb in length, measuring from the 5’ LTR 
(long terminal repeat) to the 3’ LTR (116) and contains all the necessary information for 
infectious virus production (Figure 1-3). The 5’ UTR (untranslated region) does not 
encode for any viral proteins but does contain several sequence elements needed for viral 
replication, including: 1) the trans-activating response element (TAR), a RNA hairpin 
that Tat binds to for transcription initiation, 2) the primer binding site (pbs) needed to 
initiate reverse transcription, 3) the 5’ Poly A Stem Loop, a region used to stabilize the 
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tRNALys primer, 4) the dimerization site, which includes the self-complementary DIS 
(dimerization initiation sequences) that form a “kissing loop” to facilitate RNA dimer 
incorporation into the virion, 5) the major splice donor site (MSD), which is the sequence 
used to produce all spliced RNAs and finally 6) the translation initiation codon for Gag 
(111, 116). Found downstream are the nine overlapping open reading frames (ORFs) 
which encode for the 15 viral proteins.  HIV-1 is able to produce all proteins from a 
single transcript through the utilization of alternative splicing by the selection of one of 5 
splice donor and more than 10 splice acceptor sites (sd and sa, respectively) (266), and 
the production of polyprotein precursor translation products.  Unspliced RNA produces 
the Gag and Gag-Pol polyproteins that during virion maturation become cleaved to 
generate MA, CA, NC, p6, PR, RT and IN proteins.  RNAs that are singly spliced 
produce the proteins Vif, Vpr, Vpu (viral protein U), and the Env polyprotein which is 
later cleaved by cellular proteases to produce SU and TM proteins.  Completely spliced 
RNAs give rise to Nef, Tat, and Rev viral proteins.  Rev is required for the expression of 
the unspliced and singly spliced RNAs by mediating their export to the cytoplasm 
through sequence-specific binding to a stem-loop structure, termed the Rev response 
element (RRE), located within the env coding region.  Another element found within the 
genome is the polyadenylation signal used to generate the 3’ end of the transcripts which 
is located in the 3’ LTR.  The complexities of the genome are also reflected in the 
functional roles of the individual proteins themselves and are categorized based on such, 
into structural, enzymatic, regulatory or accessory proteins.  
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Figure 1-3. The HIV-1 genome and mature virion organization.  Adapted from 
H.L. Robinson Nat. Rev. Immunol. ( 2002). 
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1.3.2 Structural proteins 
 The structural proteins are comprised of the Gag and Env polyproteins and their 
cleavage products. Gag is synthesized on cytosolic polysomes as a 55 kD polyprotein 
precursor (Pr55Gag) comprised of four domains: matrix (MA/p17), capsid (CA/p24), 
nucleocapsid (NC/p7) and p6 with two spacer peptides, SP1, located between CA and 
NC, and SP2, found between NC and p6.  These domains are separated by five flexible 
linker regions that contain sites that are cleaved by PR during virion maturation to 
liberate processed forms of the proteins.  The Gag proteins direct virus particle 
production and perform critical roles in the early stages of viral replication. 
 The MA domain, found at the N-terminus of the Gag precursor, performs several 
essential functions during the virus lifecycle.  Following synthesis, MA directs Gag to the 
plasma membrane through a multipartite membrane binding signal consisting of a 
myristate moiety covalently attached to the N-terminal glycine of MA and an N-proximal 
highly basic region (300).  Mutational studies have demonstrated the importance of these 
regions (131, 247, 339)  and demonstrate the ability of the highly basic region to interact 
with acidic phospholipids (344).  It has been shown that this region interacts with 
phosphatidylinositol bisphosphate (PI(4,5)P2) (246),  supporting a “mysistoyl switch” 
model for membrane targeting (246, 247, 251).  In this model, interactions of the highly 
basic region with the negatively charged acidic phospholipids stabilize membrane 
interactions, causing a conformational change in MA that exposes the myristate moiety 
and induces membrane anchoring.  In addition to directing Gag to the plasma membrane, 
MA has been shown to be important for Env incorporation during virus assembly, most 
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likely through interactions with the cytoplasmic tail of TM/gp120 (113, 115, 216). 
Following virus maturation, MA remains associated with the viral membrane, with some 
molecules present in the viral core where they were reported to contribute to viral core 
uncoating (176) and possibly PIC entry into the nucleus (40, 323). 
 C-terminal to MA in the Gag precursor is CA.  CA is made up of two structural 
and functional domains, the N-terminal core domain and the C-terminal dimerization 
domain, that together enable CA to have several roles during viral replication.   The C-
terminal domain is primarily responsible for mediating Gag:Gag and Gag:Gag-Pol 
interactions necessary for virus particle and core assembly (86, 121, 158, 217) while the 
N-terminal core domain is needed for CypA incorporation, a protein thought to be critical 
for viral infectivity (110, 313).  In the mature virion, CA is arranged into a hexameric and 
pentameric lattice that forms the outer shell of the viral core, protecting the inner viral 
ribonucleic particle (RNP) (123, 124). 
 The third domain found in Gag is NC, which has the primary function of 
encapsidation of the genomic RNA dimer.  NC mediates gRNA incorporation through 
interactions with the two zinc-finger motifs of NC and the packaging signal (ψ) on the 
vRNA; a 150 nt sequence that folds into series of four stem loops.  This interaction is also 
thought to act as a scaffold to mediate Gag nucleation and Gag multimerization (45, 79, 
112, 236, 249, 283).  NC remains tightly associated with gRNA in the mature particle and 
part of the viral core which has been demonstrated to act as a chaperone in early steps of 
virus replication by enhancing reverse transcription and integration (50, 199, 309).  NC is 
flanked by the two spacer peptides which are cleaved to not only allow proper NC 
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functions but also virus assembly, maturation and infectivity.  Specifically, the SP1 
peptide is needed for immature particle assembly and regulating the formation of the 
mature capsid (3, 257), whereas the role of SP2 is less clear.  Studies have suggested that 
while it per se may be dispensable for virus maturation and infectivity, processing of the 
NC-SP2-p6 region appears to be essential for proper viral morphology, maturation and 
infectivity (69, 82). 
 The p6 domain makes up the C-terminus of Gag and has two major functions.  
The first is to mediate Vpr incorporation into the assembling particles (254), the second is 
to promote detachment of assembled virus from the plasma membrane through motifs 
that recruit and bind to ESCRT (endosomal sorting complex required for transport) 
factors (300).  The conserved Pro-Thr-Ala-Pro (PTAP) domain in p6 binds the Tsg101 
subunit of the ESCRT-I complex (125, 321) while the Tyr-Pro-Xn-Leu (YPXnL) motif 
interacts with the ESCRT protein ALIX (297).  These interactions recruit other ESCRT 
proteins, namely ESCRT-III and VPS4 complexes, needed to complete particle 
release (300). 
 The other structural proteins are encoded within the env gene, and like Gag are 
synthesized as a polyprotein precursor.  The 160 kD Env precursor is synthesized from a 
bicistronic singly spliced mRNA on the rough endoplasmic reticulum (ER) ribosomes 
where it is co-translationally glycosylated, inserted in the lumen of the ER and 
oligomerizes (114). Following trimerization, Env is transported to the Golgi where it 
undergoes further modification and is cleaved by cellular furin or furin-like proteases to 
the mature gp120 and gp41 proteins (144).  Once cleaved, gp120 and gp41 non-
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covalently associate and are transported from the Golgi to the plasma membrane where 
they are incorporated into the assembling virus particle (114).  The primary function of 
the Env glycoproteins gp120 and gp41 is to mediate viral attachment and membrane 
fusion for viral entry into host cell.  Viral entry traditionally has been thought to begin 
with binding of gp120 to cell surface receptor CD4.  While this step is still necessary for 
viral entry limited evidence suggests that α4β7 integrins may also play a role in 
attachment and transmission in a subset of cell types (62).  Once bound to the CD4 
receptor, gp120 undergoes conformational changes that result in movement of the 
variable loops that then expose the gp120 co-receptor binding site and allow co-receptor 
binding, either CXCR4 or CCR5 (187, 332). Co-receptor binding of gp120 is thought to 
occur through its interactions of its bridging sheet and additional amino acids of the V3 
loop (61).  Co-receptor engagement induces additional rearrangements in gp120 and 
changes in gp41 that permits insertion of the gp41 fusion peptide, located at the N-
terminus of the protein, into the host membrane and formation of the fusion pore (61).  
Next, three HR1 (heptad-repeat region 1) motifs make antiparallel interactions between 
three HR2 (heptad-repeat region 2) motifs to form a six-helix bundle that bring the viral 
and cellular membranes together, thus allowing for membrane fusion and entry of the 
HIV capsid into the target cell (61).   
 
1.3.3 The Enzymatic Proteins   
 The pol gene encodes the enzymatic proteins protease (PR), reverse transcriptase 
(RT) and integrase (IN) and is found 3’ (downstream) of gag in an overlapping but 
separate translational reading frame that lacks an initiation codon.  As a result, pol is 
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synthesized as a 160 kD Gag-Pol fusion polyprotein precursor (Pr160Gag-Pol, Gag-Pol) that 
is later proteolytically cleaved to produce the enzymatic proteins.  Pol expression is 
dependent upon a the translational mechanism known as single (-1) ribosomal 
frameshifting (168), meaning ribosomes occasionally stall and shift reading frames.   This 
mechanism is promoted by two RNA cis-acting elements found within the overlapping 
pol and gag genes, a UUUUUUA heptamer known as the “slippery sequence” and a 
frameshift A-form helical stem loop with an AACA tetraloop cap (150, 293).  The exact 
mechanism of frameshifting has not yet been completely resolved, however, there is 
evidence that stem loop structure and stability are a contributing factor to its rate (24, 
311), a frequency which occurs at a level of 5%-10% of Gag synthesis and is strictly 
maintained to ensure the critical 20:1 Gag:Gag-Pol ratio for viral replication (150).  Once 
translated, Gag-Pol is targeted to sites of virus assembly at the plasma membrane, 
directed by MA, and packaged into the virion through interactions with CA.  Either 
during or shortly after virus budding from the cell membrane, PR is autocatalytically 
released and dimerizes.  PR then sequentially processes Gag and Gag-Pol to liberate the 
mature forms of their proteins, a necessary step for virion maturation and subsequent 
viral replication (150).  The liberated RT enzyme is responsible for the conversion of the 
viral single-stranded RNA into double-stranded DNA during the early stage of replication 
known as reverse transcription.  RT is able to catalyze this reaction through its three 
enzymatic functions: 1) RNA-directed DNA polymerase activity, which is necessary for 
the synthesis of the minus-strand DNA, 2) DNA-directed DNA polymerase activity, 
which is necessary for the synthesis of the plus-strand DNA and 3) RNaseH activity, 
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which is necessary for RNA degradation of RNA:DNA hybrids (279).  RT does not have 
an exonucleolytic proofreading activity, meaning the enzyme is unable to recognize or 
rectify when an incorrect base pair is inserted into the DNA. This deficiency coupled 
with frequent template switching leads to high mutation rates, measured in cell-based 
assays at 3 x 10-5 per replication cycle, allowing for the advantage of virus genetic 
diversity (264, 312). 
 After reverse transcription, IN, the last enzyme found in Pol, binds to the dsDNA 
and mediates its insertion into the host genome to establish the provirus.  IN catalyzes 
this reaction first in the cytoplasm where it binds to the linear dsDNA, processes the 3’ 
ends by removing 3-4 nucleotides and generates the PIC.  The PIC is then transported to 
the nucleus (see section 1.1.2 and Figure 1-2) where IN catalyzes the second reaction, 
known as the strand transfer reaction (STR).  IN utilizes the 3’ recessed ends of the viral 
DNA to attack the phosphodiester bonds in the major groove of cellular DNA which 
results in ligation of the ends in a 5-base pair stagger (220).  Cellular repair machinery 
then trims and fills in the gaps of the integrated proviral DNA to complete the integration 
process.  
 
1.3.4  The Accessory Proteins  
 There are four viral proteins categorized as the accessory proteins; Vif, Vpu, Vpr 
and Nef.  The term “accessory” was assigned to these proteins because of early studies 
showing they were dispensable for viral replication in cultured cells (314).  However, 
over the years the term “accessory” has been demonstrated to be quite a misnomer, as 
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each protein performs necessary functions for infectious particle production (116, 146, 
238, 314). 
 Vif is a 23 kD protein produced during the late stage of the HIV-1 replication 
cycle and is required to counteract the restriction activity of the cellular protein 
apolipoprotein B messenger RNA (mRNA)-editing enzyme catalytic polypeptide-like 3G 
(A3G) (146, 211).  A3G is a cytosine deaminase that is expressed in hematopoietic cells, 
a subset of which is a natural target for HIV-1 infection (211).  In the absence of Vif, 
A3G is incorporated into nascent virions by binding to assembling Gag ribonucleoprotein 
(RNP) complexes (298).  Thus, A3G is transferred to the target cell upon viral infection 
where it deaminates viral minus-strand cDNA, converting cytidines to uridines.  These 
mutations cause the insertion of adenosines during positive-strand viral cDNA synthesis 
of reverse transcription.  Remarkably, up to 10% of the viral cDNA cytidines are 
deaminated, which results in mutational changes in the viral genome, causing viral 
catastrophe (146, 211).  Vif is able to successfully antagonize A3G activity by 
associating it with an ubiquitin ligase complex and induce its proteosome-dependent 
degradation (146, 211). 
 The HIV-1 viral accessory protein Vpu also functions to counteract host cell 
antiviral restriction activities. Vpu is a 16 kD integral membrane protein produced from a 
Rev-dependent bicistronic vRNA that also encodes the Env polyprotein and has at least 
two major functional roles during HIV-1 replication.  First, Vpu induces the proteosomal 
degradation of the primary HIV-1 receptor CD4 molecules that are retained in the ER; a 
function most likely to prevent super-infection of the host cell as well as to counteract the 
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ability of CD4 to inhibit virus release and to interfere with the Env incorporation (8, 29, 
146, 190).  The second role for Vpu during viral replication is to regulate nascent particle 
release from the host cell surface (238).  Vpu modulates particle release by antagonizing 
the cellular protein Tetherin, also known as B cell stromal factor 2 (BST2).  In the 
absence of Vpu, Tetherin causes the accumulation of fully mature viral particles on the 
cell exterior.  The mechanism of how Tetherin inhibits virus release has not been clearly 
defined. The prevailing model is that Tetherin physically tethers viral particles to the cell 
membrane as a dimer, interacting with both the cell and the virus (8, 146, 238).  Also not 
clearly understood is the mechanism by which Vpu counteracts the antiviral activity of 
Tetherin; whether Vpu promotes the degradation, internalization or sequestration of the 
cellular protein continues to be investigated (8, 146, 238).  Nonetheless, it is clear Vpu is 
required for enhanced particle release in the presence of Tetherin.  
 Nef is a membrane-associated, 27 kD phosphoprotein critical for HIV-1 viral 
infectivity and disease progression.  There are three major functions that have been 
reported for Nef during viral replication:  1) down-regulation of CD4 and major 
histocompatability complex I (MHC I) expression from the host cell surface, 2) 
enhancement of virus infectivity, and 3) modulating T cell activation pathways (108, 116, 
320).  Nef mediates the down-regulation of CD4 and MHC I by triggering the rapid 
internalization and endosomal degradation of the proteins at the cell surface.  The 
mechanism by which Nef enhances viral infectivity is not fully understood, however, has 
been proposed the small number of Nef proteins incorporated into nascent virions may 
promote viral core penetration of the target cell by inducing cortical actin rearrangements   
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as well as activating reverse transcription.  Lastly, Nef has been shown to alter T cell 
activation pathways by modulating the activity of specific cellular kinases, a function 
suggested being important for viral persistence and pathogenesis. 
 The viral protein Vpr is incorporated at high levels into virus particles and has 
critical functional roles during viral infection (182).  Although still not clearly defined, 
Vpr is thought to have an important role in the localization of the HIV-1 PIC to the 
nucleus by promoting the binding of the PIC to cellular importins and nucleoporins.  Vpr 
nuclear localization has been proposed to have other functions, including stimulation of 
HIV-1 LTR driven transcription and, the most widely described, ability to arrest infected 
cells in the G2 phase of the cell cycle (116, 182).  Furthermore, Vpr has been implicated 
as the direct effector of immune dysfunction and neurological and renal AIDS associated 
diseases (182).  However, the precise function of Vpr during viral replication remains to 
be determined.   
  
1.3.5 The Regulatory Proteins 
 The HIV-1 genome encodes two regulatory proteins, Tat and Rev, both of which 
are essential for virus replication.  The Tat protein, encoded by two exons in the tat gene, 
is necessary for the activation of RNA polymerase II (Pol II) transcription elongation of 
the viral RNA (116).  In the absence of Tat, Pol II is unable to complete viral RNA 
synthesis; instead, it proceeds only for a couple hundred nucleotides (or less) before it 
falls off (116, 173, 174).  Tat is able to activate successful elongation through its two 
functional domains, a tripartite activation domain and a RNA domain. The activation 
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domain includes a stretch of acidic amino acids at the N-terminus, a cystine-rich region 
and a hydrophobic core that are critical in the recruitment of the TAK (Tat-associated 
kinase, P-TEFb, CDK9/ cyclin T1 complex) complex to TAR element found in all vRNA 
transcripts (116, 173, 174).  The RNA domain contains an 8 nt Lys/Arg-rich (nt 48-57) 
region that binds to the bulge region in TAR.  Tat is recruited to the transcription 
complex and binds to the TAR in the viral RNA and forms a ternary complex with TAK, 
inducing activation of the TAK complex (116, 173, 174).  Activated TAK phosphorylates 
the carboxy terminal domain (CTD) of Pol II, which improves processivity by several 
orders of magnitude.  
 The regulatory protein Rev is a 116 amino acid nuclear-cytoplasmic shuttling 
protein essential for virus replication.  Rev contains two functional domains, an arginine 
rich motif (ARM) and an effector domain, both of which are necessary to mediate the 
main function of Rev, the nuclear export and expression of intron-containing vRNAs 
(reviewed in (47, 155, 260)). The ARM domain not only confers sequence-specific 
binding to the RRE, a stem-loop structure located within the intron-containing vRNAs, it 
also contains overlapping nuclear and nucleolar localization signals (NLS, NoLS) (66, 
212, 214).  The ARM domain is flanked by two oligomerization domains which mediate 
Rev multimerization, a requirement for Rev activity (93, 294, 342).  The effector domain 
contains a leucine-rich nuclear export signal (NES) that interacts with the cellular 
proteins CRM1, Ran-GTP and other cofactors to facilitate export of intron-containing 
RNAs (13, 106, 174).  In addition to its role in the export of intron-containing vRNAs, 
there is increasing evidence to support functional roles for Rev in the cytoplasmic 
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localization and translation of these vRNAs as well as in the enhancement of gRNA 
encapsidation (reviewed in (141)).  Furthermore, Rev-dependent vRNA expression and 
regulation has been demonstrated to be tremendously complex, involving a growing list 
of host cellular factors (224, 330). 
 
1.4 Post-transcriptional Regulation of HIV-1 Gene Expression 
 HIV-1 produces a primary transcript (pre-mRNA) from the integrated proviral 
genome that encodes all the necessary information to generate every viral component for 
infectious particle production (111, 116, 266). To ensure the necessary balance of vRNA 
expression from the pre-mRNA, HIV-1 exploits a variety of cellular mechanisms to 
orchestrate proper vRNA processing, export and utilization for infectious particle 
production.  Thus, HIV-1 employs strategies that involve a dynamic interactome between 
vRNA, viral proteins and cellular co-factors that is initiated during vRNA transcription 
and continues through the cytoplasmic fate of the vRNA (139, 141, 174, 224, 330). 
 
1.4.1  HIV-1 RNA Processing 
 Similar to cellular primary transcripts, HIV-1 pre-mRNA undergoes a series of 
modifications prior to their export, such as capping, 3’ end processing and 
polyadenylation.  To carry out these post-transcriptional processes, HIV-1 usurps the host 
cellular machinery.  Importantly, in order to produce the full range of vRNAs needed for 
viral protein expression and infectious virus production from pre-mRNA, HIV-1 must 
utilize alternative splicing mechanisms (111, 116, 266). The process of alternative 
splicing of both cellular mRNA and vRNA is quite complex and still being elucidated.  
 30
Nonetheless, a basic description is that the 5’ splice donor site found within the pre-
mRNA is recognized by the cellular splicing component U1 snRNP, while the 3’ splice 
site is recognized by U2 snRNP in combination with the splicing factor U2AF65/35 to 
mediate excision of the intron.  Most strains of HIV-1 pre-mRNA contain five splice 
donor sites and seven splice acceptor sites, thus providing variable usage, leading to the 
production of over 40 different transcripts during replication (Figure 1-4) (116, 167, 174, 
224).   
 The production of such a vast number of alternative transcripts is attributed to the 
inefficient splicing of imperfect splice acceptor site (174, 224).  In addition, the 
efficiency of the splice sites used during HIV-1 pre-mRNA splicing has been shown to be 
influenced by cellular factors binding to adjacent sequences (49, 174, 224).  These 
regulatory sequences can either enhance or inhibit cellular factor binding and functions 
are known as exonic and intronic splicing enhancers (ESE, ISE) and exonic and intronic 
splicing silencers (ESS, ISS).  Recent research has provided a more detailed 
understanding of which factors bind to these elements in HIV-1 pre-mRNA to regulate 
viral transcript production, however full understanding of the complexity of regulation is 
far from being realized (49, 174, 224).  For example, Zahler et al. identified an 
overlapping ESE and an ESS located within tat exon 2 which was required for regulating 
the upstream intron. They demonstrated that heterogeneous nuclear ribonucleoprotein A1 
(hnRNP A1) protein binds the ESS to repress splicing, while the SR protein SC35 binds 
the ESE to activate it, thus proposing that hnRNP A1 and SC35 compete for binding to 
the element such that binding of one protein masks the binding site for the other (341). 
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Figure 1-4. HIV-1 viral RNA splicing and export.  (A) Organization of the HIV-1 
genome. (B)  Location of the splice sites and the Rev responsive element (RRE). 5' splice 
sites: D1a-5 and 3' splice sites: A1-7. (C) Splicing patterns, the proteins they encode and 
their mode of export. The 1.8 kb and 4 kb classes of vRNAs contain obligatory sequences 
(dark grey) and alternative sequences (light grey) due to different splice site usage. 
Completely spliced vRNA do not contain the RRE therefore their export is Rev- 
independent, through the Tap/NXF1 mRNA export pathway. Nuclear export of the 
partially spliced and full-length vRNA is dependent on Rev binding to the RRE (shown) 
and shuttling through the CRM1/Exportin1 pathway.  Adapted from Kammler, A. et. al. 
Retrovirology. (2006). 
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 As a result of alternative splicing, HIV-1 produces viral transcripts that contain 
one or all of its introns. However, transcripts that contain introns are typically retained in 
the nucleus for further processing or degraded (235).  Thus, HIV-1 must overcomethis 
nuclear retention for intron-containing vRNAs for export and expression. 
 
1.4.2  HIV-1 RNA Export 
 After transcript processing, vRNAs are exported for expression.  As described in 
section 1.2 of this chapter, there are two export pathways for HIV-1 vRNA, a Rev-
independent and Rev-dependent pathway (Figure 1-4).  Viral transcripts that are fully 
spliced, which encode the regulatory proteins Tat, Rev, and Nef, are exported via the 
Tap/NXF1 pathway, typical for cellular mRNAs, are Rev-independent.  However, 
vRNAs that contain introns must overcome cellular mechanisms preventing their 
transport.  Although it is not fully understood, nuclear retention of intron-containing 
vRNAs has been attributed to partial spliceosome assembly and specific sequences 
intrinsic to these vRNAs, which are likely bound by certain cellular factors to restrict 
export (167, 224).  HIV-1 overcomes this nuclear retention by the viral protein Rev, 
which functions to export the intron-containing vRNAs through the CRM1 export 
pathway, a pathway used for ribosome subunit, U snRNA and 5S rRNA export.  This 
pathway for intron-containing vRNAs is termed Rev-dependent.   
 Although it well established that Rev mediates intron-containing vRNA export, it 
is less clear whether Rev also directly inhibits splicing of these vRNAs (56, 73, 139, 155, 
213, 260).  It has been shown that HIV-1 suboptimal splicing is necessary for Rev-
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mediated export, several splicing factors bind to Rev and Rev function may require 
partial binding of splicing factors to intron-containing vRNAs, thus suggesting Rev may 
inhibit splicing (56, 179, 262).  However, it has also been reported that the ratios of 
intron-containing vRNAs to completely spliced vRNAs in the nucleus were unchanged in 
the presence or absence of Rev (105, 215).  Rather, investigators observed a lack of 
cytoplasmic intron-containing vRNAs, thus suggesting Rev does not alter splicing 
patterns but instead only participates in the export of the intron-containing vRNAs. 
 A simple model to describe Rev-mediated export is as follows: Rev binds to the 
RRE in a sequence-specific manner, multimerizes along the vRNA and this complex 
formation causes the NES of Rev to then be exposed. CRM1 and RanGTP (Ras-related 
nuclear protein, guanosine triphosphate) are recruited to the Rev-vRNP complex, which 
then interacts with nuclear pore proteins while trafficking through the nuclear pore to the 
cytoplasm.  Once in the cytoplasm, RanBP1 (Ran binding protein 1) and RanGAP (Ran 
GTPase activating protein) convert RanGTP to RanGDP (Ras-related nuclear protein, 
guanosine diphosphate) causing vRNP export complex disassembly.  After Rev releases 
its cargo, Importin β binds to the NLS of Rev and interacts with RanGDP to mediate the 
transport of Rev back into the nucleus through the nuclear pore (155, 260).  Although the 
export of the intron-containing vRNAs is directed by Rev, it is not exclusive to Rev; Rev 
has been demonstrated to coordinate with other cellular factors to mediate vRNA export 
and its nuclear import (reviewed in (224)).  RNA helicases DDX1 and DDX3 have been 
shown to associate with Rev and/or the vRNA (99, 273, 333, 336).  DDX1 has been 
suggested to modulate Rev nuclear localization and promote Rev binding to the RRE, and 
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thus may be important for Rev-mediated export.  DDX3 has been suggested to be central 
in Rev-vRNP complex release from the nuclear pore and mediate the cytoplasmic release 
of the vRNAs from the complex.  Other factors, such as Sam68 (Src-associated substrate 
during mitosis of 68 kD) and hRIP (human Rev-interacting protein), have also been 
shown to have a functional role in Rev-mediated export, either for cytoplasmic transport 
or release from the perinuclear space, respectively (201, 231, 278, 292, 338). However, 
the mechanistic details and importance of the aforementioned proteins, and others 
identified, during Rev-mediated export is still being elucidated.  
  
1.4.3 Rev-dependent vRNA Localization and Utilization 
 Increasing evidence suggests Rev-vRNP composition during RNA processing and 
export can dictate cytoplasmic utilization of the cognate vRNA which can be determined 
in the nucleus, at the nuclear pore or in the cytoplasm (2, 19, 58, 59, 60, 65, 71, 147, 206, 
209, 223, 228, 232, 233, 292).  The influence of vRNP composition for cytoplasmic 
localization and utilization has been particularly observed for full-length gRNA. The 
gRNA serves as an mRNA template for Gag and Pol polyprotein synthesis as well as the 
genome that is packaged into nascent virions.  Despite these multiple roles, HIV-1 is not 
known to have distinct pools of gRNA to select transcripts for translation or packaging 
(42). It has been suggested that Sam68 may enhance 3’ end processing of unspliced 
vRNA and mark the gRNA in the nucleus to promote cytoplasmic utilization (71, 223).  
The RNA helicase DDX24 has been shown to promote gRNA packaging (209).  
Moreover, hnRNP A2 and Staufen have been demonstrated to associate with the genomic 
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RNP, promoting gRNA trafficking and packaging (2, 19, 58, 59, 60, 228).  
 In addition to cellular proteins, Rev has also been suggested to have a functional 
role in cytoplasmic utilization of vRNAs (139, 141).  Several groups have shown Rev to 
enhance polysomal association of different intron-containing vRNAs, leading to their 
increased protein expression (11, 12, 76, 138, 141, 194, 256).  Intriguingly, cells 
expressing cytoplasmic NLS-deficient Rev mutants were unable to promote intron-
containing vRNA translation, thus indicating the translation enhancement function of Rev 
is determined in the nucleus (26, 237).  Furthermore, nuclear Rev-vRNP composition has 
also been implicated to mediate Rev enhancement of gRNA encapsidation (26, 35, 134, 
136). Überla et al. demonstrated that although a Rev-independent gagpol expression 
plasmid was efficiently expressed in the cytoplasm, it was inefficiently packaged; only 
when Rev was co-expressed with these transcripts was packaging enhanced (26, 35).  
However, the precise mechanism for Rev and vRNP components coordinating with Rev 
to promote gRNA packaging is presently unclear. 
 
1.4.4  HIV-1 and the Nucleolus 
 The eukaryotic nucleolus is most notably recognized as the site for ribosomal 
RNA (rRNA) synthesis, processing and ribosomal subunit assembly.  However, research 
over the past decade has demonstrated the nucleolus is multifunctional, involved in 
various aspects of cell biology, including cell stress sensing, cell cycle regulation and 
signal recognition particle biosynthesis (reviewed in (27, 245)).  Several of the proteins 
that function at various aspects of HIV-1 post-transcriptional gene regulation described 
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herein have also been found to localize to the nucleolus The proteins that have been 
identified include both viral and cellular proteins (7, 77, 271, 282, 294, 333).  As 
mentioned in section 1.3.5 above, the RNA binding domain of Rev also contains an 
overlapping NLS/NoLS, which mediates it predominate nucleolar localization (66, 155, 
156).  However, whether Rev nucleolar localization in necessary for function remains 
inconclusive.   
 It has been reported that Rev can induce the relocalization of CRM1 and Nup 98 
and Nup214, nucleoporins (Nups) suggested to be important for Rev-directed RNA 
export, from the nucleus to the nucleolus, which suggests that the formation of the Rev 
export complex occurs in the nucleolus (346).  Furthermore, studies indicate Rev can 
multimerize in the nucleolus and can actively bind and export a nucleolar targeted RRE 
when localized in this compartment, demonstrating Rev is functional while in the 
nucleolus (41, 70).  The cellular proteins DDX1, hnRNP A1 have also been demonstrated 
to localize to the nucleolus (99, 192). Importantly, the nucleolus has been implicated to 
be the site for vRNA localization. Collectively, these results suggest a nucleolar 
localization step for vRNA during HIV-1 replication. More specifically, the nucleolus 
may have a functional involvement in Rev-directed RNA export. 
 
1.4.4.1 HIV-1 Rev and Nucleophosmin/ NPM1 
 The nucleolar phosphoprotein Nucleophosmin (NPM1) is a ubiquitously 
expressed shuttling protein that has a role in numerous cellular activities regulated 
through the phosphorylation, acetylation, ubiquitylation, and SUMOylation of its 
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functional domains (117, 205, 241).  NPM1 has been demonstrated to bind both DNA 
and RNA, promote processing of RNA, prevent protein misfolding and interact with 
several RNA processing factors (205, 241).  NPM1 has also been identified to interact 
with HIV-1 Rev and has been suggested to be a Rev co-factor (100, 304, 305, 306). More 
specifically, several groups have shown Rev co-localizes with NPM1 in the nucleolus 
and in vitro analysis has demonstrated NPM1 directly interacts with Rev (91, 100, 151, 
229, 230, 304, 306).  Thus, it has been proposed NPM1 is the receptor mediating Rev 
nuclear import and/or nucleolar localization.  However, its precise role in Rev function 
has yet to be identified. 
 
1.5 Scope of Thesis 
 Although the nucleolus has been implicated to have a role during HIV-1 viral 
replication, its precise function has not been elucidated.  In this thesis I present findings 
to support a functional involvement of the nucleolus during viral replication.  My 
research addresses whether there is Rev-mediated nucleolar localization for intron-
containing vRNAs prior to export.  Moreover, I investigate whether NPM1 participates in 
Rev nucleolar localization and function and/or has a post-transcriptional role during viral 
replication.  Since the viral protein Rev and the expression of intron-containing vRNAs 
are required for the production of infectious virus, establishing the functional 
involvement of the nucleolus during this process would not only enhance our current 
understanding of HIV-1 replication but could potentially provide new mechanistic 
insights, possibly leading to alternative therapeutic strategies. 
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CHAPTER II: MATERIALS AND METHODS 
 
2.1  Cell culture 
2.1.1  HeLa, 293T, TZM-bl and HeLa-LAV cell line derivation and culture 
 HeLa, 293T (American Type Culture Collection, ATCC), TZM-bl and HeLa-
LAV cell lines (obtained through the NIH AIDS Research & Reference Program, 
Division of AIDS, NIH:  TZM-bl from Dr. John C. Kappes, Dr. Xiaoyun Wu and 
Tranzyme Inc. and HeLa-LAV from Dr. Joerg Berg and Dr. Matthias Walb)  The HeLa 
cell line is derived from human cervical epithelial cells (127). 293T cells are a derivative 
of the 293 human embryonic kidney epithelial cell line that carries the Simian 
Vacuolating Virus 40 (SV40) large T antigen. Expression of SV40T antigen allows for 
episomal replication of transfected plasmids containing the SV40 origin and the 
production of high titers of retrovirus (132, 255).  TZM-bl cells are a HeLa-derived 
indicator cell line that can be used in quantitative analysis of HIV-1. These cells express 
the receptor CD4 and co-receptors CCR5 and CXCR4 on the cell surface and contain 
integrated copies of the luciferase and β-galactosidase reporter genes that are under the 
transcriptional control of the HIV-1 promotor (43, 259, 308, 328).  HeLa-LAV cells are a 
HeLa-derived cell line that is stably infected with the HIV-1BRU (LAV) strain, thus 
produce all viral proteins and release infectious virus particles (17, 18).  Cells were 
maintained in 1X Delbecco Modified Eagle Medium (DMEM; Invitrogen) supplemented 
with 3.7 g/L sodium bicarbonate, 2.0 g/L HEPES [4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid], 10% fetal bovine serum (FBS; BioWhittiker) and 0.5% 
Penicillin/Streptomycin (Pen/Strep; Invitrogen) at 37˚C and 5% carbon dioxide (CO2).   
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2.1.2 Primary human monocyte-derived macrophages (MDM) 
 Elutriated primary human monocytes were obtained from the University of 
Massachusetts Medical School CFAR Core.  Cells were differentiated into macrophages 
by culturing in 1.5 mL of 1X DMEM supplemented with 10% human AB male serum 
(SeraCare Life Sciences), 1% L-glutamine (Invitrogen) and 10 ng/mL of monocyte-
colony stimulating factor (M-CSF; R&D Systems) in 6-well plates at a density of 1.25 x 
106 cells per well for 4 days at 37˚C and 5% CO2.  On day 5, 1 mL of fresh media 
without M-CSF (referred to as macrophage media) was added to each well. 
 
2.2 Plasmids 
pCMV-βgal:  a mammalian reporter plasmid expressing high levels of β-galactosidase, 
an internal control in experiments to monitor transfection efficiency.  This reagent is 
commercially available from Clontech (cat. no. 631719). 
pGFP-NPM1:  a plasmid that expressed wild type, full length mammalian NPM1 fused 
 to the enhanced green fluorescent protein (EGFP, GFP; a kind gift from Dr. 
 Brunangelo Falini (97, 98)). 
pGFP-NPM1MutA:  a plasmid that expresses a mutant form of mammalian NPM1, a 
duplication of  TCTG at positions 956-959 of the reference sequence.  This frame 
shift causes amino acid changes (addition and replacements) at the C-terminal of the 
protein and results in a dominant-negative phenotype (a kind gift from Dr. 
Brunangelo Falini (97, 98)). 
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pBC12/CMV/IL-2: a plasmid that expresses secreted human interleukin-2 (IL-2) under 
the control of the cytomegalovirus (CMV) promotor and was used as a control.  This 
reagent was a kind gift from Dr. Bryan R. Cullen (74). 
pCX4pur: a retroviral cloning vector (Accession no. AB086386) carrying the 
 puromycin N-acetyl-transferase (pac) gene from Streptomyces that confers cells 
 expressing the vector resistant to puromycin.  This reagent was a kind gift from Dr. 
 Heinrich Gottlinger. 
pcRev:  a plasmid that expresses the viral protein Rev from the HXB3 strain of HIV-1 
 IIIB.  This expression construct is derived from pBC12/CMV/IL2 in which IL-2 was 
 excised from the Hind III and Xho I sites and replaced with Rev cDNA.  This reagent 
 was a kind gift from Dr. Bryan R. Cullen (214). 
pHEF-VSV-G: a plasmid that expresses the Vesicular Stomatitis Virus Envelope 
 Glycoprotein G (VSV-G) and was used to pseudotype HIV-1 particles. This reagent 
 was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, 
 NIH from Dr. Lung-Ji Chang (57). 
pMLVgagpol:  a plasmid that expresses the Moloney murine leukemia virus Gag and 
 Pol proteins.  This reagent was a kind gift from Dr. Heinrich Gottlinger.  
pNL4-3:   a chimeric proviral clone that expresses full-length, replication and infection 
 competent virus (NY5 and LAV HIV-1 strains).  This reagent was obtained through 
 the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH from Dr. Malcolm 
 Martin (4). 
pNL4-348,71: a proviral clone derivative of pNL4-3 that contains two G:A point 
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 mutations at positions 48 and 71 of the 234 nucleotide Rev-Response Element (RRE) 
 which results in increased binding affinity of Rev to the RRE (16).  This construct 
 was generated from pNL4-3 using the QuikChange site-directed mutatgenesis kit 
 (Stratagene) with oligonucleotides: (forward) 5’-
 CAGGAAGCACTATGGACGCAGCGTCAATGACGCTGACGATACAGGCCAG
 ACAAT-3’ and  
 (reverse) 5’- 
 ATTGTCTGGCCTGTATCGTCAGCGTCATTGACGCTGCGTCCATAGTGCTTC
 CTG-3’.   
 The coding sequence of the resultant plasmid was validated by Sanger sequencing. 
pNL4-3∆env: a proviral clone derivative of pNL4-3 derivative containing two tandem 
 premature stop codons in the Env reading frame and therefore lacks Env expression 
 (a kind gift  from Dr. Adonia L. Kim). 
pNL4-3∆Rev: a proviral clone derivative of pNL4-3 that contains a premature stop codon 
 at amino acid 12 in the Rev open reading frame therefore prohibiting Rev expression, 
 rendering the provirus replication incompetent (a kind gift from Dr. Marie-Louis 
 Hammarskjöld (36)).    
pRev-GFP: a plasmid that expresses the HIV-1 viral protein Rev fused to GFP.  The Rev 
 protein lacks the last six amino acids of the C-terminal and is followed by an Asp-
 Ala-Gln-Glu peptide linker and GFP (a kind gift from Dr. Barbara Felber (294)).  
pTZ18U:    an empty plasmid used as carrier DNA for transfections.  This reagent was a 
 kind gift from Dr. Heinrich Gottlinger.  
  43   
 
 
 
                                                                                                                                                 
 
  
2.3 Virus production 
 Viral stocks of VSV-G pseudotyped NL4-3, NL4-348,71, NL4-3∆Rev or NL4-3∆env 
were produced in 293T cells by transient transfection using the calcium phosphate 
method. Cells were seeded on 10 cm tissue culture dishes at 50-60% confluence in 
antibiotic-free 1X DMEM 24hrs prior to transfection. The following day, each 
transfection reaction was set up as follows: 10 μg of pHEF-VSV-G and 10 μg of either 
NL4-3, NL4-348,71, NL4-3∆Rev or NL4-3∆env was diluted in sterile water with the addition 
124 μL of calcium phosphate up to total volume of 1 mL.  1 mL of 2X HEPES Buffered 
Saline [50 mM HEPES pH 7.05, 10 mM KCL, 12 mM Glucose, 250 mM NaCl, 1.5 mM 
Na2HPO4] was added drop-wise to the DNA mixture as it was being vortexed,  and 
incubated at room temperature for 10 minutes.  Culture media was replaced with 8 mL of 
fresh antibiotic-free 1X DMEM supplemented with 4 μL of 25 mM chloroquine per plate 
before the drop-wise addition of the transfection reaction then cells were maintained at 
37˚C, 5% CO2.  After 14-to 16hrs, cells were washed twice with 1X Phosphate Buffered 
Saline (PBS) and fresh antibiotic-free 1X DMEM was added. Culture supernatants were 
collected at 48hrs post-transfection, clarified by centrifugation at 1200 rpm for 5 minutes 
at room temperature, then aliquoted and stored in liquid nitrogen until used. 
 
2.4 Virus titer and infectivity assay 
2.4.1 Virus titer 
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 Virus stock titers were determined as follows: TZM-bl cells were seeded in 48-
well dishes at a density of 2.0 x 104 cells per well in antibiotic-free 1X DMEM one day 
prior to infection.  The next day, virus stock was thawed at 37˚C.  300 μL was transferred 
to a sterile tube to start three subsequent 10-fold serial dilutions made up to a total 
volume of 300 μL in serum-free media. Cell monolayers were inoculated in duplicate 
with 100 μL of serum-free 1X DMEM, virus or diluted virus for 3hrs prior to the addition 
of 400 μL of serum-free 1X DMEM to each well.  At 48hrs post infection, culture media 
was removed, cells washed twice in 1X PBS and fixed with 0.5% gluteraldehyde in 1X 
PBS for 10 minutes at 4˚C.  Fix solution was then removed and cells were washed twice 
in 1X PBS/0.05% sodium azide and stored in solution until assayed for β-galactosidase 
(β-gal) activity.  To determine virus titer, TZM-bl cells were stained for 2hrs at room 
temperature with 200 μL of 0.5 mg/mL 5-Bromo-4-chloro-3-indolyl-β-D-
galactopyranocide diluted in a 1X PBS, 3 mM potassium ferricyanide, 3 mM potassium 
ferrocyanide, 1 mM magnesium chloride solution.  Viral titer (Infectious Units per μL) 
for each stock was determined by counting the number of β-gal expressing cells (blue 
cells) in duplicate wells.  
 
2.4.2 Virus infectivity assay 
 The infectivity of virus produced from siRNA treated and/or infected HeLa cells 
(Chapter IV) was determined using the same protocol detailed above for determining 
virus titer with one exception: instead of undiluted virus, equivalent reverse-transcriptase 
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activity units in a total volume of 300 μL were used for infection and to prepare the three 
subsequent 10-fold serial dilutions. 
 
2.5 Virus infection 
 Prior to infection, HeLa, TZM-bl or MDM cells had culture media removed and 
were washed 3 times in 1X PBS.  Cells were either uninfected (media only) or infected 
with VSV-G pseudotyped virus diluted in antibiotic-free 1X DMEM.  Cells were infected 
at a multiplicity of infection (MOI) 1 or 4, as determined by section 2.4, for 4hrs at 37˚C, 
5% CO2.  At 4hrs post infection, culture media was removed, cells were washed 3 times 
in 1X PBS and fresh antibiotic-free 1X DMEM was added.  Cells were maintained at 
37˚C, 5% CO2 for the duration of the experiments. 
 
2.6 Reverse transcriptase (RT) activity assay 
 Culture supernatants were lysed with 0.5% Triton X100 in 0.25 M Tris, pH 7.4 
and assayed in triplicate for the quantification of reverse transcription activity. For each 
reaction, 10 μL supernatant and 10 μL of solution A [100 mM Tris-HCL pH 7.9, 300 mM 
potassium chloride, 10 nM dithiothreitol, 0.1% Igepal CA-630] was mixed in a 96-well 
round bottom plate and incubated at 37˚C for 15 minutes.  Next, 25 μL of solution B [50 
mM Tris-HCL pH 7.9, 150 mM potassium chloride, 5 mM dithiothreitol, 15 mM 
magnesium chloride, 0.5% Igepal CA-630, 10 μg/mL polyadenylic acid, 5  μg/mL oligo-
dT15, 10 μCi [3H]-dTTP/mL] was added, mixed and incubated overnight at 37˚C.  
Reactions were blotted onto 2.3 cm DE81 Whatman ion exchange filter disks, air dried, 
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washed twice in 2X SSC [0.3 M sodium chloride, 0.03 M sodium citrate] on a shaker 
table for 5 minutes and rinsed briefly in 100% ethanol.  Air dried filter disks were placed 
into scintillation vials and 5 mL of Ecoscint scintillation fluid (National Diagnostics) was 
added.  A Beckman Coulter LS6500 Scintillation Counter was used to detect and measure 
tritium counts per minute (cpm) for 2.5 minutes per vial.   To calculate percent virus 
production, the mean cpm for each infection condition within each experiment was first 
determined and subtracted from the mean cpm of each corresponding sample lacking 
virus. The adjusted cpm mean was normalized to the Mock condition within the 
experiment to obtain the resulting percentage.  Data graphs represent the total mean 
percent virus production from the indicated number of experiments in the figure legends 
± Standard Error of the Mean (SEM).  Multiple student T-test was used for statistical 
analysis (GraphPad Prism6). 
 
2.7 Western blot analysis 
2.7.1 HeLa, TZM-bl, HeLa LAV and HeLa-derived stable cell lines  
 Culture media was removed by aspiration, cells were washed 3 times in 1X PBS, 
then a volume of 1X PBS was added to each culture vessel: 500 μL per well of a 6-well 
plate or 1mL per 60 mm2 and 10 cm2 dish.  Adherent cells were removed using a plastic 
cell scraper and collected by pipette into a 1.5 mL microfuge tube.  500 μL more of 1X 
PBS was added to each culture vessel and collected into the microfuge tube.  Cells were 
maintained on ice.  Next, cells were pelleted by centrifugation at 3000 rpm for 3 minutes 
at room temperature, supernatants were removed by aspiration, and whole cell lysates 
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were prepared by re-suspending cells in either lysis buffer [0.5% Triton X100, 0.25 M 
Tris, pH 7.4] or 1X RIPA buffer [100 mM Tris-HCL, pH 7.4, 300 mM NaCL, 2% NP-40, 
1% Sodium deoxycholate, 0.2% SDS (Boston BioProducts)] and incubating on ice for 15 
to 30 minutes. Solubilized proteins were clarified by centrifugation at 14000 rpm and 
supernatants were transferred to new tubes.  Total protein concentration of cell lysates 
were determined using colormetric Bradford assays (BioRad). A total protein 
concentration of 12.5 μg of each lysate (unless otherwise noted in a specific material and 
methods subsection) was resolved on a 12% SDS-polyacrylamide gels and transferred to 
a nitrocellulose membrane (BioRad) using a semi-dry blotter. Membranes were 
subsequently blocked in Blotto (10% dry milk in 1X TBST buffer [25 mM Tris, 150 mM 
NaCl, 2 mM KCl, pH 7.4, and 0.1% Tween-20]) at room temperature for 1 hour, then 
incubated with primary antibody diluted in Blotto overnight at 4˚C.  Primary antibodies 
used include: mouse monoclonal antibodies directed against NPM1 (Sigma, cat. no. 
B0556, diluted 1:10,000), HIV-1 Gag (NIH AIDS Research and Reference Reagent 
Program, cat. no. 183-H12-5C, diluted 1:500), HIV-1 Nef (NIH AIDS Research and 
Reference Reagent Program, cat. no. 1539, diluted 1:1000), GFP (Roche, cat. no 
11814460001, diluted 1:500), FLAG (Sigma, cat. no. F4042) and rabbit or goat 
polyclonal antibodies directed against Sam68 (Santa Cruz Biotechnology, cat. no. sc-333, 
diluted 1:1000), human Actin (Santa Cruz Biotechnology, cat no. sc-1616, diluted 1:500), 
and hRIP (Santa Cruz Biotechnology, cat. no. sc-1424, dilution 1:500). Following three 5 
minute washes in 1X TBST buffer, membranes were incubated with sheep anti-mouse 
(GE Healthcare, cat. no. NA931), donkey anti-rabbit (GE Healthcare, cat. no. NA934), or 
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donkey anti-goat (Santa Cruz Biotechnology, cat. no. SC2056) secondary antibodies 
conjugated to horseradish peroxidase (diluted 1:5000) for 1hr at room temperature. 
Membranes were washed 3 times for 5 minutes in 1X TBST and protein expression was 
visualized using enhanced chemiluminescence (Amersham Biosciences).  Multiple 
protein expression profiles were detected from a single membrane by a strip and reprobe 
process.  Briefly, membranes were washed 3 times in 1X TBST, incubated with Restore 
Stripping Buffer (Thermo Scientific) for 10 minutes at room temperature, followed by 3 
washes in 1X TBST, then Western blotting proceeded as described. 
 
2.7.2 MDM 
 Western blotting of MDM lysates followed the same protocol detailed above with the 
following exceptions: culture media and 1X PBS were manually removed by serological 
pipette instead of aspiration, cells were lysed directly in the culture vessels with lysis 
buffer [0.5% Triton X100, 0.25 M Tris, pH 7.4] rather than by cell scraping and lysates 
were not clarified by centrifugation. 
 
2.8 siRNA transfections 
2.8.1 HeLa, TZM -bl, HeLa-LAV and HeLa-derived stable cell lines 
 Cells were seeded on 6-well plates at a density of 7.25 x 104 cells per well (unless 
otherwise noted under a specific material and methods subsection) in antibiotic-free 1X 
DMEM 24hrs prior to siRNA transfection. Cells were transfected using Oligofectamine 
reagent (Invitrogen) according to manufacturer’s protocol for 6-well culture dishes, with 
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reagent alone (Mock), 5 nM of Allstars Negative Control siRNA, a validated control 
siRNA duplex with no known homology to any mammalian gene (siANC; Qiagen cat. 
no. 1027281), or 5 nM of human nucleophosmin 1 (NPM1)-specific siRNA duplexes 
(siNPM1; Qiagen) at time 0-and 24hrs. Treatment with siNPM1 is an equimolar mixture 
of 2.5 nM of two validated NPM1-specific siRNA duplexes with the following 
sequences: Hs_ NPM1_7 siRNA: sense strand 5’-AGGUGGUUCUCUUCCCAAATT-3’ 
and antisense strand 5’-UUUGGGAAGAGAACCACCUTT-3’.  Hs_NPM1_8 siRNA: 
sense strand 5’-UGUCUGUACAGCCAACGGUTT-3’ and antisense strand 5’-
ACCGUUGGCUGUACAGACATT-3’.  An alternative control siRNA used was 5 nM of 
siScr (Qiagen).  Treatment with siScr is an equimolar 2.5 nM mixture of two validated 
scrambled sequences analogous to the Hs_ NPM1_7 and Hs_NPM1_8 target siRNAs 
with no known homology to any mammalian gene and the following sequences: 
NPM_7Scr: sense strand 5’-UGAACACUUAAGGUGCCAUTT-3’ and antisense strand 
5’-AUGGCACCUUAAGUGUUCAAG-3’.  NPM1_8Scr: sense strand 5’-
UAUGUAACUAACCGUGGCATT-3’ and antisense strand 5’-
UGCCACGGUUAGUUACAUAGC-3’.  Cells were maintained at 37˚C, 5% CO2 for the 
duration of the experiment. 
 
2.8.2 MDM 
 Primary human monocytes were differentiated to MDM as described above in 
section 2.1.  On day 6, cell culture media was collected in a 50 mL conical tube and 
diluted in half with fresh macrophage media [1X DMEM, 10% human AB male serum, 
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1% L-glutamine] to make a 50/50 conditioned media; meanwhile, cells were washed 
once with 1X PBS using a serological pipette and subsequently Mock transfected or 
transfected with either 10 nM of siANC or 10 nM siNPM1 using Lipofectamine 2000 
reagent (Invitrogen) and a modified protocol.  Briefly, for each siRNA reaction 10 nM of 
siRNA was diluted in Opti-MEM I media (Invitrogen) to a total volume of 500 μL in a 
1.5 mL microfuge tube.  In a separate tube for each reaction, 5 μL of Lipofectamine 2000 
was diluted in 495 μL of Opti-MEM I media and incubated at room temperature for 5 
minutes.  Next, the diluted Lipofectamine 2000 was combined with the diluted siRNA 
reactions, mixed, and incubated at room temperature for 20 minutes.  Each 1 mL reaction 
mixture was then added directly to cells and incubated at 37˚C, 5% CO2 for 4hrs.  The 
transfection reactions were subsequently removed from cells using a serological pipette, 
washed once with 1X PBS, and 1.5 mL of 50/50 conditioned media was added.  Cells 
were maintained at 37˚C, 5% CO2 for the duration of the experiment. 
 
2.9 In situ hybridization and indirect immunofluorescence microscopy  
 Several experiments described in this thesis had slight method variations for in 
situ hybridization and indirect immunofluorescence microscopy analysis and are 
described below.  For all experiments, cells were visualized using a Zeiss Axioplan 2 
wide-field fluorescence microscope equipped with a 63x Plan Apochromat objective and 
standard fluorescence filters.  Images were captured and analyzed using Open Lab 2.2.5 
software. 
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2.9.1 Chapter III: Rev localization in HeLa LAV and provirus transfected HeLa cells 
 Cells were seeded on 10 cm2 culture dishes containing 4 cover slips at a density of 
7 x 105 cells per plate in antibiotic-free 1X DMEM 24hrs prior to transfection.  HeLa 
LAV cells remained untreated. While HeLa cells were either transfected with reagent 
alone (Mock) or 3 μg of either pNL4-3, pNL4-3ΔRev or pNL4-348,71 and 1.5 μg of 
pCMVβ-gal using FugeneHD (Roche) transfection reagent according to the 
manufacturer’s protocol at the 3:2 FugeneHD to DNA ratio.  24hrs later, culture 
supernatants were collected and assayed for RT activity as described in section 2.6, cells 
were collected, lysed and analyzed by Western blotting as described in section 2.7 and  
cover slips were placed into 6-well culture dishes, washed 3 times in 1X PBS, then fixed 
with 2 mL of ice cold 100% methanol for 5 minutes.  Following fixation, cells were 
washed 3 times with 1X PBS, twice with 70% ethanol, and stored at 4˚C in 70% ethanol 
until stained.  Next, cover slips were washed 3 times in 1X PBS for 10 minutes/wash, 
incubated with 1% Bovine Serum Albumin (BSA) in 1X PBS for 1hr, then incubated 
with an anti-Rev mouse monoclonal primary antibody (Santa Cruz cat. no. sc-69729) 
diluted at 1:200 in 1% BSA/1X PBS for 1.5hrs.  Cells were subsequently washed 3 times 
in 0.1% BSA/1X PBS for 10 minutes/wash, and incubated with Alexa Fluor 488 goat 
anti-mouse secondary antibody (Life Technologies, cat. no. A11001) diluted in 1% 
BSA/1X PBS at 1:1500 for 1hr, covered in foil. Following antibody incubation, cover 
slips were washed twice in 1X PBS for 5 minutes and incubated with DAPI [4’, 6-
DiamidinO-2-phenylindole] at a dilution of 1:10,000 from a 10 mg/mL stock solution in 
1X PBS for 5 minutes.  Excess DAPI was removed by washing twice in 1 X PBS for 5 
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minutes followed by a wash in double distilled water (ddH20) for 20 minutes. All steps 
described were carried out at room temperature while rocking on a shaker table.  Finally, 
cover slips were mounted onto slides with Prolong Gold Antifade Reagent (Invitrogen, 
cat. no. P36930) and sealed with clear nail lacquer.  Slides were dried overnight in the 
dark and stored in a slide box at 4˚C until used. 
  
2.9.2 Chapter III: Rev-dependent viral RNA (vRNA) localization 
 HeLa cells were seeded on 10 cm2 culture dishes containing 4 cover slips at a 
density of 7 x 105 cells per plate in antibiotic-free 1X DMEM 24hrs prior to infection.  
Cells were infected with VSV-G pseudotyped NL4-3, NL4-3ΔRev or NL4-348,71 virus as 
described in section 2.5 at a MOI of 1.  At 6-, 12-, 24-, or 30hrs culture supernatants were 
collected and assayed for RT activity as described in section 2.6.  Cells were collected, 
lysed and analyzed by Western blotting as described in section 2.7.  And cover slips were 
placed into 6-well culture dishes, washed 3 times in 1X PBS, then fixed [2% 
paraformaldehyde, 1 mM Magnesium Chloride, 1X PBS] for 15 minutes at room 
temperature, washed 3 times with 70% ethanol and stored in 70% ethanol at 4˚C until 
stained.  Cells on cover slips were first rehydrated by washing twice in 1X PBS and then 
pretreated in hybridization solution [0.2X SSC, 1 mg/ml BSA, 30% deionized 
formamide, 10% dextran sulfate, 0.1 mg/mL herring sperm DNA, 0.1 mg/mL tRNA] 
sealed with parafilm for 1hr at 37˚C.  Cover slips were further incubated in the dark with 
hybridization solution containing 100-150 ng of Cy3-conjugated (Amersham) RRE-
specific oligonucleotide probe complimentary to nucleotides 7796-7872 of the HIV-1 
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NL4-3 strain (Accession no. M19921) or Cy3-conjugated gag-pol-specific 
oligonucleotide probe complimentary to nucleotides 2462-2553 of the HIV-1 NL4-3 
strain, sealed with parafilm for 1hr at 37˚C.  Excess hybridization solution was removed 
and cover slips were placed into 6-well culture dishes where they were subsequently 
incubated twice for 30 minutes in hybridization solution in the dark at 37˚C.  Cover slips 
were then washed once in 2X SSC, 20% deionized formamide for 30 minutes followed 
by one wash in 1X SSC, 20% deionized formamide, two washes in 1X SSC and one wash 
in 1X PBS, for 15 minutes each at room temperature.  Cells were blocked in 1% BSA/1X 
PBS overnight at 4˚C with rocking.  The next day, cells were incubated in primary 
antibody, either anti-fibrillarin (abcam, cat. no. 18380, dilution 1:500) or anti-NPM1 
(dilution 1:500), diluted in 1% BSA/1X PBS for 1hr in the dark at room temperature.  
Cover slips were then washed 3 times in 0.1% BSA/1X PBS for 10 minutes per wash and 
incubated in Alexa Fluor 488 conjugated goat anti-mouse secondary antibody at a 1:1500 
dilution in 1% BSA/1 XPBS for 1hr, at room temperature. Following antibody 
incubation, cover slips were washed twice in 1X PBS for 5 minutes and incubated with 
DAPI at a dilution of 1:10,000 from a 10 mg/mL stock solution in 1X PBS for 5 minutes.  
Excess DAPI was removed by washing twice in 1 X PBS for 5 minutes followed by a 
wash in ddH20 for 20 minutes. Lastly, cover slips were mounted onto slides with Prolong 
Gold Antifade Reagent and sealed with clear nail lacquer.  Slides were dried overnight in 
the dark and stored in a slide box at 4˚C until used. 
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2.9.3 Chapter III: Visualizing NPM1 depletion in HeLa cells 
 HeLa cells were seeded on 60 mm2 culture dishes at a density of 16.5 x 104 cells 
per plate in antibiotic-free 1X DMEM 24hrs prior to siRNA transfection.  Cells were 
either untreated or transfected using Oligofectamine reagent according to the 
manufacturer’s protocol with reagent alone (Mock) or 5 nM of siNPM1 at time 0 and 
24hrs. At 24hrs post siRNA treatment, cells were washed 3 times with 1X PBS, 
trypsinized, and collected in 8 mL of antibiotic-free 1X DMEM for re-seeding.  A 
volume of 1 mL of cells were re-seeded in triplicate onto cover slips in 6-well plates and 
brought to a final volume of 3 mL with media to be analyzed by indirect 
immunofluorescence microscopy.  A volume of 4 mL of cells were re-seeded onto 60 
mm2 culture dishes to be analyzed by Western blotting.  The next day, cells were washed 
3 times in 1X PBS.  Cells collected for Western blotting were harvested and processed as 
described in section 2.7 (a total protein concentration of 25 μg per lysate per analysis). 
Cover slips were fixed [4% paraformaldehyde, 1 mM Magnesium Chloride, 1X PBS] for 
15 minutes at room temperature, washed 3 times with 70% ethanol and stored in 70% 
ethanol at 4˚C until used.  Cover slips were washed twice in 1X PBS for 20 minutes, 
permeabolized [0.1% Triton X-100, 1X PBS] for 5 minutes, washed twice in 1X PBS for 
5 minutes and finally incubated with 1% BSA/1X PBS overnight at 4˚C. The next day, 
cover slips were incubated with a mouse monoclonal anti-NPM1 primary antibody 
diluted in 1% BSA/1X PBS at 1:500 for 2hrs.  Cover slips were subsequently washed 3 
times in 0.1% BSA/1X PBS for 10 minutes and incubated with Alexa Fluor 488 goat 
anti-mouse secondary antibody diluted in 1% BSA/1X PBS at 1:1500 for 1hr. Following 
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antibody incubation, cover slips were washed twice in 1X PBS for 5 minutes and 
incubated with DAPI at a dilution of 1:10,000 from a 10 mg/mL stock solution in 1X 
PBS for 5 minutes.  Excess DAPI was removed by washing twice in 1 X PBS for 5 
minutes followed by a wash in ddH20 for 20 minutes. All steps described were carried out 
at room temperature with rocking.  Lastly, cover slips were mounted onto slides with 
Prolong Gold Antifade Reagent and sealed with clear nail lacquer.  Slides were dried 
overnight in the dark and stored in a slide box at 4˚C until used. 
 
2.9.4 Chapter III:  Effect of NPM1 depletion on Rev intracellular localization 
  The same protocol detailed above in Visualizing NPM1 depletion in HeLa cells 
was used to analyze the effect of NPM1 depletion on Rev intracellular localization with 
the following exceptions:  at 10hrs after the second siRNA transfection cells were washed 
3 times in 1X PBS, trysinized, and 8.85 x 104 cells were re-seeded in triplicate onto cover 
slips in 6-well plates while 8.85 x 104 cells were re-seeded in duplicate on 6-well plates 
without cover slips for analysis by Western blotting.  The day after re-seeding, cells were 
washed 3 times in 1X PBS, fed 3 mL of fresh antibiotic-free 1X DMEM, then transfected 
with 1 μg of pBC12/CMV/IL-2 (Mock) or  1 μg pRev-GFP for each siRNA treatment 
condition using FugeneHD reagent according to the manufacturer’s protocol at the 3:2 
FugeneHD to DNA ratio. Cover slips were fixed and cells were harvested for indirect 
immunofluorescence analysis and Western blotting, respectively, at 24-and 48hrs post-
DNA transfection. 
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2.9.5 Chapter IV: Effect of NPM1 depletion on vRNA intracellular localization  
 HeLa cells were seeded on 60 mm2 culture dishes at a density of 16.5 x 104 cells 
per plate in antibiotic-free 1X DMEM 24hrs prior to siRNA transfection.  The next day, 
cells were transfected with siRNA as described in section 2.8. At 10hrs past the second 
siRNA transfection, cells were washed 3 times in 1X PBS, trysinized, and 8.85 x 104 
cells were re-seeded in triplicate onto cover slips in 6-well plates while the remaining 
cells were re-seeded onto 60 mm2 culture dishes without cover slips for analysis by 
Western blotting.  The day after re-seeding, cells were washed 3 times in 1X PBS, fed 3 
mL of fresh antibiotic-free 1X DMEM, then were either uninfected or infected with 
VSV-G pseudotyped NL4-3 virus at an MOI of 4 as described in section 2.5.  At 24hrs 
post infection, culture supernatants were collected and assayed for RT activity as 
described in section 2.6, cells were collected, lysed and analyzed by Western blotting as 
described in section 2.7.  Cover slips were washed 3 times in 1X PBS, then fixed [4% 
paraformaldehyde, 1 mM Magnesium Chloride, 1X PBS] for 15 minutes at room 
temperature, washed 3 times with 70% ethanol and stored in 70% ethanol at 4˚C until 
used.  Cells on cover slips were rehydrated by washing twice in 1X PBS, then pretreated 
in hybridization solution [0.2X SSC, 1 mg/ml BSA, 30% deionized formamide, 10% 
dextran sulfate, 0.1 mg/mL herring sperm DNA, 0.1 mg/mL tRNA for cells to hybridize 
with an RRE-specific, gag-pol-specific probes; 40% deionized formaldehyde was used 
for hybridization with env-specific and GAPDH-specific probes] sealed with parafilm for 
1hr at 37˚C.  Cover slips were incubated in the dark with hybridization solution 
containing 100-150 ng of a Cy3-conjugated RRE-specific oligonucleotide probe, a Cy3-
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conjugated gag-pol-specific oligonucleotide probe, a Cy3-conjugated env-specific 
oligonucleotide complimentary to nucleotides 6432-6503 of the HIV-1 NL4-3 strain, or 
Cy3-conjugated human glyceraldehyde-3-phoshate dehydrogenase (GAPDH)-specific 
oligonucleotide complimentary to nucleotides 121-179 of the mRNA (Accession no. 
M17851) and sealed with parafilm for 1hr at 37˚C.  Excess hybridization solution was 
removed and cover slips were placed into 6-well culture dishes and incubated for 60 
minutes in hybridization solution in the dark at 37˚C.  Cover slips were then washed once 
in 2X SSC, 20% deionized formamide for 30 minutes followed by one wash in 1X SSC, 
20% deionized formamide, two washes in 1X SSC and one wash in 1X PBS, for 15 
minutes each at room temperature.  Cells were blocked in 1% BSA/1X PBS overnight at 
4˚C with rocking.  The next day, cells were incubated in anti-NPM1 primary antibody 
diluted 1:500 in 1% BSA/1X PBS for 3hrs in the dark at room temperature.  Cover slips 
were washed 3 times in 0.1% BSA/1X PBS for 10 minutes per wash and incubated in 
Alexa Fluor 488 conjugated goat anti-mouse secondary antibody at a 1:1500 dilution in 
1% BSA/1 XPBS for 1hr at room temperature.  Following antibody incubation, cover 
slips were washed twice in 1X PBS for 5 minutes and incubated with DAPI at a dilution 
of 1:10,000 from a 10 mg/mL stock solution in 1X PBS for 5 minutes.  Excess DAPI was 
removed by washing twice in 1 X PBS for 5 minutes followed by a wash in ddH20 for 20 
minutes. Lastly, cover slips were mounted onto slides with Prolong Gold Antifade 
Reagent and sealed with clear nail lacquer.  Slides were dried overnight in the dark and 
stored in a slide box at 4˚C until used. 
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2.10 Chloramphenicol aceytltransferase (CAT) activity assays 
 HeLa cells were seeded on 6-well plates at a density of 7.25 x 104 cells per well in 
antibiotic-free 1X DMEM 24hrs prior to siRNA transfection.  Cells were transfected 
using Oligofectamine reagent according to manufacturer’s protocol with reagent alone 
(Mock), 5 nM of siANC, or 5 nM siNPM1 at time 0hrs and 24hrs.  At 24hrs post siRNA 
treatment, cells were washed 3 times in 1X PBS, fed 3 mL of fresh antibiotic-free 1X 
DMEM, then transfected with 2 μg of plasmid DNA using FugeneHD transfection 
reagent according to the manufacturer’s protocol at the 3:2 FugeneHD to DNA ratio.  
Cells were transfected with 2 μg of pBC12/CMV/IL-2 (Mock), 1 μg of pCMV128 and 1 
μg pBC12/CMV/IL-2, or 1 μg of pCMV128 and 1 μg pcRev in the absence or presence 
of each siRNA.  At 24-or 48-hrs post-transfection, cells were washed with 1X PBS, 
scraped and collected in 1 mL of 1X PBS into microfuge tubes.  Cells were pelleted by 
centrifugation at 3000 rpm for 3 minutes at room temperature, supernatants were 
removed, lysed in 100 μL of lysis buffer (0.5% Triton X-100 in 0.25 M Tris pH 7.4) and 
incubated on ice for 15 minutes.  Supernatants were separated from cellular debris by 
centrifugation at 14,000 rpm for 10 minutes at 4˚C and transferred to new microfuge 
tubes.  Total protein concentration of cell lysates was determined using colormetric 
Bradford assays.  A total protein concentration of 12.5 μg of each lysate was resolved on 
a 12% SDS-PAGE gel, transferred to a nitrocellulose membrane, then analyzed with anti-
NPM1 and anti-Actin antibodies as described in section 2.7.  A total protein 
concentration of 15 μg of each lysate was aliquoted to new tubes, volume adjusted to 30 
μL with lysis buffer then assayed for CAT enzyme activity.  The assay mixture 
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containing 100μL of 0.25 M Tris pH 7.4, 0.1 μCi of  [14C] Chloramphenicol, 30 μL of 5 
mg/mL Acetyl Coenzyme A, 4 μL of 80% glycerol, 20 μL of water and 30 μL of lysate, 
was incubated at 37˚C for 90 minutes.  Reactions were stopped by the addition of 400 μL 
of ethyl acetate, vortexed, and centrifugated for 2 minutes at 14,000 rpm at room 
temperature.  The organic layer was removed, air dried to a pellet, resuspended in 10 μL 
of ethyl acetate, spotted on a silica gel thin-layer plates and assay products were resolved 
using thin layer chromatography and autoradiography (342). To calculate the mean 
percent acetylation of each sample, the total percent of conversion of each point was first 
determined and then subtracted from the total percent acetylation of each corresponding 
sample lacking Rev using densitometric analysis using Image J software.  A randomized 
block one-way ANOVA was used for statistical analysis at each time point (GraphPad 
Prism6). 
 
2.11 p24 enzyme-linked immunosorbent assay (ELISA) 
 The quantification of HIV-1 p24 protein present in MDM culture supernatants 
obtained 24-and 48hrs post infection, was performed using a p24 ELISA kit (UMMS 
CFAR Core) according to the provided protocol.  Culture supernatants were diluted in 
macrophage media [1X DMEM supplemented with 10% human AB male serum, 1% L-
glutamine] to ensure measurement within the linear range of the assay. For each 96-well 
plate assay, a four-point calibration curve was prepared in duplicate from the provided 
p24 standard while two dilutions of each sample were assayed in duplicate.  Protein 
concentration of the 96-well pate was determined by measuring the absorbance of each 
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well at 450/570 nm using a Bio-Tek EL800 microplatereader.  The measured values were 
calculated and analyzed with KC Junior software (Bio-Tek Instruments).  To calculate 
percent p24 production, the mean value for each condition was determined and 
normalized to the Mock condition within the experiment to obtain the corresponding 
percentage. Data graphs represent the total mean percent p24 production from the 
indicated number of experiments indicated in the figure legends ± SEM.  Multiple student 
T-test was used for statistical analysis (GraphPad Prism6). 
   
2.12 Development of NPM1 siRNA-resistant expressing stable cell lines 
2.12.1 Generation of GFP-NPM1 siRNA resistant plasmids 
  Wild type pGFP-NPM1 was used to generate the pGFP-NPM1 siRNA-resistant 
clones.  Silent mutations were introduced using the QuikChange site-directed 
mutagenesis kit according to the manufacturer’s protocol, and the following primers: 
NPM7siR_2 (forward) 5’-
GTATAGAAAAAGGTGGCAGCTTGCCCAAAGTGGAAGCC-3’ and (reverse) 5’-
GGCTTCCACTTTGGGCAAGCTGCCACCTTTTTCTATAC; NPM7siR_6 (forward) 
5’- GCAAGTATAGAAAAAGGCGGCAGCTTGCCTAAGTGGAAGCCAAATTC-3’ 
and (reverse) 5’-
GAATTTGGCTTCCACTTAGGCAAGCTGCCGCCTTTTTCTATACTTGC-3’; 
NPM18siR_4 (forward) 5’-
GCAACTTTGAAAATGAGCGTGCAACCAACGGTTTCCC-3’ and (reverse) 5’- 
GGGAAACCGTTGGTTGCACGCTCATTTTCAAAGTTGC-3’; NPM18siR_8 
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(forward) 5’-GCAACTTTGAAAATGAGCGTGCAACCCACGGTTTCCCTTGG-3’ and 
(reverse) 5’-CCAAGGGAAACCGTGGGTTGCACGCTCATTTTCAAAGTTGC-3’.  
The mutations within each expression construct were validated by Sanger sequencing.  A 
diagram of the GFP-NPM1 siRNA-resistant clones and the silent mutations is shown in 
Figure 2-1.  The GFP-NPM1 siRNA-resistant plasmids were cloned into the pCX4pur 
expression vector via the EcoRI and NotI restriction enzyme sites.  The EcoRI and NotI 
restriction enzyme sites were introduced into GFP-NPM1 siRNA-resistant plamids using 
the TOPO® XL PCR Cloning Kit (Life Technologies) and PCR primers GFP-EcoRI 
(forward) 5’-GATCGAATTCATGGTGAGCAAGGGCGAGGA-3’ and NPM1-NotI 
(reverse) 5’-GATCGCGGCCGCTTAAAGCTTCCTCCA-3’.  The resultant mutant 
expression vectors were verified using Sanger sequencing. 
 
2.12.2 Retrovirus production and generation of stable cell lines 
 To generate GFP-NPM1 siRNA-resistant expressing viruses, 293T cells were 
seeded on 60 mm2 culture dishes at a density of 1.2 x 106 cells per plate in antibiotic-free 
1X DMEM 24hrs prior to transfection. The following day, cells were transfected by 
calcium phosphate method as described in section 2.3, with transfection reactions that 
included 2 μg of GFP-NPM1 siRNA-resistant plasmid, 2 μg of pMLVgagpol, 1.5 μg of 
pHEF-VSV-G and 2.5 μg of pTZ18U. Culture supernatants containing the virus were 
collected and stored as described in section 2.3 at 48hrs post-transfection.  To generate 
the GFP-NPM1 siRNA-resistant stable cell lines, HeLa cells were seeded on 60 mm2 
culture dishes at a density of 2.8 x 105 cells per plate in antibiotic-free media 24hrs prior 
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to infection.  The next day, cells were infected with 1.5 mL of culture supernatants 
containing the GFP-NPM1 siRNA-resistant expressing viruses with 0.5 mL of antibiotic-
free 1X DMEM for 6hrs, washed 3 times in 1X PBS then 2 mL of fresh antibiotic-free 
1X DMEM media was added.  Selection with 1 μg of puromycin/ml in 1X DMEM was 
initiated 24hrs after infection.  Pooled, stably transduced cells were maintained in 1X 
DMEM containing 1 μg of puromycin/ml, replaced every 48hrs, at 37˚C, 5% CO2. 
 
2.13 NPM1 reconstitution experiments 
 HeLa and HeLa-derived NPM1 siRNA-resistant stable cells were seeded on 6-
well plates at a density of 7.25 x 104 cells per well in antibiotic-free 1X DMEM 24hrs 
prior to siRNA transfection.  The next day, cells were treated with reagent alone (Mock), 
siANC or siNPM1 as described in section 2.8.  At 24hrs post siRNA treatment, cells were 
washed 3 times in 1X PBS and either uninfected or infected with VSV-G pseudotyped 
NL4-3 virus at an MOI of 4 as described in section 2.5. Culture supernatants were 
collected and assayed for RT activity as described in section 2.6 at 24-and 48hrs post 
infection. Cells were collected 48hrs post infection, lysed and analyzed by Western 
blotting as described in section 2.7.  To calculate percent virus production, the mean cpm 
for each infection condition within each experiment was first determined and subtracted 
from the mean CPM of each corresponding sample lacking virus. The adjusted cpm 
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Figure 2-1. Schematic representation of siNPM1 target regions and silent point 
mutations used to generate GFP-NPM1 siRNA-resistant clones and stable cell lines.   
(A)  Diagram of NPM1 functional domains and the siNPM1 target regions.  siNPM1 is an 
equivalent molar mix of two NPM1-specific siRNA duplexes. NPM1_7 targets 
nucleotides within amino acids (aa) 257-262 and NPM1_8 targets nucleotides within aa 
80-87, indicated by arrows.  Diagram adapted from Mitsuru Okuwaki. J. Biochem 
(2008).  (B)  Depicted are the four GFP-NPM1 siRNA-resistant clones generated (blue) 
and the silent mutations introduced (red) to confer resistance to the two NPM1-specific 
siRNA duplex target sequences (black). 
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mean was normalized to the HeLa Mock condition within the experiment by to obtain the 
percentage.  Data graphs represent the total mean percent virus production from the 
number of experiments indicated in the figure legends ± SEM.  Multiple student T-test 
was used for statistical analysis (GraphPad Prism6). 
 
2.14 Reverse transcription quantitative real-time polymerase chain reaction (RT-
qPCR) 
 HeLa cells were seeded on 6-well plates at a density of 7.25 x 104 cells per well in 
antibiotic-free 1X DMEM 24hrs prior to siRNA transfection.  The next day, cells were 
treated with reagent alone, siANC or siNPM1 as described in section 2.8.  At 24hrs post 
siRNA treatment, cells were washed 3 times in 1X PBS and either uninfected or infected 
with VSV-G pseudotyped NL4-3 virus at an MOI of 4 as described in section 2.5. At 24-
and 48hrs post infection, culture supernatants were collected and assayed for RT activity 
as described in section 2.6.  In addition, cells were washed with ice cold 1X PBS, 
trypsinized, and collected into RNase-free 1.5 microfuge tubes and kept on ice.  Cells 
were subsequently counted and 104 cells were aliquoted to separate tubes for RT-qPCR 
analysis.  Cells were washed, lysed, RNA isolated, RNA was reverse transcribed (RT) 
and cDNA amplified using the TaqMan Fast Cells-to-CT Kit (Life Technologies cat. no. 
4399003) according to the manufacturer’s recommended protocol, including the added 
XenoRNA control. Each 20 μL real-time PCR reaction contained 4 μL of cDNA or 
diluted standard, 10 μL of TaqMan Fast Universal PCR Master Mix, 5 μL of nuclease-
free water, and 1 μL of TaqMan Gene Expression Assay primer (Life Technologies) for 
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the detection of NPM1 (Hs023394979_g1), CLEC2D (Hs00203174_m1) or the DH10β 
diluted standard control (Ac00010015_a1) expression levels.  The TaqMan Cells-to-CT 
Control Kit (Life Technologies cat. no. 4386995) included Gene Expression Assay 
primers to detect the XenoRNA control target and the endogenous control gene β-actin 
(ACTB) expression levels. Real-time PCR reactions were assayed in duplicate. 
Amplification and fluorescence measurements were performed using the Applied 
Biosystems 7500 Fast Real-Time PCR System equipped with SDS v1.4 software under 
the following cycling conditions: 20 seconds at 95˚C followed by 40 cycles at 95˚C for 3 
seconds and 60˚C for 30 seconds.  Expression levels of the targeted cDNA were based on 
a standard curve generated from a DH10β control reference library (Life Technologies, 
cat. no. 4392545) serially diluted 10-fold for a range of 1 pg/μL to 0.001 pg/μL .  Data 
graphs represent the mean cDNA concentration (pg/μL) from one experiment ± SEM.   
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I conceived and performed all experiments presented in this chapter.  Nicholas P. Stone is 
credited for the Western blots depicted in Figure 3-6C and 3-7C, generated from lysates I 
provided. 
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CHAPTER III: THE ROLE OF THE NUCLEOLUS IN HIV-1 REV-DEPENDENT 
VIRAL RNA EXPORT 
 
3.1 Introduction 
 The eukaryotic nucleolus is a highly organized non-membrane bound 
compartment found in the nucleus with the primary function of ribosomal RNA (rRNA) 
synthesis, processing and ribosomal subunit assembly. The complex process of ribosomal 
biogenesis occurs within three distinct sub regions of the nucleolus: the fibrillar center 
(FC), where ribosomal RNA (rRNA) transcription takes place; the surrounding dense 
fibrillar component (DFC), where pre-rRNAs are processed and modified; and the outer 
region, the granular component (GC), where rRNAs are further processed and assembled 
into ribosomes (reviewed in (27, 316)).  Research over the past decade coupled with over 
700 identified nucleolar associated cellular proteins (6, 7, 200, 282) has demonstrated the 
nucleolus is more than a ribosome generator; it is a plurifunctional organelle with 
dynamic protein exchange involved in various aspects of cell biology, including cell 
stress sensing, cell cycle regulation and signal recognition particle biosynthesis (27, 245, 
328).   
 Since the nucleolus plays a central role in numerous cellular processes, it is then 
not surprising that the majority of viruses have been found to utilize the nucleolus and/or 
its associated proteins during viral replication (reviewed in (135, 152, 153, 327)).  Some 
viruses, such as the borna disease virus and the hepatitis delta virus, use the nucleolus as 
the site for viral RNA (vRNA) transcription and replication (159, 203, 267).  Others 
recruit nucleolar proteins to alternative locations for virus replication. For example, both 
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poliovirus and hepatitis C virus recruit nucleolin to the cytoplasm to stimulate translation 
(166, 324, 337), while upstream binding factor (UBF) is relocated to the DNA replication 
centers of adenovirus and herpes simplex virus 1 (193, 296). Furthermore, many viral 
proteins localize to the nucleolus either through interactions with nucleolar proteins 
and/or nucleolar localization signal(s) (NoLS) usually embedded within an overlapping 
nuclear localization signal (NLS) and RNA binding domain (RBD) (33, 66, 95, 184, 197, 
198, 269). 
 Nucleolar localization of viral proteins has been demonstrated to be functionally 
coupled to processes such as virus assembly, vRNA processing, genome packaging, 
ribonucleoprotein formation and vRNA export.  The adeno-associated virus (AAV) Cap 
(capsid) and Rep (replication) proteins localize to the nucleolus, where Cap assembles 
and interacts with nucleolar protein NPM1 (nucleophosmin 1, B23) through Rep, a step 
necessary for genome encapsidation and export (22, 171, 331).  Additionally, the 
influenza A NP (nucleoprotein) requires nucleolar localization for vRNA synthesis and 
ribonucleoprotein complex formation (250). A nucleolar trafficking step is also required 
for the herpesvirus saimiri nucleocytoplasmic shuttling protein ORF57 where it recruits 
human TREX (hTREX) proteins to the nucleolus for vRNA export (33).  Interestingly, 
when ORF57 nucleolar localization is abolished but RNA binding maintained, ORF57 is 
unable to export vRNA to the cytoplasm and this inhibition is rescued only when an 
alternative NoLS is introduced, thus suggesting vRNA processing and/or 
ribonucleoprotein export complex formation occurs in the nucleolus (33).  Similarly, the 
Kaposi’s sarcoma associated herpesvirus (KSHV) ORF57 homologue also requires 
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nucleolar trafficking for vRNA export (30, 32).  Moreover, there is evidence the KSHV 
ORF57 ribonucleoprotein complex formed in the nucleolus has additional roles 
downstream of export, in the enhancement of vRNA translation (31).   
 Nucleolar localization and trafficking has also been demonstrated to play a role in 
HIV-1 replication (77, 225, 226, 227, 346).  During replication, HIV-1 produces a long 
primary transcript, which is either further processed by splicing machinery to produce an 
intronless, fully spliced vRNA or retains some or all introns to produce partially spliced 
or unspliced transcripts, respectively.  All transcripts are exported from the nucleus; 
however the intron-containing vRNAs are exported through a distinct pathway requiring 
the viral protein Rev and are therefore termed Rev-dependent vRNA.  Several groups 
have reported HIV-1 vRNA localization within the nucleolus (46, 225, 274).  Romanov 
et. al. detected intron-containing subgenomic gag mRNA in transiently transfected HeLa 
cells constitutively expressing Tat by gold antibody labeling and in situ hybridization 
then visualized by electron and light microscopy respectively (274).  The nucleolar 
localization of vRNA was also detected by electron microscopy using in situ 
hybridization and several overlapping DNA probes of in vitro infected lymphocytes, a 
natural target of HIV-1 (46).  Perhaps the most compelling experiments, and the first to 
demonstrate a functional role for vRNA nucleolar localization, were performed by the 
Rossi group.  They reported that lymphocytes stably transduced with a nucleolar 
localized hammerhead ribozyme designed to site-specifically cleave a conserved region 
within all HIV-1 RNA transcripts inhibits HIV-1 virus production for sustained periods 
of more than a few weeks (225).  Together these results suggest a previously unidentified 
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nucleolar localization step for viral RNA during HIV-1 replication.  However, these 
experiments failed to distinguish the class(es) of viral RNAs that localize to the nucleolus 
or establish how their nucleolar localization is mediated.  Moreover, the temporal 
dependence of nucleolar localization of the vRNAs during replication has yet to be 
determined.    
 In addition to viral RNA localization to the nucleolus, it is well established that 
the essential HIV-1 protein Rev localizes to this compartment (66, 91, 155, 156, 212). 
Rev functions post-transcriptionally to control the nucleocytoplasmic export of the 
intron-containing unspliced and partially spliced viral RNA (155, 260).  Rev contains two 
functional domains, an arginine rich motif (ARM) and an effector domain, both of which 
are necessary to mediate export (155, 156, 212, 260).  The ARM domain not only confers 
sequence-specific binding to a stem-loop structure located within unspliced and partially 
spliced RNA, termed the Rev Response Element (RRE), it also contains the overlapping 
NLS/NoLS (66, 155, 156, 212).  The effector domain contains a leucine-rich nuclear 
export signal (NES) that interacts with the cellular proteins CRM1, Ran-GTP and other 
cofactors to facilitate export of RRE-containing RNAs (13, 21, 99, 106, 155, 201, 202, 
275, 336).  Several studies have reported that Rev can induce the relocalization important 
export factors CRM1, Nup98 (nucleoporins) and Nup214 from the nucleus to the 
nucleolus (70, 161, 178, 271, 346).  Furthermore, Rev multimerizes in the nucleolus and 
can actively bind and translocate a nucleolar targeted RRE when localized in this 
compartment, demonstrating Rev is functional while in the nucleolus (41, 70).  Therefore, 
it can be hypothesized that the nucleolus is the site for Rev export complex formation.  
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Taken together with the observation that viral RNAs may require a nucleolar localization 
step and the detection of intron-containing vRNA in the nucleolus of cells not producing 
virus extends this hypothesis to suggest that the nucleolus has a specific role in Rev-
mediated vRNA export.  This model is further supported by the observations that a 
nucleolar localized Rev binding peptide is able to inhibit HIV-1 replication by 
sequestering Rev export function (226).  However, although some studies have examined 
intron-containing vRNA localization in the presence or absence of Rev using fluorescent 
in situ hybridization in vivo, none used viral infection to monitor Rev influence on 
localization and none have detected the nucleolus (or regions within) as a localization 
point (195, 213, 343).  
  Rev nucleolar localization is mediated by an overlapping NLS/NoLS/RBD (aa 
positions 34 to 50, 5’ TRQARRNRRRRWRER 3’) (66, 155, 156).  Nucleolar 
accumulation occurs early after Rev expression (91) and requires continued synthesis of 
rRNA (75, 91).   Moreover, several studies have suggested that this nucleolar localization 
is dependent upon interaction with cellular NPM1 (100, 204, 229, 230, 294, 306). NPM1 
is an abundant, multifunctional nucleolar shuttling phosphoprotein that has nucleic acid 
binding (DNA and RNA), ribonuclease and molecular chaperone activities carried out by 
distinct functional regions (151).  Interaction of Rev with NPM1 has been mapped to a 
short sequence required for nucleolar localization in the NLS (aa 37-47) (304) while 
NPM1 interacts with Rev in its N terminal molecular chaperone region and a putative 
secondary site (305).  However, studies examining the NPM1: Rev interaction has been 
limited to in vitro analysis and in vivo reports have failed to demonstrate a direct 
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interaction (204, 229, 230, 304, 305, 306).  One model for Rev nucleolar localization is 
that NPM1 mediates the import of Rev from the cytoplasm to the nucleolus (100, 306).  
However, other cellular factors, including 5 importin β family member proteins and 
transportin, have also been identified in the role of binding REV NLS for nuclear import 
(10, 143, 148, 162, 315).  It has been suggested the use of transportin is the dominant 
mode for import (162), while other reports show import factor use is cell type dependent 
(143).  Thus, the role of NPM1: Rev interaction remains to be demonstrated.  More 
specifically, whether NPM1 mediates the nucleolar localization of Rev or has a role in 
the nucleocytoplasmic shuttling of Rev during Rev-mediated vRNA export has not been 
examined. 
  Here, I investigate whether the nucleolus is a site for intron- containing vRNA 
localization and/or plays a role in Rev-mediated vRNA export.  I have analyzed the 
temporal and intracellular distribution of vRNAs containing site-specific mutations in the 
RRE post-infection, using coupled fluorescence in situ hybridization and indirect 
immunofluorescence (FISH-IF). This experimental approach was also used to analyze the 
intracellular distribution of HIV-1 RNA in cells infected with wild type or Rev-deficient 
virus.  In addition, I have examined the role of NPM1 in the nucleolar localization of Rev 
and Rev-mediated vRNA export  in vivo using a RNA interference (RNAi)-based 
approach, a first utilizing this strategy.    
 
3.2 Results 
3.2.1 Localization of intron-containing viral RNA is coincident to the nucleolus and 
does not require Rev expression 
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 Studies have suggested nucleolar localization of HIV-1 vRNA is an essential step 
during viral replication (225). Although it has been speculated that Rev mediates intron-
containing vRNAs to the nucleolus prior to export, the identity of the vRNAs that 
localize to the nucleolus, how their nucleolar localization is mediated or the temporal 
dependence of nucleolar localization during replication has yet to be demonstrated. To 
investigate vRNA localization in the context of virus replication and the dependence of  
Rev on localization, I utilized a wild type proviral clone (pNL4-3), a proviral clone with 
two point mutations in the RRE that confers higher affinity Rev binding (pNL4-348,71) 
and a Rev-deficient provirus (pNL4-3∆Rev) expressed in HeLa cells (16, 36). To compare 
Rev localization in the context of viral replication, I used HeLa-LAV cells, a HeLa-
derived cell line that is stably infected with the HIV-1BRU (LAV) strain thus producing all 
viral proteins and releases infectious virus particles as a positive control (17, 18).  HeLa-
LAV cells were fixed in 100% methanol, immunostained for Rev and analyzed for the 
intracellular localization by indirect immunofluorescence microscopy.  I observed that 
Rev exhibited two localization phenotypes, either concentrated in the nucleolus or as 
punctae distributed in the cytoplasm, with a concentration near the perinuclear region, 
consistent with previous reports (Figure 3-1A) (91, 155).  Similar localization of Rev was 
observed in HeLa cells transfected with either pNL4-3 or pNL4-348,71, thus confirming 
proper Rev localization when these proviral clones were expressed (Figure 3-1B, second 
and third panel respectively). Rev was not detected in the reagent only (Mock) 
transfected negative control or in cells transfected with the Rev-deficient provirus (Figure 
3-1B top and bottom panel, respectively).  To further confirm the proviral clones were 
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Figure 3-1. Localization of Rev is both nucleolar and cytoplasmic in cells 
expressing virus. (A) HeLa-LAV cells were fixed in 100% methanol and immunostained 
for Rev (green) and the nucleus (blue) using an anti-Rev primary antibody followed by 
the Alexa Fluor (AF) 564-conjugated secondary antibody and DAPI, respectively.  Cells 
were analyzed by indirect immunofluorescence microscopy.  (B, C) HeLa cells were 
transfected with either reagent alone (Mock), a wild type proviral clone (pNL4-3), a 
proviral clone with a mutated RRE that confers higher affinity Rev-binding (pNL4-348,71) 
or a Rev-deficient provirus (pNL4-3∆Rev) and harvested 24hrs post transfection. (B) HeLa 
cells were fixed in 100% methanol and immunostained as described in A.  (C) Cell 
lysates were analyzed by Western blotting for the detection of the viral proteins Gag and 
Nef and endogenous Actin as a loading control using anti-Gag, anti-Nef and anti-Actin 
antibodies, respectively.   Data demonstrates two independent experiments. 
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transcribed and translated, cell lysates were also assayed for viral protein expression and 
analyzed by Western blot.  Intracellular Gag, a Rev-dependent viral protein, and Nef, a 
Rev-independent viral protein, were detected for both the wild type and RRE-mutated 
proviral expressing cells (Figure 3-1C).  Conversely, barely detectable levels of Gag and 
increased expression of Nef were observed in cells expressing the Rev-deficient provirus 
(Figure 3-1C).  This observation not only supports expression of pNL4-3∆Rev, it also 
suggests increased expression of fully spliced viral transcripts, an expected occurrence in 
the absence of Rev (104).  Collectively, these results demonstrate expression of the 
proviral and mutant clones, qualifying them for use in further experiments. 
 Next, I examined the temporal expression of Rev-dependent vRNA to determine 
the optimal time frame to detect these vRNAs distinctly in subcellular regions of the 
nucleus.  HeLa cells seeded on cover slips were uninfected, infected with VSV-G 
pseudotyped wild type or Rev-deficient virus. At 6, 12, 24 or 30hrs post infection cells 
were fixed and analyzed by FISH using a Cy3-conjugated RRE-specific DNA probe and 
visualized by fluorescence microscopy. I was able to detect intron-containing vRNA as 
early as 6hrs post wildtype infection as a single, bright nuclear focus in a small 
percentage of cells (Figure 3-2B top panel).  To my knowledge this is the first time RRE-
containing vRNA has been visualized this early in infected cells using a FISH technique.  
Similar bright, single nuclear foci of intron-containing vRNA were observed at 12hrs 
post infection, consistent with previous observations that also demonstrated these were 
active sites of vRNA transcription (Figure 3-2B second panel) (195, 343). By 24hrs more 
than one intron-containing vRNA nuclear foci could be detected in wild type infected 
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cells and they remained discrete and discernable in localization (Figure 3-2B third panel).  
Comparable localization was also observed at the same time point in the absence of Rev 
expression (Figure 3-2C top panel). Conversely, by 30hrs post-infection accumulation of 
intron-containing vRNA was detected in the cytoplasm and discrete nuclear foci was not 
observed in wildtype infected cells, demonstrating 30hrs as the saturation point for 
distinct vRNA foci detection (Figure 3-2B bottom panel).  This result is best represented 
in NL4-3∆Rev infected cells at 30hrs, where almost the entire nucleus is filled with intron-
containing vRNA (Figure 3-2C bottom panel).  It is important to note the absence of foci 
detection in the Mock infected cells, thus confirming the specificity of the probe (Figure 
3-2A). Collectively, these results demonstrate the earliest detection of intron-containing 
vRNA is 6hrs post infection, while 24hrs is the optimal time point to detect distinct 
nuclear vRNA foci, with vRNA nuclear saturation occurring 30hrs post infection. 
 After the time point of 24hrs for optimal discrete nuclear vRNA detection was 
determined, I examined whether these foci were localized in the nucleolus.   To this end, 
HeLa cells seeded on cover slips were uninfected, infected with a VSV-G pseudotyped 
wild type or Rev-deficient virus and fixed 24hrs post-infection, then analyzed by FISH 
followed by indirect immunofluorescence and visualized by fluorescent microscopy.   A 
Cy3-conjugated RRE-specific probe was used to detect the vRNA while an anti-
Fibrillarin primary antibody followed by an AF-488 conjugated secondary antibody was 
used to detect the nucleolus (Figure 3-3A). More specifically, the nucleolar protein 
Fibrillarin localizes to the fibrillar center (FC) and the dense fibrillar component (DFC) 
regions of the nucleolus (25, 245).  I detected distinct foci of intron-containing vRNA in 
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Figure 3-2. Localization of Rev-dependent vRNA can be detected as early as 6hrs 
post-infection as distinct foci in the nucleus.  HeLa cells were either uninfected (Mock; 
A), infected with VSV-G pseudotyped wild type virus (NL4-3; B) or infected with a 
VSV-G pseudotyped Rev-deficient virus (NL4-3∆Rev; C) at an MOI of 1 then fixed at the 
indicated time points in 2% paraformaldehyde/5 mM MgCl2/1X PBS.  Rev-dependent 
vRNA localization (red, foci indicated by arrows) was analyzed by fluorescent in situ 
hybridization using a Cy3-conjugated RRE-specific probe.  The nucleus (blue) was 
detected by DAPI.  Arrows indicate discrete vRNA foci detected in the nucleus.  Data 
shown is representative of multiple fields examined in one to two independent 
experiments. 
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close proximity to the FC and DFC, however these vRNAs did not co-localize with 
Fibrillarin, the marker for these regions (Figure 3-3A).  Moreover, this localization was 
not dependent on Rev expression, as a comparable localization of the vRNA was detected 
for both NL4-3 and NL4-3∆Rev (Figure 3-3A, compare middle and bottom panel).  
Importantly, there were no distinct Cy3-labeled foci detected in the Mock infected 
negative control cells, further demonstrating specific detection of vRNA (Figure 3-3A top 
panel).  Together, these results indicate that although distinct intron-containing vRNA 
foci do not localize to the FC or DFC of the nucleolus, they are in close proximity to 
these regions and this localization is independent of Rev expression.   
 To extend these results, I used a Cy3-conjugated gag-pol oligonucleotide probe to 
localize full-length vRNA in infected HeLa cells in the presence or absence of Rev 
expression (Figure 3-3B).  Since the Cy3-conjugated RRE-specific probe detects all 
transcripts containing the cis-acting element and my results support previous studies that 
the observed localization of distinct intron-containing vRNA foci are accumulation of 
nascent vRNA, then it would be likely that a gag-pol intron-specific probe would yield 
the same localization pattern as the RRE-specific probe (Figure 3-2) (180, 195). 
Therefore, HeLa cells were seeded on cover slips, then were mock infected or infected 
with VSV-G pseudotyped NL4-3 or NL4-3∆Rev virus, and fixed 24hrs post-infection. 
Cells were analyzed by FISH using a gag-pol RNA-specific probe, followed by indirect
immunofluorescence to detect Fibrillarin, and visualized by fluorescent microscopy. I 
observed the same discrete nuclear foci localized in close proximity to the DFC and FC 
that also did not co-localize with Fibrillarin in the presence or absence of Rev expression,
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Figure 3-3. Distinct foci of intron-containing vRNA localize in proximity to the 
FC and DFC of the nucleolus independent of Rev expression and do not co-localize 
with Fibrillarin.  HeLa cells were uninfected (Mock) or infected with a VSV-G 
pseudotyped wild type (NL4-3) virus or a Rev-deficient virus (NL4-3ΔRev) at an MOI of 
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1. At 24hrs post infection, cells were fixed with 2% paraformaldehyde/5 mM MgCl2/1X 
PBS and analyzed using coupled FISH- IF.  A Cy3-conjugated RRE-specific probe (A) or 
Cy3-conjugated gag-pol RNA-specific probe (B) was used to detect vRNA (red, foci 
indicated by arrows).  Immune detection of Fibrillarin (green) was performed using anti-
Fibrillarin primary antibody and an AF-488 conjugated secondary antibody.  The nucleus 
(blue) was detected by DAPI. Arrows indicate discrete vRNA foci detected in the 
nucleus.  Data shown is representative of multiple fields examined from one experiment. 
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which was detected using the RRE-specific probe (Figure 3-3C, compare middle and 
bottom panels and compare Figure 3-3B and Figure 3-3C).  Moreover, no Cy3-labeled 
foci were observed in the Mock infected negative control (Figure 3-3C, top panel).  
Therefore, these results further demonstrate the localization of distinct intron-containing 
vRNA foci is not dependent on Rev expression and are in close proximity to, but do not 
localize within, the FC or DFC of the nucleolus.  In addition, these results support the 
implication that these discrete foci of vRNA are nascent transcripts. 
 Although Rev-dependent vRNAs were not detected in the FC or the DFC of the 
nucleolus, they were localized in proximity to these areas, suggesting they may be 
located in the GC, the outermost region of the nucleolus.  To investigate this possibility, 
uninfected or infected HeLa cells were fixed 24hrs post infection then analyzed by FISH 
using the Cy3-conjugated gag-pol probe followed by indirect immunofluorescent staining 
for NPM1, an abundant nucleolar protein found in the GC, and visualized using 
fluorescent microscopy.  Again, I observed no detectable Cy3-labeled foci in the Mock 
infected negative control cells (Figure 3-4 top panel).  Conversely, bright, multiple, 
discrete foci of Rev-dependent vRNA were localized in close proximity to and adjoining 
NPM1 in HeLa cells infected with the wild type virus (NL4-3), the virus with a mutated 
RRE that confers higher affinity Rev binding (NL4-348,71) and the Rev-deficient virus 
(NL4-3ΔRev) (Figure 3-4) (16). These results illustrate three exciting insights. 
First, these results suggest that Rev-dependent vRNA may localize to the GC and/or with 
NPM1.  The second novel insight is that the possible nucleolar localization of the full-
length transcripts is not dependent on Rev expression.  This is demonstrated two-fold; 
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Figure 3-4. Distinct foci of intron-containing vRNA localize coincidently to the 
GC of the nucleolus and NPM1 independent of Rev expression.  HeLa cells were 
uninfected (Mock), infected with a VSV-G pseudotyped wild type (NL4-3) virus, a virus 
with a mutated RRE that confers increased affinity for Rev binding (NL4-348,71) or a Rev-
deficient virus (NL4-3ΔRev) at an MOI of 1. At 24hrs post-infection, cells were fixed with 
2% paraformaldehyde/5 mM MgCl2/1X PBS and analyzed using coupled FISH- IF using 
a Cy3-conjugated gag-pol RNA-specific probe to detect vRNA (red).  Immune detection 
of NPM1 (green) was performed using anti-NPM1 primary antibody and an AF-488 
conjugated secondary antibody.  The nucleus (blue) was detected by DAPI.  Arrows 
indicate coincident localization of vRNA foci coincident to the GC.  Data shown is 
representative of multiple fields examined from one experiment. 
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the localization of the Rev-dependent vRNA foci is similar in NL4-3 and NL4-3ΔRev 
infected cells and the localization of vRNA foci in NL4-348,71 infected cells is similar to 
both NL4-3 and NL4-3ΔRev (Figure 3-4).  More specifically, it has been previously 
demonstrated that the mutations in the RRE that enable increased Rev binding affinity to 
the RRE results in an increase of Rev export activity, measured by expression of a 
chloramphenicol acetyltransferase (338) reporter in transiently transfected cells (16).  
Therefore, one would expect the same mutations in the context of a viral infection would 
lead to increased export and accumulation of Rev-dependent vRNA in the cytoplasm 
resulting in increased virus production when compared to wild type virus.  I did observe 
an increase in virus production at 24hrs, measured by standard Reverse Transcriptase 
(RT) activity assay compared to wild type (data not shown).  However, the nuclear 
localization of the Rev-dependent vRNA was unchanged compared with Rev-dependent 
vRNA in wild type and the Rev deleted virally infected cells (Figure 3-4).  Therefore, 
these results suggest the coincident localization of intron-containing vRNA to the GC of 
the nucleolus does not require Rev expression.  Lastly, these results further support 
previous reports that the observed Rev-dependent vRNA foci are nascent transcripts.  
 
3.2.2 Depletion of cellular NPM1 does not effect Rev localization or Rev- mediated 
vRNA export 
 It is well established that Rev localizes to the nucleolus and studies have 
suggested this localization is mediated by the nucleolar shuttling protein NPM1, 
however, no reports have demonstrated a direct involvement of NPM1 in the localization 
of Rev in vivo.  To examine whether NPM1 alone mediates the nucleolar localization of 
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Rev in vivo, I employed an RNAi-based approach.  Initially, I determined whether 
NPM1-specific gene silencing could be achieved in HeLa cells.  Based on the results of 
my RNAi optimization, HeLa cells were either untreated, transfected with reagent only 
(Mock) or 5 nM of siNPM1 (Figure A1-1).  After 48hrs, cells were trypsinized, counted 
and seeded onto cover slips to be analyzed by indirect immunofluorescence for NPM1 
expression. A fraction of the counted cells were lysed and analyzed by Western blot for 
NPM1 and Actin protein expression.  I observed no substantial difference in cell death or 
cell cycle kinetics in HeLa cells treated with siNPM1 compared with cells untreated or 
Mock treated (Figure 3-5). Moreover, in untreated and Mock treated cells, NPM1 
exhibited similar concentrated localization in the GC of the nucleolus, seen as green 
ring(s), with detection to a lesser extent in the nucleus, consistent with previous reports 
(Figure 3-5A, top and middle panels) (245).  In contrast, siNPM1 treated cells revealed 
significant diminution in visible levels of cellular NPM1 in the GC and nearly absent 
detection in the nucleus (Figure 3-5A, bottom panel).  Depletion of NPM1 was confirmed 
by Western blot analysis.  Nearly undetectable levels of NPM1 were observed in the 
siNPM1 treated cells while similar NPM1 expression was evident in untreated and Mock 
treated cells (Figure 3-5B).  Collectively, these results demonstrate that I am able to 
achieve effective NPM1 depletion in siNPM1 treated cells.  
 To investigate whether depletion of NPM1 had an effect on Rev localization, I 
visualized the subcellular localization of Rev in cells transfected with the previously 
characterized, functional, enhanced green fluorescent protein fused to the C-terminal of 
Rev (pRev-GFP) in the absence or presence of NPM1-specifc siRNA (294).  Cells were 
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Figure 3-5. Efficient NPM1 depletion is achieved in siNPM1 treated cells.  HeLa 
cells were untreated or transfected with reagent alone (Mock) or 5nM of siNPM1.  Cells 
were harvested 72hrs post-siRNA transfection. (A) Cells were fixed in 4% 
paraformaldehyde/5 nM MgCl2/1X PBS and immunostained for NPM1 (green) and the 
nucleus (blue) using an anti-NPM1 primary antibody followed by the AF-488-conjugated 
secondary antibody and DAPI, respectively. (B) Cell lysates were analyzed by Western 
blotting for the detection of NPM1 and Actin using anti-NPM1 and anti-Actin antibodies, 
respectively. Data shown is representative of one experiment performed in triplicate. 
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Mock treated,  treated with a non-silencing control siRNA (siANC) or siNPM1 for 48hrs 
then seeded onto cover slips to be analyzed by indirect fluorescent microscopy or lysed to 
be analyzed by Western blotting for the expression of NPM1, Rev-GFP and Actin.  Cells 
were subsequently transfected with a control vector (pBC12/CMV/IL-2, Mock) or Rev-
GFP and harvested 24- or 48-hrs later. Nearly undetectable levels of NPM1 were 
observed in HeLa cells treated with siNPM1, whereas similar basal levels of NPM1 were 
observed in the Mock and siANC-treated cells after 24-and 48hrs (Figure 3-6 and Figure 
3-7).  Transfection of Mock or siANC and an expression vector did not effect NPM1 
intracellular localization or expression at any time point (Figure 3-6 and Figure 3-7).   In 
these treated cells, cellular NPM1 was observed predominately concentrated in the GC of 
the nucleolus with some nuclear localization, consistent with my previous observations 
(Figure 3-6A, B and Figure 3-7A, B).  Moreover, Rev-GFP was primarily visualized in 
the nucleolus and co-localized with NPM1 (Figure 3-6B top, middle panel and Figure 3-
7B top, middle panel).  However, despite almost complete reduction in intracellular 
NPM1 by siRNA treatment, demonstrated by Western blotting and indirect fluorescence 
microscopy, Rev-GFP retained its predominant nucleolar localization 24hrs and 48hrs 
after transfection (Figure3-6B and Figure 3-7B).  These results suggest that NPM1 is not 
required for nucleolar localization of Rev.  
 Although I found that depletion of NPM1 did not affect Rev nucleolar 
localization, it was unclear whether NPM1 participates in the nucleocytoplasmic shuttling 
of Rev during Rev-mediated vRNA export.  To determine whether NPM1 depletion has 
an effect on Rev-mediated vRNA export, I used a CAT reporter co-transfection assay to
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Figure 3-6. Depletion of cellular NPM1 by RNAi does not alter the localization of 
Rev 24hrs post-transfection.  (A, B) HeLa cells were transfected with reagent alone 
(Mock; A, B top panel), siANC (B middle panel) or siNPM1 (B lower panel). At 48hrs 
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post siRNA treatment, cells were transfected with a control plasmid (Mock; A) or a Rev-
GFP (pRev-GFP, green) expressing plasmid. Cells were fixed with 4% 
paraformaldehyde/5 nM MgCl2/1X PBS 24hrs after DNA transfection.  Cellular NPM1 
(red) was analyzed by indirect immunofluorescence with an anti-NPM1 primary antibody 
followed by an AF-546-conjugated secondary antibody as a reference for Rev-GFP 
localization and to demonstrate gene-specific knock down.  Cell nuclei (blue) were 
detected with DAPI. Images shown are representative of multiple fields examined in two 
independent experiments. (C) HeLa cell lysates from A and B were analyzed by Western 
blotting for Rev-GFP expression and NPM1 gene-specific knock-down using an anti-
GFP and anti-NPM1 antibody, respectively.  Actin was detected with an anti-Actin 
antibody as a total protein loading control.  Data shown is representative of two 
independent experiments. 
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Figure 3-7. Depletion of cellular NPM1 by RNAi does not alter the localization of 
Rev 48hrs post-transfection.   (A, B) HeLa cells were transfected with reagent alone 
(Mock; A, B top panel), siANC (B middle panel) or siNPM1 (B lower panel). At 48hrs 
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post siRNA transfection, cells were transfected with a control plasmid (Mock; A) or Rev-
GFP (pRev-GFP, green) expressing plasmid.  Cells were fixed with 4% 
paraformaldehyde/5 nM MgCl2/1X PBS 48hrs after DNA transfection.  Cellular NPM1 
(red) was analyzed by indirect immunofluorescence with an anti-NPM1 primary antibody 
followed by an AF-546-conjugated secondary antibody as a reference for Rev-GFP 
localization and to demonstrate gene-specific knock down.  Cell nuclei (blue) were 
detected with DAPI. Images shown are representative of multiple fields examined in two 
independent experiments. (C) HeLa cell lysates from A and B were analyzed by Western 
blotting for Rev-GFP expression and NPM1 gene-specific knock-down using an anti-
GFP and anti-NPM1 antibody, respectively.  Actin was detected with an anti-Actin 
antibody for a total protein loading control. Data shown is representative of two 
independent experiments. 
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monitor Rev activity (156, 157).  The CAT reporter plasmid (pCMV128) is derived from 
the env region of HIV-1.  Transcripts from pCMV128 do not encode any HIV-1 proteins, 
but do contain the RRE and the CAT coding sequence within a single intron.  When 
pCMV128 is expressed alone in cells, the intron contained in the transcripts is excised 
during RNA splicing, which leads to minimal to no measurable CAT enzyme activity in 
the cytoplasm.  However, when pCMV128 is cotransfected with a functional HIV-1 Rev 
expression vector (pcRev), Rev binds to the RRE present in the transcripts and exports 
the unspliced RNA to the cytoplasm which allows for the expression of CAT.  HeLa cells 
were either Mock, siANC, or siNPM1 treated for 48hrs then transfected with either a 
control vector or pCMV128 in the absence or presence of pcRev.  Cells were harvested 
and lysates were prepared 24- or 48hrs later then analyzed for CAT enzyme activity by 
thin-layer chromatography and protein expression by Western blotting.  My Western blot 
analysis data demonstrate efficient and specific NPM1 depletion was obtained in siNPM1 
treated cell lysates at both 24- and 48hrs, irrespective of transfected plasmid expression 
(Figure 3-8A, C).  In addition, I show the expression of NPM1 was comparable for the 
transfected Mock and siANC treated cell lysates at all time points (Figure 3-8A, C).  
Evaluation of CAT enzyme activity in cell extracts of Mock and pCMV128 DNA 
transfected cells also treated with Mock, siANC or siNPM1 revealed no detectable levels 
of expression at 24- and 48hrs (Figure 3-8A, B).  However, CAT enzyme activity was 
detected in cell lysates co-transfected with pCMV128 and pcRev at all time points.  I 
observed that despite efficient NPM1 depletion in siNPM1 treated pCMV128 and pcRev 
lysates, there was minimal reduction in acetylation activity compared to pCMV128 and 
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pcRev Mock and siANC treated lysates at 24hrs and 48hrs (Figure 3-8A, C, compare last 
lanes with two preceding lanes).  To compare the effect of NPM1 depletion on Rev 
activity, the total percent of acetylation in siRNA treated pCMV128 and pcRev cell 
lysates was quantified by densitometric analysis of the autoradiographs and found similar 
mean percent acetylation between cell treatment groups and time points (Figure 3-8B, D). 
Using a randomized block one-way ANOVA for statistical analysis, there was no 
significant difference in Rev-mediated vRNA export between treatment groups at 24- or 
48hrs (P= 0.1319 and P= 0.1355, respectively).  Therefore, these data suggest NPM1 
does not participate in nucleocytoplasmic shutting of Rev during Rev-mediated vRNA 
export.  
 
3.3 Discussion 
 In this study, I aimed to elucidate the currently undefined role the nucleolus has in 
Rev-dependent vRNA export.  Specifically, I investigated whether there is a Rev-
mediated nucleolar localization step of intron-containing vRNA prior to export.  
Moreover, I examined whether Rev nucleolar localization and function requires the 
nucleolar protein NPM1, a previously identified Rev co-factor.  I used a coupled 
fluorescence in situ hybridization and indirect immunofluorescence approach to visualize 
intron-containing vRNA in reference to the nucleolus of infected HeLa cells in the 
presence or absence of Rev expression.  Although several studies have examined Rev- 
dependent vRNA intracellular localization using this technique, none have selectively 
labeled the nucleolus for a reference or monitored Rev influence on vRNA localization 
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Figure 3-8. Depletion of NPM1 by RNAi does not affect Rev-mediated vRNA 
export. Functional analysis of Rev was determined by CAT enzyme activity in a 
transient transfection assay. HeLa cells were transfected with reagent alone (Mock), non-
silencing siANC or siNPM1.  At 48hrs post initial siRNA transfection, cells were either 
transfected with a control vector (Mock) or the CAT reporter plasmid pCMV128 in the 
absence (pCMV128) or presence of pcRev, a HIV-1 Rev expressing plasmid 
(pCMV128+pcRev).  Cell lysates were analyzed for CAT enzyme activity by thin-layer 
chromatography (A, C; top) and protein expression by Western blotting with anti-NPM1 
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(A, C; middle) and anti-Actin (A, C; bottom) antibodies at 24hrs (A) and 48hrs (C) after 
DNA transfection. (B, D) Comparisons of Rev-specific RNA export ability by 
quantification of chloramphenicol acetylation in the presence of siRNA duplexes.  The 
total percent of acetylation was determined by densitometric analysis of audioradiographs 
using the Image J software as described in the Material and Methods.  Bars represent the 
mean total percent of acetylation of four (B) and three (D) independent experiments ± 
standard error of the mean (SEM).  A randomized block one-way ANOVA was used for 
statistical analysis and determined non-significant (NS) P values at 24hrs (P= 0.1319) and 
48hrs (P= 0.1355).  Data shown in (A) and (C) is representative of four and three 
independent experiments, respectively. 
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during viral infection (20, 195, 285, 343). For example, one report utilized a transient 
cotransfection of Rev and subgenomic plasmid expression vectors (343) while another 
used a stable cell line expressing env mRNA with tetracycline-dependent Rev expression 
for vRNA localization (285). Consistent with these previous studies, I detected intron-
containing vRNA as intense, discrete foci in the nucleus (Figure 3-2B) (20, 195, 285, 
343).  These distinct intron-containing foci have been previously characterized as an 
accumulation of nascent viral transcripts (20, 195, 285, 343), with the earliest detection 
of intron-containing vRNA foci at 12hrs (195, 343).  I show for the first time localization 
of the Rev-dependent vRNA foci as early as 6hrs post infection (Figure 3-2B). My results 
also demonstrate that the intron-containing vRNA foci remain as discrete, bright foci up 
to 24hrs, with a saturation point of 30hrs post-infection (Figure 3-2B, also see Figure 3-3 
and 3-4).  Unlike one previous report, I did not observe a diffuse signal of intron-
containing vRNA in addition to the foci in the presence of Rev expression (Figure 3-2A, 
B) (285) .   
 Although I did not observe a discernable difference in the localization of the 
bright, intron-containing vRNA foci in the absence or presence of Rev expression or with 
a mutated RRE enabling higher Rev binding affinity, I observed coincident nucleolar 
localization of the intron-containing vRNA foci in these infected cells (Figure 3-3 and 
Figure 3-4). It is tempting to assign the localization of Rev-dependent vRNAs as a co-
localization to the GC of the nucleolus and/or with NPM1 (Figure 3-4).  However, since 
the localization of vRNA and cellular proteins are visualized using a Zeiss Axioplan 2 
wide-field fluorescence microscope and the images are taken in a single optical axis (Z) 
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and specimen plane (X and Y), the images lack sufficient serial spatial depth resolution to 
definitively conclude this nucleolar localization.  Electron microscopy in situ 
hybridization offers the ultrastructural resolution required for specific nucleolar 
localization.  Several studies have examined intron-containing vRNA localization using 
this method, however the results are inconclusive (46, 64, 274).  Two conflicting reports 
examine intron-containing vRNA localization in the absence or presence of Rev 
expression in transiently transfected cells, one observed nucleolar localization of intron-
containing vRNA in HL-Tat cells, while the other, using COS cells, did not (64, 274). 
Another study, using infected lymphocytes, detected intron-containing vRNA nucleolar 
localization, however they did not examine the dependence of Rev expression for Rev-
dependent vRNA localization (46).  A direct comparison of intron-containing vRNA 
localization during infection with my wild type, Rev-deficient or enhanced RRE-
containing virus using electron microscopy in situ hybridization might resolve these 
observed discrepancies and further strengthen my FISH results. 
 Of importance, my observation of discrete intron-containing vRNA foci at 
intranuclear localizations irrespective of Rev expression is consistent with several reports 
from other groups (20, 195, 285, 343).  It has been demonstrated that the intron-
containing vRNA foci are an accumulation of nascent transcripts (20, 195, 285, 343).  
Moreover, these sites were shown to be distinct from Rev-independent vRNA 
localization (20, 285, 343) and did not localize with the splicing factor SC35 (20, 64, 167, 
285, 343).  Interestingly, elements within the Rev-dependent vRNA transcript were 
shown to dictate discrete localization (20, 285, 347).  The collective results support a 
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model in which factors redirect the intron-containing vRNA to distinct regions for 
alternative processing and expression. 
 An abundant number of host cellular factors have been identified to influence the 
processing and transport of Rev-dependent vRNAs, such as Rev-interacting protein 
(hRIP) (278, 338), several of the DEAD-box RNA helicases (99, 273, 333, 336), 
peroxisome proliferator-activated receptor-interacting protein with methyltransferase 
(hPIMT) (335), and nuclear matrix component MATR3 (Matrin 3) (80, 106, 185, 334).  
Furthermore, some of the known cellular factors bind directly to intron-containing 
vRNAs and can also localize to the nucleolus. Nucleolar localization has been reported 
for both U2AF and the heterogeneous nuclear ribonucleoprotein (hnRNP) A1, which are 
splicing factors that bind to sites found within the nascent vRNAs (85, 192, 240, 310).  
Also included is the polypyrimidine tract-binding protein associated splicing factor (PSF) 
(7, 347).  PSF is a multifunctional protein involved in several gene expression pathways, 
including alternative splicing control (109, 286).  Recent studies have demonstrated PSF 
binds to intron-containing vRNA and found to shuttle between paraspeckles, a distinct 
nuclear compartment that is adjacent to splicing speckles, and the nucleolus (92, 106, 
109, 186, 347).  A model for the role of PSF in Rev-dependent vRNA processing has 
been proposed; PSF binds nascent vRNA and redirects the transcripts to an alternative 
localization for Rev-mediated export (185, 347).  I did not examine localization of the 
aforementioned factors and intron-containing vRNA in the absence or presence of Rev 
expression.  However, my findings of intron-containing vRNA foci localizing to similar 
discrete nuclear regions support a model involving cellular factors mediating intron-
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containing vRNA localization rather than the viral protein Rev (Figure 3-3 and 3-4). 
Furthermore, the observed localization of the intron-containing vRNAs coincident to the 
nucleolus, a domain found to be enriched in Rev and Rev binding partners, supports the 
role of the nucleolus as a site for Rev-mediated export (Figure 3-4).  Further vRNA 
localization and cellular protein analyses are necessary to make such a conclusion. 
Nonetheless, my localization studies presented here together with data demonstrating Rev 
is able to multimerize in the nucleolus (77), co-localize with the cellular export factor 
CRM1 in the this compartment as well as recruit other export co-factors to the nucleolus 
(78, 346) retain evidence for a nucleolar localization step for intron-containing vRNA 
during Rev-mediated vRNA export.  
 As an alternative approach to elucidate the role of the nucleolus in Rev-dependent 
vRNA export, I examined whether Rev nucleolar localization and function requires the 
nucleolar protein NPM1.  Studies have demonstrated Rev co-localizes and interacts with 
nucleolar shuttling protein NPM1, and suggested to be the receptor mediating Rev 
nuclear import and/or nucleolar localization (91, 100, 151, 229, 230, 304, 306).  More 
precisely, research has shown NPM1 binds Rev (100, 304, 305, 306), stimulates the 
nuclear import of Rev in vitro (306) and may be a component of the Rev export complex 
(204).  However, evidence is lacking to demonstrate NPM1 is responsible for Rev import 
and/or nucleolar localization in vivo or established a functional link between a 
NPM1:Rev interaction, nucleolar localization and Rev function.  This is the first report 
using an RNAi-based strategy to examine NPM1 involvement in Rev nucleolar 
localization and nucleocytoplasmic shuttling during Rev-mediated vRNA export in vivo.   
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 Here, specific siRNA-mediated knock down of cellular NPM1 was achieved, as 
assessed by indirect immunofluorescence microscopy and Western blotting, using a 
NPM1 specific antibody (Figure 3-5 through 3-8).  Several studies have demonstrated a 
role for NPM1 in various aspects of cell cycle regulation, suggesting inhibition of NPM1 
by RNAi would cause defects in cell cycle progression and cell death (34, 170, 241, 268).  
However, I observed no discernable difference in cell viability in HeLa cells treated with 
siNPM1 (Figure 3-5 through 3-8).  Consistent with previous reports, I also observed Rev 
and NPM1 co-localize in the nucleolus (91, 204, 229, 230).  Although I was able to 
achieve efficient and specific depletion of NPM1 expression in siNPM1 treated cells 
without evident cytotoxicity, I did not observe a localization change of Rev from the 
nucleolus in NPM1 depleted cells (Figure 3-6 and 3-7).  These results strongly suggest 
that NPM1 does not have a role in the nucleolar localization of Rev.  Other studies have 
demonstrated NPM1 interacts with Rev, however, none examined whether a disruption of 
this interaction affects Rev localization (151, 229, 230, 304, 306). Therefore, my results 
are the first report of an examination of NPM1 and Rev localization.  Rev has been 
demonstrated to interact with other nucleolar proteins and requires active rRNA synthesis 
for nucleolar localization.  Given that Rev retains nucleolar localization in NPM1 
depleted cells; my results support the premise that other cellular factors or Rev itself 
mediate this localization.  Interestingly, a study showed a redistribution of Rev from the 
nucleolus to the nucleoplasm and cytoplasm by Nullbasic, a mutant HIV-1 Tat protein, 
which also redistributed NPM1 in a Rev-dependent manner (204).  These data suggest 
disruption of a specific, common factor for nucleolar accumulation. 
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 I am also the first to investigate whether NPM1 participates in the 
nucleocytoplasmic shuttling of Rev during Rev-mediated vRNA export in vivo. I used a 
CAT reporter co-transfection assay to monitor Rev export activity in the presence or 
depletion of cellular NPM1, there was no significant inhibition of CAT activity, at either 
time point examined, despite efficient cellular NPM1 depletion (Figure 3-8).   Thus, these 
data indicate NPM1 does not participate in the nucleocytoplasmic shuttling (import and 
export) of Rev during vRNA export.  If NPM1 was required for either of these activities, 
one would expect to detect a noticeable difference in CAT activity in its absence. This 
reduction has been demonstrated in similar studies examining the effects of other 
identified Rev-cofactors on Rev-mediated export (e.g. (143, 165, 231). However, it is 
important to note that I did not examine whether NPM1 participates in Rev-mediated 
export in the context of viral replication.  Furthermore, my studies presented here do not 
address whether NPM1 has a role in other identified Rev functions, such as vRNA 
localization, utilization or translation.  Therefore, further investigation is necessary to 
delineate whether NPM1 has a role in Rev function, and is explored in the following 
chapter.  
 103
 
 
 
 
CHAPTER IV:  THE ROLE OF NPM1 IN HIV-1 VIRAL REPLICATION 
 
 
 
I conceived and performed all experiments presented in this chapter.  Nicholas P. Stone is 
credited for generating GFP-NPM1siR6-4 and GFP-NPM1siR6-8 by site directed 
mutagenesis using the mutagenesis primers I designed.  Nicholas P. Stone cloned the 
GFP-NPMsiR mutants into pCX4pur using my cloning strategy and assisted me in 
establishing the stable cell lines.  Nicholas P. Stone is also credited for the Western blot 
depicted in Figure 4-5C, generated from lysates I provided. 
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CHAPTER IV:  THE ROLE OF NPM1 IN HIV-1 VIRAL REPLICATION 
 
4.1 Introduction 
 From transcription initiation in the nucleus to its cytoplasmic end, cellular 
messenger RNAs (mRNAs) are associated with RNA-binding and other proteins, forming 
ribonucleoprotein particles (mRNPs) (reviewed in (89, 128, 235, 270)).  The composition 
and arrangement of these proteins on mRNA is dynamic, with protein exchange 
occurring at all steps of RNA metabolism.  As a result, these proteins drive the functional 
fate of the cognate mRNA through interactions with the cellular machinery.  These 
interactions not only promote pre-mRNA processing, but continue through the transport 
out of the nucleus to the cytoplasmic stability, translation and/or localization of the 
mRNAs (reviewed in (89, 128, 235, 270)).   Thus, the nuclear history of the mRNA can 
affect its fate in the cytoplasm.  
 HIV-1 produces a primary transcript (pre-mRNA) from the integrated proviral 
genome that encodes all the necessary information to generate every viral component for 
infectious particle production (111, 116, 266). This capability is accomplished through 
the utilization of alternative splicing and as a result, gives rise to transcripts that contain 
none, one or all introns. Thus, HIV-1 must exploit a variety of cellular post-
transcriptional gene expression mechanisms to regulate the pre-mRNA and ensure 
balanced nuclear export and translation of vRNAs. A necessary step in this process is the 
export of intron-containing vRNAs, which normally would be retained in the nucleus.  
HIV-1 is able to overcome this cellular requirement for complete splicing and promote 
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the export of incompletely spliced vRNA through highly specialized interactions between 
the cis-acting Rev Response Element (RRE) found within the intron-containing vRNAs, 
cellular proteins and the HIV-1 regulatory protein Rev.  Rev contains two functional 
domains, an arginine rich motif (ARM) and an effector domain, both of which are 
required for the protein-mediated nuclear export of RRE-containing vRNA (155, 156, 
212, 260).  The ARM domain confers sequence-specific binding to the RRE, while the 
effector domain contains a leucine-rich nuclear export signal (NES) that interacts with the 
cellular proteins CRM1, Ran-GTP and other cofactors to facilitate export of the intron-
containing RNAs (13, 21, 99, 106, 155, 201, 202, 275, 336).   
 It is well documented that Rev mediates the nucleocytoplasmic export of the 
intron-containing vRNAs (73, 155, 213, 260).  However, research over the years has 
demonstrated that nucleocytoplasmic export of vRNAs is not the only function of Rev 
(reviewed in (138, 141, 174, 299, 301)).  Several groups have established a functional 
role for Rev in the translation of Rev-dependent vRNAs (reviewed in (138, 141)).  
Specifically, Rev has been shown to enhance polysomal association of different intron-
containing vRNAs, leading to their increased protein expression (11, 12, 76, 138, 141, 
194, 256).  D'Agostino et al. demonstrated Gag protein expression was Rev- and RRE-
dependent using HL-Tat cells transiently co-transfected with a plasmid expressing 
unspliced gag vRNA in the absence or presence of Rev (76).  These results were further 
extended via fractionation studies of HeLa cells transiently transfected with proviral 
clones that could or could not express Rev.  These experiments revealed a Rev-dependent 
increase in gag/pol and vpu/env vRNA association with polysomes, thus demonstrating a 
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functional link between Rev and translation (76).  These results are in agreement with the 
findings of Arrigo and Chen which showed Rev-dependent expression and enhanced 
polysomal association of vpu/env vRNAs in COS and lymphoid cells (11). Interestingly, 
these and other studies also illustrated cell type dependent differences in the requirement 
of Rev for the cytoplasmic accumulation of the intron-containing vRNAs, suggesting Rev 
failed to interact with specific RNP components in the nucleus (11, 76, 141, 256). 
 Another functional role that has been identified for Rev is in the enhancement of 
genomic RNA (gRNA) encapsidation (9, 35, 134, 136, 137). Überla and colleagues 
observed that the removal of either Rev or the RRE from lentiviral vectors caused no 
discernible differences in the cytoplasmic accumulation of vRNAs but significantly 
reduced viral infectivity (208). They further demonstrated in 293T, lymphoid and 
primary peripheral blood mononuclear cells that the observed reduction in infectivity was 
due to inefficient packaging of gRNA, thus, linking a Rev: RNA interaction for the 
selection of full-length RNAs for encapsidation (26, 35, 136).  Moreover, this suggests 
packaging efficiency can be influenced by the cellular pathway used for the export of 
vRNAs.  This hypothesis is further supported by studies of viral replication in murine 
cells. It has been shown that the subcellular localization of Gag and virus assembly 
depends on the export pathway of the gag vRNA, largely attributed to the inability of one 
or more factors to function and/or interact properly with the exported vRNP (288, 289, 
302).  Moreover, the Lever group identified an additional Rev binding site in the leader 
sequence of Gag, termed loop A (119, 133, 140).  They showed two A:G point mutations 
within the highly conserved loop caused a replication defect, characterized by altered 
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vRNA trafficking and packaging (134). Interestingly, there were no observed differences 
between wildtype and mutant virus expression levels of Gag protein (134).  Taken 
together, these results strongly support a model where cytoplasmic vRNA localization 
and utilization is dictated by post-transcriptional events and vRNP composition.  
 A number of host cellular factors have been identified to associate with Rev-
dependent vRNPs and facilitate post-transcriptional Rev functions.  Examples include the 
Rev-interacting protein (hRIP), which is necessary for the release of the Rev-dependent 
vRNA from the perinuclear region during Rev-mediated vRNA export (278, 338). 
Several of the DEAD-box RNA helicases have been demonstrated to have both nuclear 
export and translation enhancing roles in Rev function (99, 273, 333, 336).  Furthermore, 
some of the known cellular factors bind directly to intron-containing vRNAs and can also 
localize to the nucleolus. Nucleolar localization has been reported for both U2AF and the 
heterogeneous nuclear ribonucleoprotein (hnRNP) A1, which are splicing factors that 
bind to sites found within the nascent vRNAs (85, 192, 240, 310).  Moreover, hnRNP A1 
has been shown to be relocalized to the cytoplasm during viral infection and form part of 
the vRNP, stimulating cap dependent translation (232). 
 The nucleolar protein NPM1 has also been identified to interact with Rev and 
shown to be a Rev co-factor (100, 304, 305, 306).  NPM1 is an abundant nucleolar-
cytoplasmic shuttling phosphoprotein that has nucleic acid binding properties (DNA and 
RNA) and ribonuclease and molecular chaperone activities located in distinct functional 
regions (151).  However, its precise role in Rev function during viral replication has yet 
to be identified. One study has suggested NPM1 acts as a molecular chaperone for Rev; 
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however this function has not been demonstrated in vivo or in the presence of vRNA 
(305).  Other studies have suggested NPM1 is responsible for the nuclear import and 
nucleolar localization of Rev (100, 204, 229, 230, 294, 306).  Yet, these studies have 
been limited to in vitro analyses and in vivo reports did not demonstrate a direct 
interaction (204, 229, 230, 304, 306). Importantly, these reports were unable to establish 
a functional link between NPM1 and Rev.   
 In Chapter 3, I investigated the role of NPM1 in the nucleolar localization of Rev 
and Rev-mediated vRNA export which, to date, is the only study to examine NPM1 
involvement in Rev export in vivo.  My results indicate that NPM1 did not have a role in 
Rev-mediated vRNA export.  However, this study was limited to a transient transfection 
reporter-based system to examine Rev function.  Notably, it is currently unknown 
whether NPM1 has a role in Rev-mediated export in the context of viral replication.  
Furthermore, whether NPM1 has a role in other identified Rev functions, such as vRNA 
localization, utilization, translation or affects virus production post-transcriptionally has 
not been explored.  
 Here, I investigate whether NPM1 has a role in Rev function and/or post-
transcriptional events during viral replication. I examined the effect of NPM1 depletion 
on virus production in cell lines and primary human macrophages using an RNAi-based 
approach.  In subsequent experiments, I established stable cell lines that express siRNA-
resistant GFP-NPM1 proteins for use in functional rescue experiments. In addition, I have 
examined the role of NPM1 in Rev-mediated vRNA localization by analyzing the 
intracellular distribution of intron-containing vRNAs post-infection, using coupled RNA 
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fluorescence in situ hybridization and indirect immunofluorescence. 
 
4.2 Results 
4.2.1 Depletion of cellular NPM1 significantly inhibits virus production in infected cell 
lines and primary human macrophages  
 Despite being identified as a Rev interacting partner, a role for NPM1 in Rev 
function has not been established (100, 304, 305, 306). Surprisingly, to date, no study has 
examined whether NPM1 has a post-transcriptional role during HIV-1 replication.  I 
employed an RNAi-based approach to investigate a possible role for NPM1 in Rev 
function and/or other post-transcriptional events in the context of viral replication.  I have 
previously demonstrated the ability to achieve specific, efficient NPM1 gene silencing in 
HeLa cells (Figure A1-1, Figure 3-5 to 3-9).  To determine whether depletion of NPM1 
protein expression could affect virus production, HeLa cells were transfected with 
reagent alone (Mock), 5 nM of a non-silencing control siRNA (siANC) or 5 nM of 
NPM1-specifc siRNA (siNPM1).  After 48hrs of siRNA treatment, cells were infected 
with VSV-G pseudotyped wild-type virus (NL4-3; MOI= 4).  Culture supernatants were 
collected 24- and 48hrs post infection and quantified for virus production by viral RT 
enzyme activity assays.  Cell lysates were analyzed for NPM1 and HIV-1 Gag protein 
expression by Western blotting 48hrs post infection.  Intriguingly, I observed a 
substantial reduction in virus production in cells depleted of NPM1 expression 24- and 
48hrs after infection (Figure 4-1A).  My results revealed a mean of 29% virus production 
24hrs post infection and 50% 48hrs post infection (SEM ± 1.3 and ± 4.4, respectively). 
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Figure 4-1. Depletion of NPM1 expression by RNAi inhibits HIV-1 production in 
HeLa cells.  HeLa cells were transfected with reagent alone (Mock), 5 nM of siANC or 5 
nM of siNPM1.  At 48hrs post siRNA transfection, cells were uninfected or infected with 
VSV-G pseudotyped NL3-4 virus at an MOI of 4.  (A) Virus production was determined 
by quantifying viral RT enzyme activity of culture supernatants 24- and 48hrs post 
infection as described in Material and Methods.  Bars represent the total mean percent of 
virus production from five independent experiments, four performed in duplicate ± SEM.  
Multiple student T-test analysis determined significant P values at 24hrs (****, P 
0.0001) and 48hrs (***, P 0.001).  (B) Cell lysates were analyzed for NPM1 gene-
specific knock-down and intracellular Gag expression by Western blotting 48hrs post 
infection with an anti-NPM1 and anti-Gag antibody, respectively. Actin was detected 
with an anti-Actin antibody as a total protein loading control. Data shown is 
representative of cell lysates prepared from experiments in A. 
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Moreover, multiple student T-test analysis comparing virus production in siNPM1 treated 
cells to siANC treated cells, determined this reduction to be significant, with P values of 
P 0.0001 at 24hrs and P 0.001 at 48hrs.  Depletion of NPM1 expression was confirmed 
by Western blot analysis.  Nearly undetectable levels of NPM1 were observed in the 
siNPM1 treated cells in the absence or presence of virus, while similar NPM1 expression 
was evident in siANC and Mock treated cells (Figure 4-1B).  Interestingly, the 
intracellular Gag expression levels were only slightly reduced, with no significant 
qualitative differences in the presence of siNPM1 (Figure 4-1B; compare lane 6 with 
lanes 4 and 5). The findings of an observed reduction in virus production and nearly 
unchanged intracellular Gag expression in siNPM1 infected HeLa cells are in agreement 
with initial experimental results performed in siRNA treated cells transiently transfected 
with wildtype provirus (Figure A1-2).  Furthermore, these results were also recapitulated 
in siRNA treated HeLa cells infected at a lower MOI (MOI=1; Figure A1-3). 
 To extend these findings, I examined whether NPM1 depletion could affect virus 
production in a relevant cell type for HIV-1 pathogenesis, monocyte derived primary 
human macrophages (MDM).  Based on my RNAi optimization data, differentiated 
MDM were Mock transfected or transfected with 10 nM of siANC or 10 nM siNPM1 
(Figure A1-4).  After 48hrs of siRNA treatment, cells were infected with VSV-G 
pseudotyped virus (NL4-3∆env; MOI= 4) and culture supernatants were analyzed for virus 
production 24- and 48hrs post infection by viral RT enzyme activity assays.  Consistent 
with results obtained in HeLa cells, I observed a considerable reduction in virus 
production in NPM1 depleted cells only (Figure 4-2A).  Specifically, virus production in 
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Figure 4-2. Depletion of NPM1 expression by RNAi inhibits HIV-1 production in 
primary human macrophages.  Monocyte-derived primary human macrophages were 
transfected with reagent alone (Mock), 10 nM of siANC or 10 nM of siNPM1.  At 48hrs 
post siRNA transfection, cells were uninfected or infected with VSV-G pseudotyped 
NL4-3∆env virus at an MOI of 4.  (A)  Virus production was determined by quantifying 
RT enzyme activity of culture supernatants 24- and 48hrs post infection as described in 
Material and Methods. Bars represent the total mean percent of virus production from 
nine independent experiments ± SEM.  Multiple student T-test analysis determined 
significant P values at 24- and 48hrs (***, P  0.001).  (B)  Cell lysates were analyzed for 
NPM1 gene-specific knock-down and intracellular Gag expression by Western blotting 
48hrs post infection with an anti-NPM1 and anti-Gag antibody, respectively.  Data shown 
is representative of cell lysates prepared from experiments in A. 
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siNPM1 treated cells was reduced to 47% and 42% at 24- and 48hrs, respectively, a 
statistically significant reduction when compared with virus production in siANC treated 
cells (P  0.001; 24hrs SEM ± 5.9; 48hrs SEM ± 6.8). Analysis of cell lysates by Western 
blotting 48hrs post infection confirmed specific and efficient depletion of NPM1 
expression in siNPM1 treated cells and, again, revealed only a slight, non significant 
qualitative reduction in intracellular Gag protein production (Figure 4-2B). Taken 
together with my data from HeLa cells, these data strongly support a role for NPM1 
during virus replication. 
 Next, I examined whether virus production could be restored in cells depleted of 
NPM1 expression.  To this end, I developed stably transduced cell lines expressing 
siRNA-resistant GFP-tagged variants of cellular NPM1.  The previously characterized 
wildtype pGFP-NPM1 (97, 98) was used to generate four pGFP-NPM1 siRNA-resistant 
clones, each containing silent point mutations introduced by site-directed mutagenesis 
(Figure 2-1).  The resultant plasmids were subsequently cloned into the pCX4pur 
expression vector and sequence verified.  Next, VSV-G pseudotyped GFP-NPM1 siRNA-
resistant viruses were produced in 293T cells and culture supernatants were collected 
48hrs later, then used to infect HeLa cells (Chapter 2).  Selection of infected HeLa cells 
by puromycin was initiated 24hrs later and successful transduction produced four stable 
cell lines: GFP-NPMsiR2-3, GFP-NPMsiR2-4, GFP-NPMsiR6-4 and GFP-NPMsiR6-8.  A 
more detailed description of how the stable cell lines were generated is provided in 
Chapter 2.  For simplicity, when referring generally to the GFP mutant variants of NPM1, 
the term GFP-NPMsiR will be used.   
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 Before the GFP-NPMsiR stable cell lines could be used in virus production rescue 
experiments, characterization of each cell line was necessary.  I first examined whether 
the four stable cell lines exhibited correct localization of their respective GFP-tagged 
NPM1 proteins.  To compare the localization of GFP-NPMsiR expressed in the stable 
cell lines, I used HeLa cells transiently transfected with wildtype pGFP-NPM1.  
Transfected HeLa and GFP-NPMsiR stable cell lines were seeded on cover slips and 
fixed 24hrs later.  Cells were stained with DAPI and the intracellular localization of GFP-
NPM(196) was analyzed by fluorescence microscopy.  I observed bright, concentrated 
nucleolar localization of GFP-NPM1 (Figure 4-3A).  In addition, I observed a minor 
nucleoplasmic and, to an even lesser extent, cytoplasmic localization of the GFP-tagged 
wildtype protein (Figure 4-3A). Collectively, these observations were consistent with 
previous reports (97, 98).  Bright, concentrated nucleolar localization of GFP-NPMsiR 
was also observed for all four stable cell lines (Figure 4-3B).  Moreover, I visualized 
GFP-NPMsiR localization in the nucleoplasm and cytoplasm in all cell lines, albeit to a 
slightly greater degree than observed in the transiently expressed GFP-NPM1.  These 
observations confirmed proper localization of each GFP-NPMsiR protein (Figure 4-3A, 
B).  To further confirm expression of the respective GFP-NPMsiR for each cell line, cell 
lysates were assayed for protein expression and analyzed by Western blotting. Expression 
levels of GFP-NPMsiR and cellular NPM1 was determined using an anti-GFP and anti-
NPM1 antibody, respectively.  I detected similar expression of GFP-NPMsiR in GFP-
NPMsiR2-3, GFP-NPMsiR2-4 and GFP-NPMsiR6-8 stable cells; however, GFP-NPMsiR6-4 
expression was considerably greater (Figure 4-3C, top panel).  Furthermore, an 
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Figure 4-3. GFP-NPMsiR stable cell lines efficiently express nucleolar localized 
GFP-NPM1 proteins.  (A)  HeLa cells were transfected with a GFP-NPM1 expressing 
plasmid (green) and fixed 48hrs later with 4% paraformaldehyde/5 nM MgCl2/1X PBS.  
Cell nuclei (blue) were detected with DAPI.  GFP-NPM1 intracellular localization was 
analyzed using fluorescence microscopy.  (B)  GFP-NPMsiR stable cell lines were fixed 
24hrs after seeding onto cover slips in 4% paraformaldehyde/5 nM MgCl2/1X PBS.  Cell 
nuclei (blue) were detected with DAPI. GFP-NPMsiR intracellular localization (green) 
was analyzed using fluorescence microscopy. (C)  Cell lysates prepared from 
experiments shown in B were analyzed for GFP-NPMsiR and cellular NPM1 expression 
by Western blotting using an anti-GFP and anti-NPM1 antibody, respectively.  Sam68 
was detected with an anti-Sam68 antibody as a total protein loading control.  
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enhancement of cellular NPM1 expression was detected in GFP-NPMsiR6-4 lysates.  This 
noticeable increase in NPM1 was not due to a difference in total protein loading, as 
similar expression levels of the control protein, Sam68, was observed (Figure 4-3C, 
bottom panel). Conversely, GFP-NPMsiR2-3, GFP-NPMsiR2-4 and GFP-NPMsiR6-8 
lysates revealed comparable levels of NPM1 expression to that in HeLa lysates (Figure 4-
3C, middle panel).  Collectively, these results demonstrate comparable stable expression 
profiles for GFP-NPMsiR2-3, GFP-NPMsiR2-4 and GFP-NPMsiR6-8 cell lines, validating 
them for use in further experiments. Because the GFP-NPMsiR6-4 cell line had notable 
discrepancies detected for both GFP-NPMsiR and cellular NPM1 expression as well as in 
virus production capability (Figure A1-5 and discussed below), this cell line was 
excluded. 
 Next, I examined whether the GFP-NPMsiR stable cell lines were able to support 
viral replication.  HeLa and GFP-NPMsiR stable cells were uninfected or infected with 
VSV-G pseudotyped NL3-4 virus (MOI= 4).  At 24- and 48hrs post infection, culture 
supernatants were collected to quantify virus production, while cells were harvested and 
lysed 48hrs post infection to assay for protein expression.  Analysis of culture 
supernatants for RT enzyme activity showed similar quantities of virus produced from the 
infected GFP-NPMsiR2-4 and GFP-NPMsiR6-8 stable cells at 24- and 48hrs (Figure 4-4A). 
When comparing virus production capability of the stable cells with infected HeLa cells 
at the same time points, GFP-NPMsiR2-4 and GFP-NPMsiR6-8 stable cells produced an 
average of 88% at 24hrs and 119% at 48hrs (average SEM 24hrs ± 28, 48hrs ±19).  Thus, 
these data illustrate virus production in these cell lines parallels what is observed for 
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HeLa cells.  Importantly, infected GFP-NPMsiR2-4 and GFP-NPMsiR6-8 stable cells also 
exhibited similar NPM1 and intracellular Gag expression compared with HeLa cells 
(Figure 4-4B, third, fourth and fifth panel).  Analogous expression of GFP-NPMsiR2-4 
and GFP-NPMsiR6-8 was also observed for these cell lines, however, the level of 
expression detected differed between the two antibodies used to identify the same protein 
(Figure 4-4B, first and second panel).  Specifically, use of the anti-GFP antibody to 
detect GFP-NPMsiR revealed a greater amount of protein detected than the anti-NPM1 
antibody.  This suggests the possibility that the three-dimensional folded structures of the 
GFP-tagged NPM1 could be altered from that of the native form.  This insight is further 
supported by the inability of the mouse monoclonal anti-NPM1 antibody to detect GFP-
NPMsiR2-3, despite only differing in sequence from GFP-NPMsiR2-4 by one nucleotide 
point mutation (Figure A1-5B, first and second panel; Figure 2-1).  The failure to detect 
expression of GFP-NPMsiR2-3 with an anti-NPM1 antibody was one reason this cell line 
was excluded from additional experiments.  Although reports using a GFP-NPM1 protein 
to examine NPM1 function have not reported experimental difficulties (196, 244), these 
observations were kept in consideration during additional studies. 
 The final characterization of the GFP-NPMsiR2-4 and GFP-NPMsiR6-8 cell lines 
determined whether the silent point mutations in the expressed GFP-NPMsiR2-4 and GFP-
NPMsiR6-8 proteins rendered resistance to siNPM1-mediated gene silencing.  HeLa and 
GFP-NPMsiR cells were transfected with reagent alone (Mock), 5 nM siANC or 5 nM 
siNPM1.  Cells were harvested and lysed 72hrs post treatment, the time point previously 
identified as the nadir for NPM1 expression during siRNA treatment (Figure 
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Figure 4-4. GFP-NPMsiR stable cell lines support HIV-1 production and are 
resistant to NPM1-specific RNAi. (A, B) HeLa and GFP-NPMsiR stable cell lines were 
uninfected or infected with VSV-G pseudotyped NL4-3 virus at an MOI of 4.  (A)  Virus 
production was determined by quantifying viral RT enzyme activity of culture 
supernatants 24- and 48hrs post infection as described in Material and Methods.  Bars 
represent the total mean percent of virus production from three independent experiments 
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± SEM.  (B)  Cell lysates were analyzed for GFP-NPMsiR, NPM1 and intracellular Gag 
expression by Western blotting 48hrs post infection using anti-GFP, anti-NPM1 and anti-
Gag antibody, respectively.  Data shown is representative of cellular lysates prepared 
from experiments in A.  (C)  HeLa cells or GFP-NPMsiR stable cells lines were 
transfected with reagent alone (Mock), 5 nM of siANC or 5 nM of siNPM1.  At 72hrs 
post siRNA transfection, cells were harvested, lysed and were analyzed for GFP-NPMsiR 
and NPM1 expression by Western blotting with an anti-GFP and anti-NPM1 antibody. 
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A1-1).  Consistent with my previous results, I achieved specific, efficient depletion of 
NPM1 using RNAi.  Western blot analysis showed nearly undetectable levels of cellular 
NPM1 expression for all cell lines, while comparable amounts of NPM1 were detected 
for Mock and siANC treated cells (Figure 4-4C, third panel).  Significantly, I confirmed 
the expression of GFP-NPMsiR was comparable regardless of siRNA treatment type in 
the GFP-NPMsiR2-4 and GFP-NPMsiR6-8 cell lines using the anti-GFP antibody (Figure 
4-4C, top panel).  Of note, I again observed a difference in the level of GFP-NPMsiR 
expression detected between the anti-GFP and anti-NPM1 antibodies used to identify the 
protein; there was considerably less GFP-NPMsiR detected with the anti-NPM1 antibody 
(Figure 4-4C and Figure 4-4B, compare first and second panels).  Thus, these results 
further support the possibility the three-dimensional folded structures of the GFP-tagged 
NPM1 are altered from the native form. More specifically, the ability of the antibody to 
recognize the NPM1 antigen may be occluded by misfolding.  Nonetheless, the anti-GFP 
antibody data demonstrate the GFP-NPMsiR2-4 and GFP-NPMsiR6-8 expressing stable 
cell lines are resistant to siNPM1-mediated depletion, qualifying them for use in the viral 
production rescue experiments.  In contrast, GFP-NPMsiR2-3 cells treated with siNPM1 
revealed a decrease in GFP-NPMsiR protein expression, thus providing further rationale 
for exclusion of this stable cell line from additional experiments (Figure A1-5C, first 
panel). 
 Utilizing the characterized and validated siRNA-resistant stable cell lines GFP-
NPMsiR2-4 and GFP-NPMsiR6-8, I next investigated whether these cells were able to 
restore virus production during RNAi-mediated depletion of cellular NPM1.  HeLa, GFP-
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NPMsiR2-4 and GFP-NPMsiR6-8 cells were Mock, siANC or siNPM1 treated for 48hrs 
followed by infection with VSV-G pseudotyped NL4-3 virus (MOI= 4).  Culture 
supernatants were collected 24- and 48hrs post infection to quantify virus production by 
viral RT enzyme activity assay analysis.  Cell lysates were analyzed 48hrs post infection 
by Western blotting to examine GFP-NPMsiR, NPM1 and intracellular Gag expression.  
RT enzyme activity assay data revealed analogous percentage of virus production in 
GFP-NPMsiR2-4, GFP-NPMsiR6-8 and HeLa cells in the presence of Mock or siANC 
treatment at 24- and 48hrs post infection (Figure 4-5A and B).  However, in the presence 
of siNPM1 treatment, expression of GFP-NPMsiR2-4 and GFP-NPMsiR6-8 did not 
augment virus production.  More specifically, despite expression of siRNA-resistant 
GFP-NPM1, the stable cell lines remained susceptible to a siNPM1-mediated virus 
replication deficiency.  The mean percent of virus production in GFP-NPMsiR2-4 and 
GFP-NPMsiR6-8 cells was nearly identical to treated HeLa cells at 24hrs, while at 48hrs 
the stable cells exhibited marginally less virus production than HeLa cells (Figure 4-5A 
and B).  The inability to rescue virus production in the siNPM1 treated stable cell lines 
was not due to inefficient expression of the siRNA-resistant forms of GFP-NPM1.  
Western blot analysis showed comparable quantities of GFP-NPMsiR protein expression 
in the presence or absence of siNPM1 using the anti-GFP antibody (Figure 4-5C, top 
panel).  Moreover, these results were validated using the anti-NPM1 antibody. 
Surprisingly, I was able to detect similar levels of GFP-NPMsiR using the anti-GFP and 
anti-NPM1 antibody (compare Figure 4-5C and Figure 4-4B,C first and second panels).  
This observed discrepancy can be partially attributed to the order in which the 
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Figure 4-5. GFP-NPMsiR stable cell lines are unable to rescue HIV-1 production 
in siNPM1 treated cells.  HeLa and GFP-NPM1siR stable cell lines were transfected 
with reagent alone (Mock), 5 nM of siANC or 5 nM of siNPM1.  At 48hrs post siRNA 
transfection, cells were uninfected or infected with VSV-G pseudotyped NL4-3 virus at 
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an MOI of 4.  (A, B)  Virus production was determined by quantifying viral RT enzyme 
activity of culture supernatants 24hrs (A) and 48hrs (B) post infection as described in 
Material and Methods.  Bars represent the total mean percent of virus production from 
four independent experiments ± SEM.  (C)  Cell lysates were analyzed for GFP-NPMsiR, 
NPM1 and intracellular Gag expression by Western blotting 48hrs post infection with 
anti-GFP, anti-NPM1 and anti-Gag antibodies, respectively.  Data shown is 
representative of cell lysates prepared from experiments in B. 
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nitrocellulose membranes were immunoblotted with the antibodies.  The anti-Gag, anti-
GFP and anti-NPM1 are monoclonal antibodies.  I observed that when the membranes 
were immunoblotted with anti-GFP antibody before using the anti-NPM1 antibody, the 
signal detected for GFP-NPMsiR using the anti-NPM1 was greater.  This is most likely 
due to residual GFP antibody remaining after membrane stripping also being detected by 
the anti-mouse secondary antibody.  Cellular NPM1 was efficiently depleted by siNPM1 
in all cell types, while GFP-NPMsiR was observed to have consistent expression in GFP-
NPMsiR2-4 and GFP-NPMsiR6-8 cells during siRNA treatment (Figure 4-5C, second 
panel).  Intracellular Gag expression was relatively unaffected by siNPM1 treatment in 
HeLa, GFP-NPMsiR2-4 and GFP-NPMsiR6-8 cells, consistent with my previous results.  
Collectively, these data indicate expression of the two GFP-NPM siRNA-resistant 
proteins, GFP-NPMsiR2-4 and GFP-NPMsiR6-8, are unable to restore virus production in 
NPM1 depleted cells. 
 
4.2.2 Depletion of cellular NPM1 results in the diffuse cytoplasmic distribution of 
select Rev-dependent viral RNAs 
 My results demonstrating depletion of NPM1 expression substantially reduced 
virus production in HeLa cells and MDM supports a role for NPM1 in viral replication 
(Figure 4-1 and 4-2).  However its precise role in Rev function during viral replication 
has yet to be identified. Although my previous work has suggested NPM1 does not have 
a role in Rev-mediated vRNA export function (Chapter 3), it remained unclear whether 
NPM1 has a role in the intron-containing vRNA localization and utilization functions of 
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Rev. To examine whether NPM1 takes part in these Rev functions during viral 
replication, I analyzed the intracellular distribution of intron-containing vRNAs post-
infection, using coupled RNA FISH and indirect immunofluorescence.  HeLa cells were 
Mock transfected or transfected with 5 nM of siANC or siNPM1.  After 34hrs of siRNA 
treatment, cells were trypsinized, counted and re-seeded onto cover slips in triplicate for 
analysis by fluorescence microscopy while the remaining cells were re-seeded onto 
culture dishes without cover slips for analysis by Western blotting.  The next day, cells 
were infected with VSV-G pseudotyped NL4-3 virus (MOI= 4) then fixed or harvested 
24hrs later.  A Cy3-conjugated RRE-specific probe was used to detect intron-containing 
vRNA while an anti-NPM1 primary antibody followed by an AF-488 conjugated 
secondary antibody was used to detect NPM1.  Treatment with reagent or siANC did not 
effect NPM1 intracellular localization or expression (Figure 4-6A and B).   In these 
treated cells, cellular NPM1 was observed predominately concentrated in the GC of the 
nucleolus with some nuclear localization, consistent with my previous observations 
(Figure 3-6A, B and Figure 3-7A, B).  NPM1 expression was markedly reduced in HeLa 
cells treated with siNPM1, whereas similar basal levels of NPM1 were observed in the 
Mock and siANC-treated cells (Figure 4-6). In the infected Mock and siANC treated 
cells, I observed two patterns of intron-containing vRNA localization.  The most distinct 
localization was abundant, large punctae accumulating at, and radiating from, the 
perinuclear region of the cells (Figure 4-6B, first and second panel).  In addition, a small 
fraction of the intron-containing vRNAs in these cells was observed to be distributed 
throughout the cytoplasm (Figure 4-6B, first and second panel).  These findings are 
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consistent with previous reports for gag vRNA localization in HeLa and Cos cells (175, 
177). However, a remarkable difference in intron-containing vRNA localization was 
observed in siNPM1 treated cells. Very few punctae were observed in these cells 
compared with Mock and siANC treated cells (Figure 4-6B).  And the punctae detected 
appeared more intracellularly dispersed rather than accumulating at the perinuclear region 
(Figure 4-6B). The most striking observation in the siNPM1 treated cells was the widely 
dispersed cytoplasmic localization of the intron-containing vRNAs (Figure (4-6B, bottom 
panel).  This observed difference of vRNA localization is unlikely attributed to a general 
affect of siNPM1 treatment on RNA localization.  I have validated this experimental 
approach, showing NPM1-specific gene silencing does not affect cellular mRNA 
localization and/or expression in infected cells. Specifically, I observed that the 
ubiquitously expressed GAPDH RNA localization was not altered when NPM1 
expression was depleted (Figure A1-6).  It is also important to note the absence of 
punctae detected in the Mock-treated uninfected cells, thus demonstrating the specificity 
of the probe (Figure 4-6A).  Of importance, Western blot analysis revealed nearly 
identical intracellular Gag expression detected in infected cells depleted of NPM1 as 
Mock and siANC treated cells (Figure 4-6C).  Collectively, these results support a role 
for NPM1 in the cytoplasmic localization of Rev-dependent vRNA.  
 To extend these results, I used a Cy3-conjugated gag-pol RNA-specific 
oligonucleotide probe to localize full-length vRNA in infected HeLa cells depleted of 
NPM1 expression (Figure 4-7B).  Since the Cy3-conjugated RRE-specific probe detects 
transcripts containing the cis-acting element and my results in Mock and siANC treated 
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cells support previous studies that the observed localization of large punctae accumulate 
at, and radiate from, the perinuclear region in addition to localization throughout the 
cytoplasm (Figure 4-6B, first and second panel) (175, 177), then it would be likely that a 
gag-pol RNA-specific probe would yield a similar localization pattern as the RRE-
specific probe (Figure 4-6). Therefore, HeLa cells were Mock or siRNA treated for 34hrs 
then trypsinized, counted and re-seeded in triplicate onto cover slips, while the remaining 
cells were re-seeded onto culture dishes without cover slips.  The next day, cells were 
infected with VSV-G pseudotyped NL4-3 virus (MOI= 4) and harvested 24hrs later.  
Fixed cells on cover slips were analyzed by FISH using a gag-pol RNA-specific probe, 
followed by indirect immunofluorescence to detect NPM1, and visualized by fluorescent 
microscopy. Again, I observed the same nucleolar and nuclear localization for NPM1 in 
Mock and siANC treated cells and substantial diminution of NPM1 detected in siNPM1 
treated cells as previously described (Figure 4-6, Figure 3-6A, B and Figure 3-7A, B).  In 
addition, I observed a similar pattern of large gag-pol vRNA punctae accumulating 
around the perinuclear region and distributed outward throughout the cytoplasm in the 
Mock and siANC treated cells, which were detected using the RRE-specific probe 
(compare Figure 4-7B and Figure 4-6B first and second panels). The siNPM1 treated 
cells exhibited limited punctae and a diffuse cytoplasmic distribution of gag-pol vRNA, 
which was also observed using the RRE-specific probe (compare Figure 4-7B and Figure 
4-B bottom panels). Moreover, no substantial difference in Gag protein expression was 
observed in NPM1 depleted cells (Figure 4-7C).  Therefore, these results further support 
a role for NPM1 in the cytoplasmic localization of Rev-dependent vRNA. More 
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specifically, no quantitative difference in Gag protein expression was observed in cells 
depleted of NPM1.  Cells depleted of NPM1 exhibit significant diminution in virus 
production and diffuse vRNA localization during viral replication, suggesting this 
difference could be due to mislocalization of gRNA and supporting a role for NPM1 in 
the utilization of Rev-dependent vRNA. 
 To further differentiate which class(es) of intron-containing vRNA were affected 
by NPM1 depletion, I examined the intracellular localization of env vRNA in siRNA 
treated cells.  The env RNA-specific oligonucleotide probes were designed based on 
HIV-1 isolates complementarity to the env splice junction, and thus do not cross 
hybridize with sequences in gag-pol vRNA.   HeLa cells were treated for 34 hrs with 
Mock, siANC or siNPM1 siRNA, then trypsinized, counted and re-seeded in triplicate 
onto cover slips. The remaining cells were re-seeded onto culture dishes without cover 
slips.  The following day, cells were infected with VSV-G pseudotyped NL4-3 virus 
(MOI= 4) and harvested 24hrs post infection.  Fixed cells on cover slips were analyzed 
by FISH using an env RNA-specific probe, followed by indirect immunofluorescence 
with an anti-NPM1 antibody and visualized by fluorescent microscopy.  Cell lysates were 
prepared and analyzed by western blotting for the expression of NPM1, Gag and Actin.  
Interestingly, I observed no discernible difference in the intracellular localization of env 
vRNA in treated cells.  Specifically, I observed bright, discrete, large punctae localized 
predominately at the cell periphery with some env vRNA accumulation also observed 
throughout the cytoplasm in Mock, siANC and siNPM1 treated cells (Figure 4-8B).  In 
contrast, I observe a decreased level of NPM1 detection in the siNPM1 treated cells only, 
 130
 
 
 
Figure 4-6. Depletion of NPM1 expression alters HIV-1 intron-containing vRNA 
cytoplasmic localization.  (A, B) HeLa ells were transfected with reagent alone (Mock; 
 131
A, B top panel), siANC (B middle panel) or siNPM1 (B lower panel). At 48hrs post 
siRNA transfection, cells were uninfected (A) or infected with VSV-G pseudotyped NL4-
3 virus at an MOI of 4 (B). At 24hrs post-infection, cells were fixed with 4% 
paraformaldehyde/5 mM MgCl2/1X PBS and analyzed using coupled FISH- IF.  A Cy3-
conjugated RRE vRNA-specific probe was used to detect intron-containing vRNA (red).  
Immune detection of NPM1 (green) was performed using anti-NPM1 primary antibody 
and an AF-488 conjugated secondary antibody.  The nucleus (blue) was detected by 
DAPI.  Data shown is representative of multiple fields examined from three independent 
experiments.  (C)  HeLa cell lysates prepared from experiments in A and B were 
analyzed for NPM1 gene-specific knock-down and intracellular Gag expression by 
Western blotting using an anti-NPM1 antibody and anti-Gag antibody, respectively. 
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Figure 4-7. Depletion of NPM1 expression alters HIV-1 gag-pol vRNA 
cytoplasmic localization.  (A, B) HeLa cells were transfected with reagent alone (Mock; 
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A, B top panel), siANC (B middle panel) or siNPM1 (B lower panel). At 48hrs post 
siRNA transfection, cells were uninfected (A) or infected with VSV-G pseudotyped NL4-
3 virus at an MOI of 4 (B). At 24hrs post-infection, cells were fixed with 4% 
paraformaldehyde/5 mM MgCl2/1X PBS and analyzed using coupled FISH- IF.  A Cy3-
conjugated gag-pol RNA-specific probe was used to detect genomic vRNA (red).  
Immune detection of NPM1 (green) was performed using anti-NPM1 primary antibody 
and an AF-488 conjugated secondary antibody.  The nucleus (blue) was detected by 
DAPI.  Data shown is representative of multiple fields examined from one experiment.  
(C)  HeLa cell lysates prepared from experiments in A and B were analyzed for NPM1 
gene-specific knock-down and intracellular Gag expression by Western blotting using an 
anti-NPM1 antibody and anti-Gag antibody, respectively. 
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Figure 4-8. Depletion of NPM1 expression by RNAi has no discernable effect on 
HIV-1 env vRNA localization.  (A, B) HeLa cells were transfected with reagent alone 
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(Mock; A, B top panel), siANC (B middle panel) or siNPM1 (B lower panel). At 48hrs 
post siRNA transfection, cells were uninfected (A) or infected with VSV-G pseudotyped 
NL4-3 virus at an MOI of 4 (B). At 24hrs post-infection, cells were fixed with 4% 
paraformaldehyde/5 mM MgCl2/1X PBS and analyzed using coupled FISH- IF.  A Cy3-
conjugated env RNA-specific probe was used to detect envelope vRNA (red).  Immune 
detection of NPM1 (green) was performed using anti-NPM1 primary antibody and an 
AF-488 conjugated secondary antibody.  The nucleus (blue) was detected by DAPI.  Data 
shown is representative of multiple fields examined from three independent experiments.  
(C)  HeLa cell lysates prepared from experiments in A and B were analyzed for NPM1 
gene-specific knock-down and intracellular Gag expression by Western blotting using an 
anti-NPM1 antibody and anti-Gag antibody, respectively. 
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indicating I achieved specific depletion of the protein (Figure 4-8B).  Efficient depletion 
of NPM1 was confirmed by Western blotting (Figure 4-8C, top panel).   Western blot 
analysis also showed no evident difference in intracellular Gag expression, consistent 
with my previous findings. Thus, these data, taken together with my other localization 
findings, strongly argues NPM1 affects the cytoplasmic localization and utilization of a 
specific subset of Rev-dependent vRNA, the gag-pol vRNA. 
 While I observed a marked reduction in virus production in cells treated with 
NPM1-specific siRNAs, it was unclear whether cells depleted of NPM1 support 
production of infectious HIV-1 particles.  To investigate this possibility, HeLa cells were 
Mock transfected or transfected with 5 nM of siANC or 5 nM of siNPM1.  After 48hrs of 
siRNA treatment, cells were infected with VSV-G NL4-3 virus (MOI = 4).  Culture 
supernatants were collected 24- and 48hrs post infection to quantify virus production by 
RT enzyme activity assays (Figure 4-9A).  To determine the infectivity of virus present in 
culture supernatants, I used a TZM-bl indicator cell-based assay that monitors Tat-
dependent β-gal expression. TZM-bl cells were infected with culture supernatants 
containing equivalent RT units of virus cultures for 48hrs, then subsequently washed, 
fixed and assayed for β-gal enzymatic activity.  RT enzyme activity assay analysis 
revealed a significant reduction in virus production in the presence of siNPM1 at both 
time points examined (Figure 4-9A). Western blot analyses show efficient depletion of 
NPM1 expression in only siNPM1 treated cells, while Gag expression levels remained 
unchanged when compared with Mock or siANC treated cells (Figure 4-9B).  These 
findings confirm results I have previously reported (Figure 4-1, Figure A1-3, Figure 4-5).  
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Although I do see a significant diminution in the level of virus produced in siNPM1 
treated cells, the corresponding TZM-bl virus infectivity assay data indicate the virus 
particles are as infectious as those produced in Mock and siANC treated cells (Figure 4-
9C, B).  Thus, production of infectious HIV-1 particles is unaltered in the absence of 
NPM1 expression.  
 In the results presented, I used viral RT enzyme activity assay analysis to quantify 
virus production.  Nevertheless, Gag proteins are necessary and sufficient for the 
assembly and release of virus-like particles (VLPs) (112, 116).  To examine whether 
siNPM1 depletion has an effect on Gag release, I utilized a standard HIV-1 p24 ELISA to 
quantify p24 concentration in siRNA treated MDM culture supernatants at 24- and 48hrs 
post infection.  The culture supernatants quantified for p24 production were those 
collected and assayed for RT enzyme activity reported in Figure 4-2.  Interestingly, my 
p24 ELISA results revealed a minor diminution in p24 production in siNPM1 treated 
cells at 24hrs post infection, where an 88% p24 production was observed (Figure 4-10).  
However, at 48hrs post infection p24 production was reduced further to 57%.  Multiple 
student T-test analysis determined the decrease in p24 production in the siNPM1 treated 
cells to be non significant at both time points (P= 0.22317, P= 0.06207).  Nonetheless, 
these findings, together with the observed decrease in virus production in siNPM1 treated 
cells quantified by RT enzyme activity assays, nearly unchanged expression of 
intracellular Gag protein as well as dispersed localization of gag-pol vRNA further 
support a role for NPM1 in the localization and utilization of gag-pol vRNA. 
 
 
  
 138
 
 
 
Figure 4-9. Depletion of NPM1 expression by RNAi has no discernable effect on 
HIV-1 infectivity.  HeLa cells were transfected with reagent alone (Mock), 5 nM of 
siANC or 5 nM of siNPM1.  At 48hrs post siRNA transfection, cells were uninfected or 
infected with VSV-G pseudotyped NL4-3 virus at an MOI of 4. (A)  Virus production 
was determined by quantifying viral RT enzyme activity of culture supernatants 24- and 
48hrs post infection as described in Material and Methods.  Bars represent the total mean 
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percent of virus production from two independent experiments, one performed in 
duplicate ± SEM.  Multiple student T-test analysis determined significant P values at 
24hrs (*, P 0.05) and 48hrs (**, P 0.01).  (B)  Cell lysates were analyzed for NPM1 
gene-specific knock-down and intracellular Gag expression by Western blotting 48hrs 
post infection with an anti-NPM1 and anti-Gag antibody, respectively.  Data shown is 
representative of cell lysates prepared from experiments in A.  (C)  The infectivity of 
virus present in culture supernatants collected 48hrs post infection was determined using 
TZM-bl indicator cells and monitoring β-gal expression. Aliquots of supernatants 
containing equivalent RT activity units were serially diluted 10-fold in antibiotic-free 
media. Duplicate cell monolayers were inoculated with the diluted virus cultures.  At 
48hrs post infection, cells were washed, fixed and assayed for β-gal enzymatic activity as 
described in Materials and Methods.  Bars represent the total mean virus infectivity of 
culture supernatants collected from experiments in A ± SEM.  A random-block one way 
ANOVA analysis determined non significant P values for virus infectivity (P= 0.2748).   
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Figure 4-10. Depletion of NPM1 expression by RNAi has a marginal effect on p24 
production in primary human macrophages.  Culture supernatants collected from 
experiments reported in Figure 4-2 were analyzed for HIV-1 Gag p24 production by 
standard HIV-1 p24 ELISA 48hrs post infection as described in Material and Methods.  
Bars represent the total mean percent of p24 production from nine independent 
experiments ± SEM.  Multiple student T-test analysis determined non significant P values 
at 24hrs (P= 0.22317) and 48hrs (P= 0.06207). 
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4.3 Discussion 
 In this study, I examined whether the previously identified Rev-cofactor, NPM1 
has a role in Rev function and/or post-transcriptional events during viral replication. 
Although a number of studies have reported NPM1 to interact with Rev and suggested a 
role for NPM1 in Rev function, these reports were unable to establish a functional link 
between NPM1 and Rev in vivo (100, 304, 305, 306).  Notably, no studies to date have 
examined whether NPM1 participates in Rev-mediated export in the context of viral 
replication.  Furthermore, it is unknown whether NPM1 has a role in other identified Rev 
functions, such as vRNA localization, utilization and translation (reviewed in (138, 141, 
174, 299, 301)) or whether NPM1 affects virus production post-transcriptionally.  Here, I 
am the first to report using an RNAi-based strategy to examine NPM1 involvement in 
Rev-dependent vRNA post-transcriptional events during viral replication in cell lines and 
primary human macrophages.  I am able to achieve specific, efficient siRNA-mediated 
depletion of cellular NPM1 in HeLa cells and MDM (Figure 4-1B and Figure 4-2B and 
Figure A1-1 through Figure A1-4).  Following siNPM1 treatment, I show a marked, 
statistically significant reduction of virus production in HeLa cells and MDM infected 
with VSV-G pseudotyped wildtype virus at 24- and 48hrs post infection (Figure 4-1A 
and Figure 4-2B).  Importantly, these results are further substantiated in NPM1 depleted 
HeLa cells transiently transfected with wildtype virus as well as NPM1 depleted HeLa 
cells infected with VSV-G pseudotyped wildtype virus at a lower MOI (Figure A1-2 and 
A1-3).  While I am the first to report a role for NPM1 during HIV-1 infection, NPM1 has 
been implicated in post-transcriptional events of other retroviruses.  Caporale et al. 
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identified the 80 amino acid signal peptide of the simple Jaagsiekte Sheep Retrovirus 
(JSRV) Envelope glycoprotein (Env) as a posttranscriptional regulator of viral gene 
expression, functioning through similar mechanisms as HIV-1 Rev (48).  Using transient 
co-transfection experiments in 293T and Cos cells, they demonstrate the JSRV signal 
peptide (JSE-SP) co-localizes with NPM1 in the nucleolus, enhances the nuclear export 
of unspliced vRNA and increases virus production (48).  Importantly, when increasing 
concentrations of dominant negative NPM1 is co-transfected with JSE-SP, a dose-
dependent decrease of virus production is observed.  They also showed JSE-SP interacts 
with NPM1 in the nucleus and the cytoplasm, and surprisingly, associated together with 
membrane/organelles (48). Thus, these data suggest JSE-SP function is dependent on 
NPM1 activity. Of significance, in these studies they utilized a HIV-1 gag-pol expression 
plasmid co-transfected with Rev and dominant negative NPM1, which also demonstrated 
a decrease in virus production comparable to what I observe in NPM1 depleted, infected 
HeLa cells and MDM.   Taken together, these studies substantiate a NPM1 role in HIV-1 
replication.  Collectively, these findings provide complimentary evidence NPM1 is 
required for HIV-1 replication. 
 To further demonstrate a role for NPM1 in HIV-1 replication, I examined whether 
virus production could be restored in cells depleted of NPM1 expression. I developed 
stably transduced cell lines expressing siRNA-resistant GFP-tagged variants of cellular 
NPM1 using the previously characterized wildtype pGFP-NPM1 to generate the mutants 
(Figure 4-3, Figure 4-4, Figure 4-5 and Figure A1-5) (97, 98).  However, despite being 
resistant to siNPM1 treatment, GFP-NPMsiR2-4 and GFP-NPMsiR6-8 stable cell lines 
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were unable to restore wildtype levels of virus production in NPM1 depleted cells (Figure 
4-5).  There are several possible explanations as to why these stable cell lines were 
unable to augment virus production. For example, the correctly folded three-dimensional 
structures of GFP-NPMsiR fusion proteins may differ considerably from that of native 
NPM1, rendering them functionally inactive. My Western blotting results show the anti-
GFP antibody is able to detect a greater amount of GFP-NPMsiR protein than the anti-
NPM1 antibody, supporting this probability.  This insight is further corroborated by the 
inability of the anti-NPM1 antibody to detect GFP-NPMsiR2-3 even though there are no 
amino acid differences from wildtype NPM1 (Figure 2-1).  It is necessary to note that all 
mutations generated within each GFP-NPMsiR are silent, meaning no amino acid 
residues were changed (Figure 2-1). Alternative folding of the GFP-NPMsiR proteins 
could occlude access to functional domains and protein: protein and/or protein: nucleic 
acid interactions necessary for virus production.  Furthermore, protein misfolding could 
hinder the ability of NPM1 to be modified by phosphorylation, acetylation, 
ubiquitylation, and SUMOylation, all of which have been indicated to regulate different 
aspects of function, localization and oligomerization (117, 205, 241). The ability for 
NPM1 to properly oligomerize via the core domain has been shown to be important for 
molecular chaperone ability and facilitate subcellular localization (117, 205, 241, 244, 
265).  Another contributing factor may be that fluorescent fusion proteins have a weak 
tendency to oligomerize and when these fusion proteins are targeted to specific cellular 
compartments, local accumulation can promote dimerization (272, 340). Since GFP-
NPM1siR proteins concentrate in the nucleoli, the propensity of GFP to self-dimerize 
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may supersede NPM1 core domain-driven oligomerization and thus affect function 
(Figure 4-3).  Lastly, my characterization of the GFP-NPMsiR cell lines was limited to 
examining fusion protein localization, the ability of these cells to support virus 
replication and confirming resistance to siNPM1 treatment.  Thus, investigating the 
functional properties of the expressed GFP-NPMsiR proteins is warranted.  Such 
functional analysis of the GFP-NPMsiR proteins could include testing the ability of these 
proteins to bind nucleic acid, decondense sperm chromatin, transfer nucleosomes to 
naked DNA and assist in renaturning chemically denatured proteins, in vitro (149, 151, 
242, 243, 307, 326)). Moreover, construction, expression and analysis of alternative 
NPM1 siRNA-resistant fusion proteins expression constructs, such as polyhistidine or c-
Myc tags, may address this unresolved issue.     
 Interestingly, the reduced level of virus production observed in HeLa cells and 
MDM was not associated with a considerable diminution of intracellular Gag expression 
in these cells, indicating the reduction in virus is not due to insufficient Gag expression.  
This data is consistent with my findings that depletion of NPM1 expression does not 
affect Rev-dependent vRNA export activity and extends my findings that NPM1 is not 
required for Rev-mediated vRNA export during replication (Chapter 3, Figure 3-8).  
Moreover, these data suggest the observed siNPM1-mediated reduction in virus 
production is also not due a virus assembly or budding defect.  HIV-1 Gag is synthesized 
on cytosolic polysomes as a 55 kD polyprotein precursor (p55) comprised of four 
domains: matrix (MA/p17), capsid (CA/p24), nucleocapsid (NC/p7) and p6 with two 
spacer peptides, SP1, located between CA and NC, and SP2, found between NC and p6.  
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These domains are separated by five flexible linker regions that contain sites cleaved by 
PR during virion maturation to liberate the processed forms of the proteins (111, 112, 
300).  Research investigating HIV-1 virus assembly and budding describe Gag processing 
defects associated with disruptions of these processes, such that accumulation of cell-
associated Gag processing intermediates can be observed (125, 130, 131, 218, 257, 297, 
321).   The Gag cell-associated processing products detected by Western blotting with the 
anti-Gag antibody reveal no significant differences between siNPM1, Mock and siANC 
treated cells, therefore indicating siNPM1-mediated reduction in virus production is not 
due to a virus assembly or budding defect (Figure 4-1B, Figure 4-2B, Figure A1-2B and 
Figure A1-3B).   
 Examination of Rev-dependent vRNA localization in the absence or presence of 
siNPM1 treatment reveals significant differences in intracellular localization of certain 
Rev-dependent vRNAs when NPM1 is depleted (Figure 4-6 through Figure 4-8).   In the 
infected Mock and siANC treated cells, I observed two patterns of vRNA localization 
using the RRE RNA-specific and gag-pol RNA-specific probes; large, abundant punctae 
accumulating at and radiating from the perinuclear region and a small fraction distributed 
throughout the cytoplasm (Figure 4-6B and Figure 4-7B). These findings are consistent 
with previous reports of gag vRNA localization in HeLa and Cos cells (175, 177). 
Remarkably, the RRE-containing and gag-pol vRNA infected siNPM1 treated cells 
localize to limited number of punctae and display diffuse cytoplasmic distribution, 
implicating NPM1 in the cytoplasmic localization of Rev-dependent vRNA (Figure 4-6B 
and Figure 4-7B).  Analysis of env-specific vRNA localization further defined the role for 
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NPM1 vRNA localization. Because the env vRNA localization was not altered when 
NPM1 was depleted, clearly suggests a role for NPM1 in the cytoplasmic localization of 
gag-pol vRNA (Figure 4-8B).  When considered with the demonstrated reduction in virus 
production in HeLa cells and MDM following siNPM1 treatment, these findings extends 
my model to include a role for NPM1 in the cytoplasmic utilization of gag-pol vRNA.  
 Identification of NPM1 as a modulator of gag-pol vRNA localization and/or 
utilization is not speculative.  A number of host cellular factors have been identified to 
associate with Rev-dependent vRNPs and facilitate post-transcriptional functions 
(reviewed in (65, 141, 224)). The gag-pol vRNA serves as an mRNA template for Gag 
and Gag-Pol polyprotein synthesis as well as the genome that is packaged into nascent 
virions (111, 112, 300).  Research to date has not found HIV-1 to have distinct pools of 
gag-pol vRNA to select transcripts for translation or packaging (42).  However, 
numerous groups have implicated the composition of the vRNP as a mediator for the 
localization and/or utilization of gag-pol vRNA, which can be determined in the nucleus, 
at the nuclear pore or in the cytoplasm (2, 19, 58, 59, 60, 65, 71, 147, 206, 209, 223, 228, 
232, 233, 292).  The cellular protein Sam68 (Src-associated during mitosis 68 kD) has 
been suggested to enhance 3’ end processing of unspliced vRNA and may mark the 
gRNA in the nucleus to promote cytoplasmic utilization (71, 223).  DEAD-box helicases 
DDX1 and DDX3 have been reported to be involved in Rev-mediated transport and 
modulate Rev subcellular localization (99, 336), while DDX24 has been shown to 
promote gRNA packaging (209).  Moreover, hnRNP A2 and Staufen have been shown to 
associate with the genomic RNP, promoting gRNA trafficking and packaging (2, 19, 58, 
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59, 60, 228).  Intriguingly, NPM1 has been implicated in mRNA 3’ end processing and 
identified as a component of an RNP containing DDX1, CRM1, Nup62, Nucleolin and 
hnRNPA1, which are also cellular factors that maintain post-transcriptional roles in HIV-
1 replication and/or Rev function (65, 141, 154, 210, 224, 233, 277, 317).  These findings 
reveal how intimately coupled NPM1 is to various Rev-dependent vRNA post-
transcriptional processes.  
 In conclusion, my data strongly supports a role for NPM1 in the localization and 
utilization of gRNA during HIV-1 replication. To date, no studies have examined NPM1 
and Rev-dependent vRNA in the absence or presence of Rev in vivo or during infection. 
Moreover, none have examined NPM1 in the context of full-length RNA or even the 
complete RRE.  My findings that depletion of cellular NPM1 has an adverse effect on 
HIV-1 production but not Gag expression and can alter the intracellular distribution of 
gag-pol vRNA support a model in which NPM1 plays an active role in the cytoplasmic 
localization utilization of gag-pol vRNA and possibly, gRNA packaging. Quantitative 
analysis of gRNA in nascent particles produced in the absence or presence of cellular 
NPM1 would provide key insights into this possibility.  Whether the functional 
involvement of NPM1 in gag-pol vRNA localization and utilization occurs in the 
cytoplasm, nucleus, or nucleolus remains to be determined. Moreover, the molecular 
mechanism by which NPM1 associates with the gag-pol vRNA/RNP (i.e.protein: protein 
or protein: vRNA) warrants further investigation. 
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CHAPTER V: DISCUSSION AND FUTURE DIRECTIONS 
5.1 Summary 
 The results from this thesis present novel findings to implicate a nucleolar and 
NPM1 involvement in distinct aspects of intron-containing vRNA export and post-
transcriptional regulation.  Using coupled RNA fluorescent in situ hybridization and 
immunofluorescent analysis, I demonstrate that intron-containing vRNA localize as 
intense, discrete foci in the nucleus.  I show for the first time localization of the intron-
containing vRNA foci that are detected as early as 6hrs post infection and remain as 
discrete, bright foci up to 24hrs, with a saturation point of 30hrs post infection.  
Importantly, I demonstrate that cells infected with wild type virus, Rev-deficient virus or 
viruses containing a mutated RRE enabling higher Rev binding affinity, all display 
distinct intron-containing vRNA foci that localize coincident to the nucleolus 
independent of Rev expression.  My findings of intron-containing vRNA foci localizing 
to similar discrete nuclear regions support a model that involves cellular factors 
mediating intron-containing vRNA localization rather than the viral protein Rev.  
Furthermore, localization of the intron-containing vRNAs coincident to the nucleolus, a 
domain found to be enriched in Rev and Rev binding partners, provides evidence for the 
nucleolus as a site for intron-containing vRNA localization during Rev-mediated vRNA 
export.  I further extend a role for the nucleolus to post-transcriptional events of intron-
containing vRNA by investigating the functional involvement of the previously identified 
Rev co-factor and nucleolar protein, NPM1 in Rev function and viral replication.  I report 
the results of the first RNAi-based strategy to examine NPM1 involvement in Rev 
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nucleolar localization and Rev-mediated vRNA export in vivo.  I show efficient, specific 
depletion of NPM1 expression in siNPM1 treated cells without toxicity.  Significantly, I 
demonstrate the nucleolar localization of Rev does not change when NPM1 expression is 
depleted, indicating NPM1 does not have a role in the nucleolar localization of Rev, thus 
supporting the premise other cellular factors mediate this localization. I used a CAT 
reporter co-transfection assay to monitor Rev export activity in the presence or depletion 
of cellular NPM1.  I demonstrate that despite efficient cellular NPM1 depletion, no 
significant inhibition of CAT activity is observed, indicating NPM1 does not participate 
in Rev vRNA export. These results are further established and extended in my viral 
replication studies. I report the first experiments to use a viral infection and an RNAi-
based strategy to examine NPM1 involvement in Rev function and viral replication.  I 
demonstrate that NPM1 depletion in cell lines and primary human macrophages confers a 
significant reduction in virus production.  I also show this reduction is not associated with 
a diminution of intracellular Gag expression, indicating that reduction in virus production 
is not due to insufficient Gag expression.  Through examination of the localization of 
Rev-dependent vRNA in the absence or presence of siNPM1 treatment, I reveal 
significant differences in specific Rev-dependent vRNAs when NPM1 is depleted. 
Instead of large, abundant vRNA punctae accumulating at and radiating from the 
perinuclear region with a small fraction of vRNA distributed throughout the cytoplasm as 
seen in reagent and siANC treated cells, the gag-pol RNA localization in siNPM1 treated 
cells have limited punctae and a diffuse cytoplasmic distribution. In contrast, the env 
vRNA localization is unaltered when NPM1 is depleted, thus supporting a role for NPM1 
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in the cytoplasmic localization of gag-pol vRNA. These data, taken together with my 
findings of reduced virus production in HeLa and MDM siNPM1 treated cells, extends 
this model to include a role for NPM1 in the cytoplasmic utilization of gag-pol vRNA. In 
addition, I show the siNPM1 treated cells release similarly infectious virions as control 
treated cells and p24 production is not significantly reduced. These data strongly support 
a model where NPM1 modulates gRNA localization and utilization during HIV-1 
replication.  Collectively, my findings provide novel insight for a functional role of the 
nucleolus and NPM1 in HIV-1 replication, which enhances our current understanding of 
HIV-1 biology. 
 
5.2 The Nucleolus and Intron-containing vRNA Export 
 Current research supports a model for nucleolar localization of vRNA during 
HIV-1 replication. Both vRNA and HIV-1 Rev have been shown to localize to the 
nucleolus and the nucleolus has been implicated as a site for Rev-mediated export 
complex formation (41, 46, 64, 75, 77, 204, 225, 227, 229, 260, 271, 274, 294, 346).  
However, the involvement of the nucleolus for vRNA localization prior to export has 
remained inconclusive.  Several studies examining intron-containing vRNA localization 
using electron microscopy in situ hybridization report conflicting evidence; some report 
detection of intron-containing vRNA in the nucleolus while others do not (46, 64, 274). 
Furthermore, research has yet to distinguish the class(es) of vRNAs that may localize to 
the nucleolus or establish how their nucleolar localization could be mediated.  In this 
thesis, I am the first to report intron-containing vRNA localization in the presence or 
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absence of Rev during a viral infection and detect the regions of the nucleolus as a 
localization reference.  Using coupled fluorescent in situ hybridization and 
immunofluorescent analysis, I demonstrate cells infected with wild type virus, Rev-
deficient virus or viruses containing a mutated RRE enabling higher Rev binding affinity, 
all display distinct intron-containing vRNA foci that localize coincident to the granular 
component of the nucleolus, independent of Rev expression. These findings add support 
to a model for intron-containing vRNA nucleolar localization prior to export.  
Surprisingly, however, these findings also suggest factor(s) other than Rev likely mediate 
intron-containing vRNA nucleolar localization.  Collectively, my results presented in this 
thesis open exciting avenues to explore, to confirm intron-containing vRNA nucleolar 
localization and to delineate how this localization may be mediated.    
 It is important to consider the possibility there is no nucleolar localization step of 
intron-containing vRNA prior to export, or is a dead-end for the intron-containing vRNA 
once in the nucleolus.  However, there are two key findings that strongly argue against 
these prospects in addition to the research presented and discussed in this thesis.  First, 
Michienzi et al. demonstrate that lymphocytes stably transduced with a nucleolar 
localized hammerhead ribozyme designed to site-specifically cleave a conserved region 
within all HIV-1 RNA transcripts inhibits HIV-1 virus production for over 24 days, the 
length of the study (225).  Second is the report that demonstrating a nucleolar localized 
Rev binding peptide is able to inhibit HIV-1 replication by sequestering Rev function for 
its export only (226).  Together, these data strongly argue that intron-containing vRNA 
localize to the nucleolus for export. 
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 There are numerous experiments that would further elucidate bone fide nucleolar 
localization for intron-containing vRNA during viral replication.  As discussed in Chapter 
3, electron microscopy in situ hybridization offers the ultrastructural resolution required 
for specific nucleolar localization. Using this technique to compare intron-containing 
vRNA localization during infection with my wild type, Rev-deficient or enhanced RRE-
containing virus would be the first report of a direct evaluation for vRNA localization and 
Rev dependence during an infection. Confocal or deconvolution microscopy to analyze 
intron-containing vRNA localization would compliment the electron microscopy in situ 
hybridization experiments and provide greater serial spatial depth resolution than the 
wide-field fluorescence microscopy analysis presented in this thesis.  Moreover, 
examination of Rev-independent vRNA localization by electron and/or fluorescence in 
situ hybridization is necessary.   
 I present evidence in this thesis to support intron-containing vRNA coincident 
nucleolar localization is Rev independent.  To address how intron-containing vRNAs 
localize to the nucleolus, localization of cellular proteins identified to interact with 
intron-containing vRNA detected by IF while vRNA localization detected by FISH in the 
absence and presence of viral infection is needed.  Proteins of interest include PSF, 
Matrin 3, DDX1 and hnRNP A1, all which have been previously shown to interact with 
intron-containing vRNA (80, 99, 185, 186, 232, 273, 286, 310, 333, 334, 347).  
Moreover, Rev localization should also be examined.  Investigating the localization of 
these proteins and intron-containing vRNA in a time course study may also provide 
insight into the temporal aspect of nucleolar localization. Certainly, co-localization of 
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cellular proteins and intron-containing vRNA do not provide functional analysis, but can 
narrow the candidate protein pool for further analysis.  Additionally, utilizing 
fluorescence resonance energy transfer  (FRET) and fluorescence recovery after 
photobleaching (FRAP) methodologies to investigate possible cellular co-factors of Rev 
in the presence or absence of intron-containing vRNA could provide a live cell imaging 
approach to examine cellular and viral protein interactions and localizations during 
export.  This method has been reported by the Pavlakis group to examine Rev 
multimerization and CRM1 cargo interactions in the nucleolus as well as the Parent 
group examining Rous Sarcoma virus (RSV) viral protein localization in the presence and 
absence of vRNA (23, 77, 78, 207). 
  An additional approach that should be employed is the isolation and examination 
of nucleoli for protein and vRNA content.  The Lamond laboratory has established 
systematic protocols for isolation, RNA extraction and proteomic analysis of nucleoli for 
various cell types (6, 7, 189, 191, 248). Jarboui et al. adapted the Lamond protocol to 
report the first nucleolar proteomic profile of stably transduced HIV-1 Tat expressing 
Jurkat cells (169). To date, examination of proteomic profiles of isolated nucleoli in 
response to Rev expression has not been investigated.  Of note, no reports have examined 
the nucleolar profiles (protein and/or vRNA) in the presence of vRNA or during a viral 
infection.  Therefore, using the viral constructs I have developed in a similar system may 
provide new insight for a mechanism of HIV-1 vRNA nucleolar localization.  
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5.3 NPM1 and HIV-1 Rev: A New Model 
 NPM1 has been demonstrated to co-localize with Rev and has been suggested to 
be the cellular factor mediating Rev nuclear import and/or nucleolar localization (91, 100, 
151, 229, 230, 304, 306).  Research has shown that NPM1 binds Rev (100, 304, 305, 
306), stimulates the nuclear import of Rev in vitro (306) and may be a component of the 
Rev export complex (204).  Nonetheless, no research to date has demonstrated NPM1 is 
responsible for Rev import and/or nucleolar localization in vivo or has established a 
functional link between a NPM1:Rev interaction, nucleolar localization and Rev function.  
Therefore, results reported in this thesis are the first to examine NPM1 involvement in 
Rev nucleolar localization and Rev-mediated vRNA export in vivo.  I report that despite 
almost complete reduction in intracellular NPM1 by siRNA treatment Rev retained its 
predominant nucleolar localization and Rev-mediated export function, thus supporting an 
alternative, NPM1 exclusion model for Rev nucleolar localization and export ability. 
 Surprisingly, it has been widely accepted that NPM1 mediates nucleolar 
localization of Rev despite the lack of in vivo evidence to support this premise (152, 204, 
245, 294, 327).  This hypothesis has been conveniently incorporated into several models 
for Rev function yet no studies have specifically examined NPM1 role in Rev function in 
the presence of full length vRNA, or even the entire RRE, in vitro or in vivo (Figure 5-
1A) (100, 151, 241, 245, 304, 305, 306).  Despite cell-free evidence, my cell-based 
results disagree with a NPM1 involvement in Rev nucleolar localization or Rev-mediated 
vRNA export (Figure 5-1B) (100, 304, 305, 306).  For the Rev localization studies 
presented in this thesis, I used a GFP-fusion Rev protein demonstrated to localize 
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predominantly to the nucleolus (294).  As previously noted, fluorescent fusion proteins 
have a weak tendency to oligomerize and when these are targeted to specific cellular 
compartments, local accumulation can promote dimerization (272, 340).  Although this 
Rev-GFP expression construct has been widely used without experimental discrepancies, 
examination of Rev localization using different fusion protein tags in the absence or 
presence of NPM1 expression would complement the findings presented here. Moreover, 
including Rev localization experiments in the presence or absence of vRNA are also 
needed to provide further evidence as to whether NPM1 has a role in Rev nucleolar 
localization.  An additional experiment would be to express a dominant negative NPM1 
that does not localize to the nucleolus, such as the previously characterized GFP-
NPM1MutA, to see whether Rev localization is altered (97, 98).  This mutant could also 
be employed in the CAT reporter co-transfection assay to monitor the affect on Rev 
export activity (156, 157).  Moreover, disruption of the identified Rev binding domains 
on an exogenously expressed NPM1 protein to monitor Rev localization could also 
clarify the reported difference in NPM1 mediating Rev localization and function (151, 
305). 
 Research has suggested other factors may mediate Rev nucleolar localization.  
Early studies proposed Rev could accumulate in the nucleolus because of the high RNA 
content present and the fact that it has been shown to bind 5S rRNA (75, 188).  However, 
upon further investigation, it is more widely acknowledged that cellular factors are likely 
to mediate the nucleolar localization. For example, several DEAD-box RNA helicases 
have been implicated, including DDX1 (99, 273, 333).  Research described by Lin et al. 
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Figure 5-1. HIV-1 Rev nucleolar localization.  (A)  Two currently accepted models 
for HIV-1 Rev nucleolar localization.  Research data has proposed NPM1 mediates the 
import of Rev from the cytoplasm to the nucleous, either as part of an import complex, or 
as the sole factor responsible (Model 1).  While Model 2 purports a nuclear interaction of 
NPM1 and Rev to mediate Rev nucleolar localization.  Interaction of Rev with NPM1 has 
been shown to be a short sequence in the NLS, while NPM1 interacts with Rev through a 
region in the N terminal.  (B)   Proposed model: HIV-1 Rev nucleolar localization does 
not require NPM1.  Rev import complex does not require NPM1 and Rev nucleolar 
localization is not mediated by NPM1.  Rev nucleolar localization is most likely mediated 
through interaction(s) with undetermined factor(s) in the nucleus (shown as X).  Adapted 
from  Massimo Caputi. RNA Processing (2011). 
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suggest a common factor between NPM1 and Rev could link their association in the 
nucleolus (204) One possible linker could be DDX1, since NPM1 has also been shown to 
be a part of a RNP with DDX1 and other cellular factors described to be a part of Rev-
mediated vRNA transport and/or expression (210).  However, these possibilities remain 
to be determined.  FRET and FRAP methodologies to examine cellular factors that may 
mediate Rev nucleolar localization could provide this insight.  Understanding the 
protein(s) and/or mechanism that mediate Rev nucleolar localization could elucidate 
whether the localization is necessary for Rev functions or Rev-dependent vRNA 
processing and/or export.  Therefore, the research presented in this thesis is a step 
towards unraveling the complexity of HIV-1 vRNA export and expression. 
 
5.4 NPM1 as a Modulator of gag-pol vRNA Localization and Utilization  
 Research has shown HIV-1 Rev not only mediates the nucleocytoplasmic export 
of the intron-containing vRNAs, but also has a functional role in the localization and 
utilization of Rev-dependent vRNAs (reviewed in (138, 141, 174, 299, 301)).  Moreover, 
recent studies indicate Rev function extends to include the enhancement of gRNA 
encapsidation (26, 35, 119, 133, 134, 136, 208).  NPM1 has also been identified to 
interact with Rev and shown to be a Rev co-factor (100, 304, 305, 306). However, no 
studies to date have examined whether NPM1 participates in Rev-mediated export in the 
context of viral replication.  Furthermore, it is unknown whether NPM1 has a role in 
other identified Rev functions or whether NPM1 affects virus production post-
transcriptionally.  In this thesis, I am the first to report NPM1 involvement in Rev-
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dependent vRNA post-transcriptional events during viral replication.  My findings that 
depletion of cellular NPM1 inhibits HIV-1 production, determined by RT activity, but not 
Gag expression and alters the intracellular distribution of gag-pol vRNA support a model 
in which NPM1 plays an active role in the cytoplasmic localization and utilization of 
gag-pol vRNA and possibly, gRNA packaging. However, whether the functional 
involvement of NPM1 in gag-pol vRNA localization and utilization occurs in the 
cytoplasm, nucleus, or nucleolus still requires investigation. Furthermore, examination of 
the molecular mechanism by which NPM1 associates with the gag-pol vRNA/RNP is 
necessary.   
 One intriguing mechanism for NPM1 and gRNA packaging has been proposed by 
the Parent group.  They have identified a NoLS in the NC domain of Rous Sarcoma Virus 
(RSV) Gag and HIV-1 Gag, and show that a fraction of expressed Gag localizes to the 
nucleolus (207).   Furthermore, they demonstrate that NPM1 co-localizes with HIV-1 
Gag in the nucleolus and HIV-1 Rev and HIV-1 Gag localize to the nucleolus when co-
expressed, thus suggesting the nucleolus could play a contributing role to HIV-1 gRNA 
packaging and virus assembly (207). However, these results are in disagreement with 
others that report HIV-1 Gag does not undergo nuclear trafficking (14, 137). Thus, 
further studies are needed to address these discrepancies. 
 Another possible post-transcriptional mechanism for NPM1 could be an effect on 
gRNA translation, more specifically, ribosomal frameshifting and the maintenance of the 
gag: gag-pol ratio.  The exact mechanism for HIV-1 ribosomal frameshifting has yet to 
be resolved; however, the proposed model supports the hypothesis that frameshift 
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efficiency can be altered when specific aspects of the translation elongation process are 
modified.  Thus, cellular factors such as ribosomal proteins, translation elongation and 
termination factors, kinase and phosphotase factors that modulate the activity of 
translation, and RNA-binding proteins that can remodel RNA structures, may contribute 
to ribosomal frameshift modulation (24, 181, 311).  NPM1 has several cellular activities 
that are regulated through the phosphorylation, acetylation, ubiquitylation and 
SUMOylation of its functional domains.  Specifically, NPM1 has been demonstrated to 
bind both DNA and RNA, promote RNA processing, act as a molecular chaperone, 
interact with several RNA processing factors, as well as interact with both the large and 
small ribosomal subunits (205, 210, 241, 277).  NPM1 has not been investigated as a 
cellular factor in ribosomal frameshifting to date and, currently, only one cellular factor 
has been reported to affect HIV-1 frameshifting fidelity, Eukaryotic release factor 1 
(eRF1) (181).  Nonetheless, increasing or decreasing HIV-1 gRNA frameshift efficiency 
has been demonstrated to cause a decrease in RT activity and virus infectivity (90, 160, 
181, 287).  Furthermore, Dulude et. al. demonstrated that a decrease in frameshift 
efficiency, caused by introducing mutations within the slippery sequence and the 
frameshift stimulatory signal, correlated with equivalently reduced viral infectivity and 
replication kinetics but not Gag processing (90).  Analysis of Gag processing in 
infectious mutant virions revealed processing defects of various extents, thus lacking 
proportionality between frameshift efficiency (90).  My findings that depletion of cellular 
NPM1 inhibits HIV-1 production but not Gag expression could support a role for NPM1 
in frameshifting efficiency.  Although I did not detect a decrease in viral infectivity in the 
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experiments reported in this thesis, it is important to note that viral infectivity was 
determined by infecting cells with equivalent RT units and not p24 quantity, thus 
essentially normalizing for infectivity. A more accurate examination of viral infectivity 
would be to infect cells with equivalent p24, which should be performed.  Interestingly, 
in the p24 ELISA experiments of macrophage supernatants, I did not detect a statistically 
significant difference in p24 activity, suggesting that VLPs could be released.  Thus, 
further experimentation is required to determine whether infectivity of the virus is 
affected.  Moreover, to examine whether a frameshift increase or decrease is observed in 
NPM1 depleted cells, examination of Pol, RT, PR and/or IN protein detection needs to be 
examined as well as Northern blot analysis of  vRNA species should be completed.   
 To further demonstrate a role for NPM1 in HIV-1 replication, I examined whether 
virus production could be restored in cells depleted of NPM1 expression through stable 
cell lines expressing siRNA-resistant forms of GFP-NPM1 proteins.  However, despite 
being resistant to siNPM1 treatment, the stable cell lines were unable to achieve wildtype 
levels of virus production.  In Chapter 4, I present some possible explanations for why 
this phenotype was observed, with improper fusion protein folding being the most 
probable.  However, it is important to address whether I could be observing an off-target 
effect from the siRNA duplexes used the experiments presented in this thesis.  The likely 
candidate to be targeted by my siNPM1 duplexes is CLEC2D.  Strikingly, CLEC2D 
mRNA has a 94% mRNA sequence identity to NPM1 when aligned 
(www.ncbi.nlm.nih.gov). Even more outstanding is all TRC lentiviral NPM1 shRNAs 
available on Open Biosystems can also target CLEC2D (1).   In fact two of the shRNAs 
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available are listed for both NPM1 and CLEC2D (TRCN0000062268 and 
TRCN0000062270).  CLEC2D is a cell membrane spanning protein that functions as a 
CD161 ligand and has been shown to be expressed on some hematopoietic cells 
(including macrophages and T cells), osteoblasts, and chondrocytes (122, 126). It is 
important to note, CLEC2D expression was not found on cells isolated from patients with 
high HIV-1 viral loads in the only study to date examining this relatively uncharacterized 
protein (126).  Nonetheless, I examined whether CLEC2D mRNA was detectable in 
HeLa cells and whether siNPM1 treatment affected CLEC2D expression in the absence 
and presence of virus.   Reverse transcriptase quantitative real-time polymerase chain 
reaction (RT-qPCR) analysis was used to compare expression levels of the targeted 
cDNA.  For a detailed description of the experimental method, I refer the reader to 
Chapter 2, Materials and Methods.  I was unable to detect any expression of CLEC2D 
cDNA for all conditions in my RT-qPCR experiments, thus supporting the premise 
CLEC2D has no role in the results reported in this thesis.  Moreover, initial RT-qPCR 
results examining NPM1 cDNA expression in siNPM1 treated cells show specific 
depletion of NPM1 (Figure A1-8).  However, to corroborate a role for NPM1 function in 
HIV-1 replication, performing parallel experiments with alternative siRNAs directed 
against NPM1 gene expression would strengthen the significance of my results. 
 In addition, to further explore the role of NPM1 as a HIV-1 gag-pol vRNA post-
transcriptional modulator and address whether NPM1 has global and/or off-target effects 
on cellular mRNA expression, examination of NPM1 depletion on HIV-1 vRNA mRNA 
expression profiles is needed and is currently in progress. HIV-1 vRNA and cellular 
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GAPDH mRNA expression will be examined using a modified RT-qPCR method 
described by Stolarchuk et al., followed by analysis of the ratio of spliced (2 kb), partially 
spliced (4 kb) and unspliced (9 kb) classes of vRNA species expressed (295). This will be 
the first study of its kind and the results could elucidate possible mechanisms for NPM1 
function in HIV-1 replication. 
 
5.5 Concluding Remarks 
 In this thesis, I present findings that identify distinct functional roles for the 
nucleolus and NPM1 in HIV-1 replication (Figure 5-2). More specifically, my research 
findings support a model for a Rev-independent nucleolar localization step of intron-
containing vRNA prior to export. My results also show NPM1 does not participate in Rev 
nucleolar localization or Rev-mediated vRNA export, as previously proposed. Instead, I 
provide evidence to support a new role for NPM1, the cytoplasmic localization and 
utilization of gRNA.  The findings herein thus provide exciting and novel insight to assist 
in resolving the complexities of HIV-1 vRNA export and expression and enhance our 
current understanding of HIV-1 biology. 
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Figure 5-2. HIV-1, the Nucleolus and NPM1:  A Potential Model.  (1.)  After 
transcription and processing intron-containing vRNAs are transported to the granular 
component of the nucleolus by cellular factor(s) (designated as X) and independent of 
HIV-1 Rev.  (2.)  Trafficking to the nucleolus allows for Rev-mediated export complex 
formation.  (3.)  HIV-1 Rev mediates intron-containing vRNA export from the nucleus. 
(4A.)  Full-length gag vRNA is localized for encapsidation (gRNA) or (4B.) translated on 
on cytosolic ribosomes to produce Gag and Pol polyproteins.  (5.)  env vRNA is 
translated on ER associated ribosomes.  A possible vRNP rearrangement to include 
NPM1 occurs to influence downstream full-length, gRNA localization and/or utilization.  
However, whether NPM1 has this effect in nucleolus (2.), nucleus (3.) or in the 
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cytoplasm (4A. and 4B.) needs to be determined.  Furthermore, whether NPM1 associates 
directly with the gRNA, with gRNA and HIV-1 Rev, or with another factor (shown as 
X?) in the absence or presence of Rev to orchestrate gRNA localization and/or utilization 
requires investigation.   
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APPENDIX 
 
 
 
I conceived and performed all experiments presented in this appendix. 
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Figure A1-1. Efficient depletion of NPM1 expression by RNAi is achieved in HeLa 
cells at a concentration of 5 nM, with a maximum reduction occurring at 72hrs post 
siRNA treatment.  (A)  HeLa cells were transfected with reagent alone (Mock) or 
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increasing concentrations of siNPM1.  At 48hrs post siRNA transfection, cell lysates 
were analyzed for NPM1 gene-specific knock-down by Western blotting with an anti-
NPM1 antibody.  Sam68 was detected with an anti-Sam68 antibody as a total protein 
loading control.  (B)  HeLa cells were transfected with reagent alone (Mock), 100 nM of 
siANC or increasing concentrations of siNPM1.  At 48- and 72hrs post siRNA 
transfection, cell lysates were analyzed for NPM1 gene-specific knock-down by Western 
blotting with an anti-NPM1 antibody.  Sam68 was detected with an anti-Sam68 antibody 
as a total protein loading control.  (C)  HeLa cells were transfected with reagent alone 
(Mock), 5 nM of a control NPM1 scrambled siRNA (siScr) or 5 nM siNPM1 once (1X) 
or twice (2X) as described in Materials and Methods.  At 48-, 72-, and 96hrs post siRNA 
transfection, cell lysates were analyzed for NPM1 gene-specific knock-down by Western 
blotting with an anti-NPM1 antibody.  Sam68 was detected with an anti-Sam68 antibody 
as a total protein loading control. 
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Figure A1-2. Depletion of NPM1 expression by RNAi inhibits HIV-1 production in 
transiently transfected HeLa cells.  HeLa cells were transfected with reagent alone 
(Mock), 100 nM of siANC or 100 nM of siNPM1.  At 48hrs post siRNA transfection, 
cells were transfected with reagent alone or with a pNL4-3 proviral clone.  (A)  Virus 
production was determined by quantifying viral RT enzyme activity of culture 
supernatants 24- and 48hrs post infection as described in Material and Methods. Bars 
represent the total mean percent of virus production from four independent experiments ± 
SEM.  Multiple student T-test analysis determined a non significant P value at 24hrs (P= 
0.145) and a significant value at 48hrs (**, P  0.01).  (B) Cells lysates were analyzed for 
NPM1 gene-specific knock-down and intracellular Gag expression by Western blotting 
48hrs post transfection with an anti-NPM1 and anti-Gag antibody, respectively. Data 
shown is representative of cell lysates prepared from experiments in A. 
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Figure A1-3. Depletion of NPM1 expression by RNAi inhibits HIV-1 production 
similarly in HeLa cells infected at different MOIs.  HeLa cells were transfected with 
reagent alone (Mock), 5 nM of siANC or 5 nM of siNPM1.  At 48hrs post siRNA 
transfection, cells were uninfected or infected with VSV-G pseudotyped NL4-3 virus at 
an MOI of 1 or 4.  (A, B)  Virus production was determined by quantifying viral RT 
enzyme activity of culture supernatants 24- and 48hrs post infection as described in 
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Material and Methods.  Bars represent the total mean percent of virus production from 
four independent experiments, two performed in duplicate ± SEM (A) or five 
independent experiments, four performed in duplicate ± SEM (B). Multiple student T-test 
analysis determined significant P values at both an MOI of 1 (A; ***, P 0.001) and an 
MOI of 4 (B; ***, P  0.001; ****, P 0.0001).  (C, D) Cells lysates were analyzed for 
NPM1 gene-specific knock-down and intracellular Gag expression by Western blotting 
48hrs post infection with an anti-NPM1 and anti-HIV-1 Gag antibody, respectively. Data 
shown is representative of cellular lysates prepared from experiments in A (C) and B (D). 
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Figure A1-4. Efficient depletion of NPM1 expression by RNAi is achieved at a 
concentration of 10 nM in monocyte-derived primary human macrophages, with 
maximum reduction occurring at 96hrs post siRNA transfection.  MDM were 
transfected with reagent alone (Mock), 10 nM of siANC or 10 nM of siNPM1 as 
described in Materials and Methods.  Cell lysates were analyzed for NPM1 gene-specific 
knock-down by Western blotting 24-, 48-, 72- and 96hrs post transfection with an anti-
NPM1 antibody.  Actin was detected with an anti-Actin antibody as a total protein 
loading control.  Data shown represents one experiment. 
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Figure A1-5. GFP-NPMsiR stable cell lines support variable levels of HIV-1 
production and intracellular GFP-NPMsiR protein expression. (A, B) HeLa and 
HeLa-derived stable cell lines were uninfected or infected with VSV-G pseudotyped 
NL4-3 virus at an MOI of 4.  (A) Virus production was determined by quantifying viral 
RT enzyme activity of culture supernatants 24- and 48hrs post infection as described in 
Material and Methods.  Bars represent the total mean percent of virus production from 
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three independent experiments ± SEM.  (B)  Cell lysates were analyzed for GFP-
NPMsiR, NPM1 and intracellular Gag expression by Western blotting 48hrs post 
infection expression with an anti-GFP, anti-NPM1 and anti-Gag antibody, respectively.  
Data shown is representative of cell lysates prepared from experiments in A.  (C)  HeLa 
or GFP-NPM1siR stable cell lines were transfected with reagent alone (Mock), 5 nM of 
siANC or 5 nM of siNPM1.  At 72hrs post siRNA transfection, cells were harvested, 
lysed and were analyzed for GFP-NPMsiR and NPM1 expression by Western blotting 
with an anti-GFP and anti-NPM1 antibody. 
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Figure A1-6. Depletion of NPM1 expression by RNAi has no discernable effect on 
GAPDH RNA localization.  (A, B) HeLa cells were transfected with reagent alone 
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(Mock; A, B top panel), siANC (B middle panel) or siNPM1 (B lower panel). At 48hrs 
post siRNA transfection, cells were uninfected (A) or infected with VSV-G pseudotyped 
NL4-3 virus at an MOI of 4 (B).  At 24hrs post infection, cells were fixed with 4% 
paraformaldehyde/5 mM MgCl2/1X PBS and analyzed using coupled FISH- IF.  A Cy3-
conjugated GAPDH RNA-specific probe was used to detect cellular GAPDH mRNA 
(red).  Immune detection of NPM1 (green) was performed using anti-NPM1 primary 
antibody and an AF-488 conjugated secondary antibody.  The nucleus (blue) was 
detected by DAPI.  Data shown is representative of multiple fields examined from two 
independent experiments.  (C)  HeLa cell lysates prepared from experiments in A and B 
were analyzed for NPM1 gene-specific knock-down and intracellular Gag expression by 
Western blotting with an anti-NPM1 antibody and anti-Gag antibody, respectively. 
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Figure A1-7. Depletion of NPM1 expression by RNAi has no discernable effect on 
HIV-1 infectivity.  HeLa cells were transfected with reagent alone (Mock), 5 nM of 
siANC or 5 nM of siNPM1.  At 48hrs post siRNA transfection, cells were uninfected or 
infected with VSV-G pseudotyped NL4-3 virus at an MOI of 1. (A)  Virus production 
was determined by quantifying viral RT enzyme activity of culture supernatants 24- and 
48hrs post infection as described in Material and Methods.  Bars represent the total mean 
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percent of virus production from two independent experiments performed in duplicate ± 
SEM.  Multiple student T-test analysis determined significant P values at 24- and 48hrs 
(**, P 0.01).  (B) Cells lysates were analyzed for NPM1 gene-specific knock-down and 
intracellular Gag expression by Western blotting 48hrs post infection with an anti-NPM1 
and anti-HIV-1 Gag antibody, respectively. Data shown is representative cell lysates 
prepared from experiments in A.  (C)  The infectivity of virus present in culture 
supernatants collected 48hrs post infection was determined using TZM-bl indicator cells 
and monitoring β-gal expression. Aliquots of supernatants containing equivalent RT 
activity units were serially diluted 10-fold in antibiotic-free media. Duplicate cell 
monolayers were inoculated with the diluted virus cultures.   At 48hrs post infection, cells 
were washed, fixed and assayed for β-gal enzymatic activity as described in Materials 
and Methods.  Bars represent the total mean virus infectivity of culture supernatants 
collected from experiments in A ± SEM.  A random-block one way ANOVA analysis 
determined non significant P values for virus infectivity (P= 0.1556).   
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Figure A1-8. RT-qPCR analysis confirms efficient RNAi-mediated depletion of 
NPM1 mRNA in the absence or presence of HIV-1 infection. (A, B) HeLa cells were 
transfected with reagent alone (Mock), siANC or siNPM1.  At 48hrs post siRNA 
transfection, cells were uninfected or infected with VSV-G pseudotyped NL4-3 virus at 
an MOI of 4.   Cells were harvested 24hrs (A) and 48hrs (B) and total RNA was prepared 
for RT-qPCR analysis as described in Materials and Methods. Life Technologies Gene 
Expression Assay primers were used to quantify control gene β-actin (Actin), NPM1 and 
the XenoRNA (Xeno) control target expression levels in the absence (-) or presence (+) 
of virus.  To confirm mRNA/ cDNA-specific amplification, samples were analyzed in the 
absence of reverse transcriptase (- RT).  (A, B)  Bars represent the mean of one 
experiment, assayed in duplicate ± SEM.  (C)  HeLa cell supernatants from A and B were 
analyzed for virus production by quantifying viral RT enzyme activity as described in 
Material and Methods.  Bars represent the total mean percent of virus production from 
two independent experiments ± SEM.  Multiple student T-test analysis determined 
significant P values at 24- and 48hrs (**, P 0.01). 
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